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RÉSUMÉ 
Régulation négative de la réponse fibrogénique hépatique par le suppresseur de la 
signalisation de cytokine 1 (SOCS1) 
Par:Rajani Kandhi 
Département de pédiatrie, Service d’immunologie 
 
Mémoire présenté à la Faculté de médecine et des sciences de la santé en vue de l’obtention 
du diplôme de maitresse science (M.Sc.) en Immunogie 
 
Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, 
Québec, Canada, J1H 5N4 
 
Le suppresseur de la signalisation des cytokines 1 (SOCS1) est un régulateur indispensable 
de la signalisation de l'IFN-γ et a été aussi impliqué dans la régulation de la fibrose 
hépatique. Cependant, on ne sait pas si les fonctions anti-fibrotiques sont médiées 
directement dans le foie par SOCS1  ou par la modulation de l'IFN-γ, qui est connu pour 
son effet atténuateur de la fibrose hépatique. En outre, il est possible que SOCS1 contrôle la 
fibrose hépatique par la régulation des cellules stellaires hépatiques (CSH), un acteur clé 
dans la réponse fibrogénique. Alors que les voies d'activation des CSH ont été bien 
caractérisées, les mécanismes de régulation ne sont pas encore clairs. Les buts de cette 
étude étaient de dissocier la régulation de la réponse fibrogénique hépatique médiée par 
SOCS1 et celle dépendante de IFN-γ et d'élucider les fonctions régulatrices de SOCS1 dans 
l'activation des CSH. La fibrose hépatique a été induite chez des souris Socs1-/-Ifng-/- par la 
diméthylnitrosamine ou le tétrachlorure de carbone.Les souris Ifng-/- et C57BL6 ont servi 
comme contrôles. Après les traitements fibrogéniques, les souris Socs1-/-Ifng-/- ont montré 
des niveaux sériques élevés d' alanine aminotransférase (ALT) ainsi que l'augmentation de 
la fibrose du foie par rapport à des souris Ifng-/-. Le dernier groupe a montré des niveaux 
plus élevés d'ALT et de fibrose par rapport aux souris C57BL6 contrôles. Les foies des 
souris déficientes en Socs1 ont montré une fibrose septale, qui a été associée à une 
augmentation de l'accumulation des myofibroblastes et à un dépôt abondant du collagène. 
Les foies déficients en SOCS1 ont montré une expression accrue de gènes codant pour 
l'actine musculaire lisse, le collagène et les enzymes impliquées dans le remodelage de la 
matrice extracellulaire, à savoir les métalloprotéinases de la matrice et l'inhibiteur tissulaire 
des métalloprotéinases. Les CSH primaires de souris déficientes en Socs1 ont montré une 
prolifération accrue en réponse à des facteurs de croissance tels que le HGF, EGF et le 
PDGF. Aussi, les foies fibrotiques de souris déficientes en Socs1 ont montré une expression 
élevée du gène PDGFB. Pris ensemble, ces données indiquent que SOCS1 contrôle la 
fibrose hépatique indépendamment de l'IFN-γ et qu'une partie de cette régulation peut se 
produire en régulant la prolifération des HSC et en limitant la disponibilité des facteurs de 
croissance. 
 
Mots clés : SOCS1, Diméthylnitrosamine, Tétrachlorure de carbone, Cellules stellaires 
hépatiques, PDGF. 
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SUMMARY 
 
Negative regulation of the hepatic fibrogenic response by suppressor of cytokine 
signaling 
 
By 
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of Sciences (M.Sc.) in Immunology  
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Suppressor of cytokine signaling 1 (SOCS1) is an indispensable regulator of IFN-γ 
signaling and has been implicated in the regulation of liver fibrosis. However, it is not 
known whether SOCS1 mediates its anti-fibrotic functions in the liver directly, or via 
modulating IFN-γ, which has been implicated in attenuating hepatic fibrosis. Additionally, 
it is possible that SOCS1 controls liver fibrosis by regulating hepatic stellate cells (HSC), a 
key player in fibrogenic response. While the activation pathways of HSCs have been well 
characterized, the regulatory mechanisms are not yet clear. The goals of this study were to 
dissociate IFN-γ-dependent and SOCS1-mediated regulation of hepatic fibrogenic 
response, and to elucidate the regulatory functions of SOCS1 in HSC activation. Liver 
fibrosis was induced in Socs1-/-Ifng-/- mice with dimethylnitrosamine or carbon 
tetrachloride. Ifng-/- and C57BL/6 mice served as controls. Following fibrogenic treatments, 
Socs1-/-Ifng-/- mice showed elevated serum ALT levels and increased liver fibrosis com- 
pared to mice Ifng-/-. The latter group showed higher alanine aminotransferase (ALT) levels 
and fibrosis than C57BL/6 controls. The livers of Socs1-deficient mice showed bridging 
fibrosis, which was associated with increased accumulation of myofibroblasts and abundant 
collagen deposition. Socs1-deficient livers showed increased expression of genes coding for 
smooth muscle actin, collagen, and enzymes involved in remodeling the extracellular 
matrix, namely matrix metalloproteinases and tissue inhibitor of metalloproteinases. 
Primary HSCs from Socs1-deficient mice showed increased proliferation in response to 
growth factors such as HGF, EGF and PDGF, and the fibrotic livers of Socs1-deficient 
mice showed increased expression of the Pdgfb gene. Taken together, these data indicate 
that SOCS1 controls liver fibrosis independently of IFN-γ and that part of this regulation 
may occur via regulating HSC proliferation and limiting growth factor availability. 
 
Keywords : SOCS1, Dimethylnitrosamine, Carbon tetrachloride, Hepatic stellate cells 
PDGF. 
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1. INTRODUCTION 
1. 1 The Liver 
The liver is one of the major organs in our body. It is involved in diverse functions such as 
metabolism, synthesis of plasma proteins and storage of vitamins, carbohydrates and fats. 
The Liver as the main detoxifying organ, liver neutralizes toxic metabolites and removes 
toxins that enter portal vein circulation (Taub 2004; Fausto, Campbell, and Riehle 2006). 
The liver has a remarkable capacity to regenerate following physical, biological and toxic 
injuries (Miyajima, Tanaka, and Itoh 2014). 
1.1.1 The Liver cells and functions 
The liver is composed of parenchymal cells and nonparenchymal cells.  The parenchymal 
cells are hepatocytes and cholangiocytes. Hepatocytes constitute about 94% of the total 
liver mass and carry out most functions in the liver (Papoulas and Theocharis 2009; 
Blomhoff R 1990). Cholangiocytes are epithelial cells that are located in intrahepatic and 
extra-hepatic biliary ducts. These are responsible for modification of the bile produced by 
hepatocytes (O’Hara et al. 2013; Alpini, McGill, and Larusso 2002). 
Hepatic non-parenchymal cells include the sinusoidal endothelial cells, Kupffer cells 
(KCs), lymphocytes, hepatic stellate cells (HSCs) and biliary epithelial cells 
(Cholangiocytes)(Lemoinne et al. 2013). Kupffer cells are the liver resident macrophages 
that reside in sinusoids and play important roles in hepatic homeostasis, phagocytosis and 
host defense (M Naito, Hasegawa, and Takahashi 1997; Makoto Naito et al. 2004). These 
cells are derived from circulating monocytes and comprise approximately 20% of hepatic 
non-parenchymal cells (Ruck and Xiao 2002). Hepatic stellate cells (HSC) store retinoids 
and serve as precursors of liver myofibroblasts (Friedman 2008). Myofibroblasts are the 
main fibrogenic effector cells and are absent in the healthy liver. However, following the 
liver damage, HSCs differentiate and start producing extracellular matrix and collagen 
(Lemoinne et al. 2013). The liver sinusoidal endothelial cells (LSEC) line the capillaries 
and sinusoids and differ from the endothelium of big vessels in lacking a basement 
membrane and containing the fenestrae structures. (Bouwens et al. 1992; DeLeve 2013). 
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The liver contains large number of lymphocytes which include natural killer (NK), natural 
killer T cells (NKT), B cells, CD4 and CD8 T cells present around the portal tracts and 
throughout the hepatic parenchyma. NK and NKT cells provide first line immune defense 
against invading pathogens and also involved in recruitment of circulating lymphocytes  
(Racanelli and Rehermann 2006). 
1.1.2 Liver lobule structure 
The liver parenchyma is structurally divided into multiple functional units called lobules, 
which are hexagonal in shape and composed of a labyrinth of interconnected hepatocyte 
plates separated by sinusoidal blood vessels. Each lobule comprises of a central vein from 
where hepatocyte plates radiate out towards the perimeter of the lobule. Each lobule is 
surrounded and separated by connective tissue. (Fig. 1a and b) (Wallace, Burt, and Wright 
2008). 
 
The liver receives both oxygenated and non-oxygenated blood supply. The portal vein 
brings nutrient rich blood from the gut, which is partially oxygenated. About 30% of the 
hepatic blood comes via the hepatic artery. The two types of blood mix up at the edge of 
the portal tracts and circulate towards central vein through sinusoids. The central veins join 
together to form the hepatic vein, which drain into the inferior vena cava. The portal vein, 
hepatic artery and bile duct together are found at the angle of each lobule forming the portal 
triad (Wallace, Burt, and Wright 2008; Miyajima, Tanaka, and Itoh 2014). 
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1.2 Chronic liver diseases (CLD) and Liver fibrosis 
1.2.1 Epidemiology 
The most common chronic liver diseases (CLD) that are accountable for the morbidity and 
mortality in humans are viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver 
disease (NAFLD), cirrhosis and hepatocellular carcinoma. These conditions are responsible 
for more than 95% of all deaths due to liver disease. Globally, more than 400 million 
individuals are chronically infected with hepatitis B virus (HBV), and above 170 millions 
of people are chronically infected with hepatitis C virus (HCV). About 9 to 36.9% of the 
population is affected with NAFLD, which is more prevalent in individuals with obesity 
and diabetes mellitus. Alcoholic liver disease (ALD) is prevalent in people who consume 
alcohol regularly (K. Zhou and Lu 2009). Other causes of CLD include overload of iron or 
copper absorption and autoimmune destruction of hepatocytes or bile duct epithelium 
(Guyot et al. 2006; Y. Liu et al. 2013). 
 
According to Canadian Liver Foundation reports, the incidence of CLD in Canada is 
increasing alarmingly. It is estimated that one in ten Canadians, or approximately more than 
three million people, have some form of liver disease. Around half a million Canadians are 
chronically infected with Hepatitis B or C virus. NAFLD is also a common liver disease 
that afflicts as much as 25% of the Canadian population. Liver cirrhosis is recorded in 
about 5,000 deaths per year. Over 2,000 Canadians are expected to develop primary liver 
cancer and about 1,000 will die of this disease. It is noted that advanced forms of fibrosis 
and cirrhosis develop in about 20–40% of patients affected with CLD (Canadian Liver 
Foundation 2013). In general, progression of CLD takes several years or even decades to 
cause overt illness. For instance, in the case of hepatitis C infection, it takes up to 10 -15 
years from the time of infection to develop fibrosis and cirrhosis (Massimo Pinzani and 
Macias-barragan 2016). 
1.2.2 Liver fibrosis (LF) 
Most chronic liver diseases are associated with liver fibrosis independent of its etiology 
(Massimo Pinzani and Macias-barragan 2016). Fibrosis is a wound healing response to any 
kind of injury to the liver and is characterized by the accumulation of interstitial or ‘‘scar’’ 
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extracellular matrix (ECM) (Guo and Friedman 2007).  
Liver fibrosis is a reversible process.  In normal conditions, there is a balance between liver 
repair and scar formation. During acute injury, changes that occur in the liver are transient 
and reversible. On the other hand, chronic liver injury is associated with recurring 
replacement of hepatic parenchyma with fibrous tissue, which leads to cirrhosis. Cirrhosis 
is the end stage of liver fibrosis characterized by the loss of the lobular architecture and the 
appearance of regenerative nodules of liver parenchyma surrounded by fibrotic septa (U. E. 
Lee, Mstp, and Friedman 2011). The resulting loss of hepatic function is the cause of 
significant morbidity and mortality associated with cirrhosis (Iwaisako, Taura, and Koyama 
2014). In cirrhosis, loss of functional hepatocytes and increased intrahepatic resistance to 
blood flow leads to hepatic insufficiency and portal hypertension, respectively (Tsochatzis, 
Bosch, and Burroughs 2014; D’Amico, Garcia-Tsao, and Pagliaro 2006). To compensate 
for the metabolic needs required by the liver, hepatocytes continuously undergo recurrent 
proliferation in an inflammatory milieu that could lead to the development of dysplastic 
nodules and eventually to hepatocellular carcinoma (HCC) (Kensler et al. 2003; Farazi and 
DePinho 2006). HCC is among the fifth most common cancer in the world, and the third 
leading cause of cancer death (M Pinzani and Rombouts 2004). It has been demonstrated 
that liver fibrosis is strongly associated with HCC, with ninety percent of HCC cases 
occurring in cirrhotic livers (D. Y. Zhang and Friedman 2014). 
 
The ultrastructural pattern of fibrosis varies with the underlying etiology. In HBV or HCV 
infections, liver fibrosis is characterized by the formation of portal–central septa. In 
alcoholic and non-alcoholic steatohepatitis, deposition of the fibrillar matrix is concentrated 
around the sinusoids and around groups of hepatocytes like a chicken-wire pattern 
(Massimo Pinzani and Macias-barragan 2016). In chronic bile obstruction, porto-portal 
septa is observed due to the activation of portal fibroblasts (Guyot et al. 2006). 
 
The development of fibrosis, and particularly cirrhosis, is associated with significant 
morbidity and mortality. Since it is the final common pathological pathway of chronic liver 
disease, regardless of etiology, developing antifibrotic strategies that target this pathway 
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would be an attractive approach to curtail the end stage of developing hepatocellular 
carcinoma. However, because fibrotic liver disease may not present clinically until an 
advanced or cirrhotic stage, development of methods for early detection of fibrosis and its 
reversal are essential issue for successful intervention (Bonis, Friedman, and Kaplan 2001). 
 
1.3 Extra cellular matrix (ECM) in normal liver 
Increased deposition of ECM is the main characteristic of liver fibrosis (Friedman 2010a). 
The main function of ECM is not only to provide structural support to cells, but also to 
regulate many cellular processes such as growth, migration, differentiation, survival, 
homeostasis and morphogenesis (Theocharis et al. 2015). ECM also serves as a reservoir 
for growth factors that are essential for liver regeneration such as the hepatocyte growth 
factor and epidermal growth factor. (Rozario and DeSimone 2010). The compositions of 
ECM vary from tissue to tissue. However, the major constituents of ECMs are fibrous-
forming proteins, such as collagens, elastin, fibronectin (FN), and non–fiber-forming 
(interfibrillar) proteins such as glycoproteins, and proteoglycans (PGs) (Frantz, Stewart, 
and Weaver 2010). 
 
Collagen is the most abundant fibrous protein which not only provides tensile strength but 
also promotes cell adhesion, support, chemotaxis, migration and tissue repair (Rozario and 
DeSimone 2010). To date, 28 types of collagen have been identified in vertebrates. Based 
on their structure and supramolecular organization, they are divided into fibril-forming 
collagens (Type I, II, III, V, XI), fibril-associated collagens (FACIT) (Type IX, XII, XIV, 
XVI, XIX), network-forming collagens (types X and VIII), anchoring fibrils type (VII), 
transmembrane collagens (type XIII, XVII), basement membrane collagens (Type IV) and 
others with unique functions (Gelse 2003). The structural hallmark of all collagens is their 
triple helix. For example, collagen 1 contains three α chains (2 α1, 1 α2) and series of Gly-
X-Y repeats (where X and Y represent any amino acids but are frequently proline and 
hydroxyproline, which facilitate fibril formation (Mouw, Ou, and Weaver 2014). 
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Structurally, collagens are present in the homopolymers or heteropolymers. Type I collagen 
is the major component of ECM and is the product of two genes, COL1A1, and COL1A2. 
Synthesis of collagen type 1 involves a number of post-translational modifications. 
Hydroxylation of proline and lysine residues and glycosylation of lysine occur in the 
endoplasmic reticulum (ER) to form pro-collagen (Gordon and Hahn 2010). Pro-collagens 
are then secreted through the Golgi apparatus into the extracellular space where the N-
terminal and C-terminal pro-peptides are cleaved by metalloproteinase enzymes to form 
collagens (Mouw, Ou, and Weaver 2014).  Lysyl oxidase (LOX) is an enzyme involved in 
cross-linking collagens and elastins (Rodríguez, Rodríguez-Sinovas, and Martínez-
González 2008). 
 
Elastin fibers are formed by cross-linking of tropo-elastin molecules and provide recoil to 
tissues that undergo repeated stretch (Wise and Weiss 2009). Fibronectin is one type of 
fibrillar collagen, which regulates cell migration and adhesion activities through direct 
interactions with cell-surface integrin receptors. (Mao and Schwarzbauer 2005; Theocharis 
et al. 2015). Proteoglycans (PG) are major components of ECM that help in buffering, 
hydration and binding and provide swelling pressure to the tissue to withstand 
compressional forces (Yanagishita 1993; Järveläinen et al. 2009). PGs contain a central 
core protein which binds covalently to several glycosaminoglycan (GAG) chains such as 
hyaluronan, through which they interact with numerous growth factors, cytokines, 
chemokines and cell surface receptors (Kresse and Schönherr 2001). 
 
Laminins are the family of glycoproteins present predominantly in basement membranes. 
They form interactions with cell surface receptors and are involved in various functions 
such as cell adhesion, migration, and differentiation and in wound repair (Malinda and 
Kleinman 1996; Durbeej 2010). 
 
1.4 Cellular Sources of ECM in Liver Fibrosis 
The ECM deposition in fibrosis is caused by the activation of myofibroblasts. 
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Myofibroblasts are usually not present in normal liver, but they are produced by 
transdifferentiation of liver resident cells, such as hepatic stellate cells (HSC) and portal 
fibroblasts (Lotersztajn et al. 2005). Many studies suggested that HSC are the major source 
of myofibroblasts in LF (Iwaisako, Brenner, and Kisseleva 2012). Portal fibroblasts are the 
major source of myofibroblasts in portal fibrosis or in cholestatic liver injury (Guyot et al. 
2006). These hepatic myofibroblasts may also originate from bone marrow-derived 
mesenchymal cells and fibrocytes, which are recruited to the liver and differentiate into 
myofibroblasts. However, these cells make only a small contribution to the myofibroblast 
population in experimental liver fibrosis (Kisseleva et al. 2006; Bellini and Mattoli 2007; J. 
Xu et al. 2015).  
 
It has been proposed that hepatic progenitor cells like hepatocytes, cholangiocytes, and 
hepatic sinusoidal endothelial cells differentiate into myofibroblasts through epithelial or 
endothelial-mesenchymal transition (EMT) and contribute to the progression of LF 
(Zeisberg et al. 2007; Robertson et al. 2007). But, two lineage tracing analysis studies 
showed that myofibroblasts originated from hepatocytes and cholangiocytes via EMT do 
not express any of the mesenchymal markers including α-SMA, FSP-1, Desmin and 
Vimentin in different LF-induced models (Taura et al. 2010; Chu et al. 2011). One recent 
study used Lrat (lecithin-retinol acyltransferase) Cre-transgenic mouse, which marks 99% 
of hepatic stellate cells (HSCs) in the liver, reported that stellate cells give rise to 82–96% 
of myofibroblasts in models of toxic, cholestatic and fatty liver disease (Mederacke et al. 
2013). However, the relative contribution of other cellular sources may depend on the 
underlying etiology and region(s) of injury within the liver. (Friedman 2010b; M Pinzani 
and Rombouts 2004; Iwaisako, Taura, and Koyama 2014; Friedman 2010a). 
 
Although hepatic myofibroblasts are heterogeneous in their origin, they show some similar 
cellular characteristics like the expression of α-SMA, collagen-α1 (J. Xu et al. 2015). 
Specific markers for cellular sources of myofibroblasts in the fibrotic liver are showed in 
Table 1. 
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Quiescent HSC or	
 Activated HSC	
Portal ﬁbroblasts	 Fibrocytes	 Hepatocytes	 Cholangiocytes	
Desmin+ 
CD146+ 
CD105+ 
GFAP+ 
LRAT+ 
P75+ 
IL17RA+ 
Synemin+ 
Synaptophysin+  
CD45- 
CD34- 
Thy1.1- 
Elastin  
Thy1.1+ 
Elastin+ 
Synemin+ 
CD105+ 
CD45- 
CD34- 
CD146- 
Desmin- 
GFAP-		
CD45+ 
CD34+ 
CD11b+ 
Gr1+ or Ly6G+ 
MHCII+ 
ICAM1+ 
CCR2+ 
CCR7+ 
CXCR4+ 
CD80+ 
 CD86+ 
CD45- 
Alb+ 
 FSP1+  
CD45- 
CK19+ 
 FSP1+  
 
 
 
 
Table 1 Sources of liver myofibroblasts and their markers 
 
 
1.5 Hepatic Stellate Cells 
Hepatic stellate cells were first described by von Kupffer in 1876 as liver sternzellen (star-
shaped cells) (Hellerbrand 2013). Ito and Nemoto described them as fat-storing cells, 
Suzuki as “interstitial cells, Bronfenmajer, Schaffner, and Popper as “lipocytes and Wake 
as peri-sinusoidal cells”. To avoid the confusion with these synonyms, a standardized name 
is given to these cells as  “Hepatic Stellate Cells (HSC)”, which refers to the resting 
(quiescent) form of this cell type found in normal liver (Senoo et al. 2010). 
HSC constitute about 1% of the total liver mass and 7% of the total number of liver cells. 
They reside in the space of Disse (sub endothelial space) which is the gap between 
hepatocytes and sinusoidal endothelial cells (Blomhoff R 1990). In the normal liver, stellate 
cells possess spindle-shaped cell bodies with long cytoplasmic processes. These processes 
wrap sinusoids and regulate circulation through the sinusoidal capillaries (Reynaert 2002). 
They also provide contacts with hepatocytes and other stellate cells, which help in the 
intercellular transport of soluble mediators and cytokines. The thorny projections on the 
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processes are involved in “sensing” chemotactic signals (Friedman 2008). 
1.5.1 Retinoid Storage 
In normal livers, HSC store vitamin A (retinoid) in their cytoplasm, which is a prominent 
characteristic feature of stellate cells in a quiescent state. About 80% of the total retinoids 
present in the entire body is stored in HSC of the liver in the form of retinyl esters in their 
lipid droplets (Senoo 2004; Weiskirchen and Tacke 2014). The lipid droplets of the stellate 
cells show intense but rapidly fading blue-green vitamin A autofluorescence when excited 
with the wavelength light of ∼328 nm (Hellerbrand 2013). The number of droplets varies 
with the species and the abundance of vitamin A stores of the organism (Friedman 2008).  
Dietary retinoid intake but not triglyceride intake affects the number and size of HSC lipid 
droplets (Blaner et al. 2009). Dietary retinoids converts to retinol before absorbption in the 
small intestine (enterocytes), where they convert into retinyl esters and packaged into 
chylomicrons for transportation to the lymphatic circulation. Then, they are taken up by 
hepatocytes, where retinoids are hydrolyzed to retinol and bind with retinol-binding protein 
(RBP) to transfer to the HSCs for storage (Iwaisako, Taura, and Koyama 2014; Senoo et al. 
2010). HSCs possess high levels of LRAT (lecithin: retinol acyltransferase) activity that is 
responsible for the esterification of retinol to retinyl ester and lipid droplet formation. It has 
been shown that Lrat−/− mice lack lipid droplets and retinyl esters in these cells but did not 
develop fibrosis suggesting a physiological role of LRAT in HSC (Fomby and Cherlin 
2011; O’Byrne et al. 2005). In response to liver injury, stellate cells become activated 
which is characterized by the loss of their lipid droplets (Friedman 2008). 
Vitamin A-storing cells are also present in other tissues such as pancreas, lungs, kidney, 
spleen, adrenal glands, testis, uterus, lymph nodes, thymus, bone and intestines, where they 
store lipid droplets and synthesize and secrete ECM components in these tissues. These 
cells are considered as extrahepatic stellate cells (Geerts 2001; Senoo et al. 2010). Among 
them, pancreatic stellate cells are similar to HSC in structure, storage of vitamin-A and 
expression of cytoskeletal markers and signaling pathways (Apte et al. 1998; Kordes, 
Sawitza, and Häussinger 2009). 
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1.5.2 Origin and Markers for identification of HSC 
Embryonic origin of HSC is not yet clearly known since they express marker genes of all 
three germ layers. These cells are thought to derive from endoderm due to the expression of 
CD34 and cytokeratin-7/8 in fetal liver. The expression of mesodermal (Wilm’s tumor 
suppressor gene (Wt1) and mesoderm posterior 1 gene (Mesp1)) suggests they have a 
mesodermal origin. Hepatic epithelial cells are thought to transdifferentiate into hepatic 
stellate cells in the injured liver through epithelial-mesenchymal transition (EMT) but, the 
contribution of EMT to the hepatic stellate cell lineage is highly controversial (Yin et al. 
2013; Kordes, Sawitza, and Häussinger 2009). Some studies have suggested that HSC 
could also be derived from neural crest due to expression of neural cell type markers such 
as glial fibrillary acidic protein (GFAP), nestin, expression of neuronal cell adhesion 
molecule (N-CAM), synaptophysin, neurotrophins and neurotrophin receptor (Senoo et al. 
2010). One study using double transgenic mouse line constitutively expressing yellow 
fluorescent protein (YFP) in the neural crest and their derivatives, showed that HSC in 
adult livers of these mice do not express YFP suggesting HSCs do not originate from the 
neural crest (Cassiman et al. 2006). 
Markers to identify HSC are shown in Table1. Desmin has been widely used as a “gold 
standard” for the identification of the stellate cells in rodent liver, but its expression is not 
reliable in humans (Friedman 2008). α-SMA is one of the six actin isoforms which is 
expressed only when HSC are activated (D C Rockey, Boyles, et al. 1992). Other methods 
employed to determine HSC staining of lipid droplets using oil red O, Sudan red, toluidine 
blue or basic fuchsine, but these are not specific to HSC as hepatocytes and Kupffer cells 
also contain fat droplets (Geerts 2001). 
 
1.6 Activation of HSC in liver fibrosis 
Activation of HSC is a pivotal event in liver fibrosis where quiescent HSC transform into 
proliferative, fibrogenic, and contractile ‘‘myofibroblasts’’ (Friedman 2010a). Also, when 
primary HSC are seeded onto plastic plates in culture, they undergo an activation process 
that mimics the fibrogenic response in the liver. Activation of HSC is comprised of two 
phases, the initiation phase and the perpetuation phase (Figure 2). 
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Figure 1 The activation of hepatic stellate cells: The pathways of HSC activation 
consist two phases; one is initiation phase (also referred to as pre-inflammatory) and 
perpetuation (continuous activation). Initiation is provoked by soluble stimuli such as 
oxidative stress (reactive oxygen intermediates), apoptotic bodies, LPS and paracrine 
stimuli from neighboring cell types including hepatocytes, Kupffer cells, sinusoidal 
endothelium and from infiltrating immune cells. In the perpetuation phase, the activated 
cells start expressing their own cytokines and growth factors that can act in autocrine and 
paracrine manner. The perpetuation phase is characterized by a number of specific 
phenotypic changes including proliferation, contractility, fibrogenesis, altered matrix 
degradation, chemotaxis and inflammatory signaling. 
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1.6.1 Initiating Pathways  
The initiation phase consists a sequence of events, which make stellate cell respond to a 
wide range of cytokines and growth factors (Friedman 2010a). Initiating stimuli include 
paracrine signals such as reactive oxygen species (ROS), apoptotic bodies, cytokines 
released from injured liver resident cells and infiltrating inflammatory cells and changes in 
ECM composition (Brenner et al. 2000; Guo and Friedman 2007). 
1.6.1.1 Oxidative stress 
Most of the CLD like HCV infection, ALD and hemochromatosis are associated with 
oxidative stress, which enhances apoptosis or necrosis of hepatocytes, thereby amplifying 
the inflammatory response and fibrosis (Poli 2000). ROS include superoxide, hydrogen 
peroxide, hydroxyl radicals, reactive nitrogen species (RNS) and lipid peroxides derived 
from the damaged hepatocytes as well as partly from activated Kupffer cells and 
neutrophils that contain damaged mitochondria (Parola and Robino 2001; Friedman 2008). 
The activation of cytochrome P450 2E1 in hepatocytes leads to the generation of ROS that 
activates HSC through redox-sensitive intracellular signaling pathways, leading to 
increased collagen production (Kisseleva and Brenner 2007; Friedman 2010a). ROS also 
stimulate the production of profibrogenic mediators from Kupffer cells and other resident 
and circulating inflammatory cells (Sánchez-Valle et al. 2012). 
 
1.6.1.2 Apoptosis of hepatocytes 
Apoptosis is a programmed cell death process usually not associated with inflammation. In 
the case of CLD, continuous damage to hepatocytes leads to the deregulation of the 
apoptotic process, which results in the generation of apoptotic bodies (Canbay, Friedman, 
and Gores 2004). These are cleared by Kupffer cells and HSC by phagocytosis or 
engulfment (Guo and Friedman 2007). Phagocytosis by Kupffer cells leads to expression of 
a death ligand (Fas ligand) and the proinflammatory cytokine TNF-α, which accelerates 
hepatocyte apoptosis and inflammation (Canbay et al. 2003). The engulfment of apoptotic 
bodies by HSC also leads to the release of free radicals, up-regulation of TGF-β1 and 
collagen I expression. Continuous activation of these cells results in enhanced hepatocyte 
apoptosis, inflammation and sustained activation of HSC, ultimately leading to LF (S.-S. 
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Zhan et al. 2006; Guicciardi and Gores 2005). 
 
1.6.1.3 Changes in ECM composition or quality and quantity 
Changes in physical properties and chemical composition of ECM influence HSC 
activation (Friedman 2008).  Increased stiffness caused by edema and inflammation also 
plays an important role in initiating fibrosis (Georges et al. 2007; Friedman 2010b).  
 
Matrix stiffness affects the structure, proliferation, differentiation, motility and survival of 
cells (Wells 2008). Cells that grow on the soft matrices (Matrigel) show less proliferation, 
and are non-invasive and non-fibrogenic, whereas cells growing on stiff matrices (like 
fibrillar collagen) show opposite effects. However, these properties may vary with cell type 
(Wells 2005; Wells 2008). Type I collagen and stimulation of cells with growth factors 
such as PDGF, TGF-β and EGF enhance HSC migration and increased MMP-2 activity 
whereas the basement membrane ECM is inhibitory. These activities are mediated through 
α1β1 and α2β1 integrins, which are heterodimeric cell surface receptors that readily sense 
changes in the ECM composition (C.-Q. Yang et al. 2008). Integrin-linked kinase (ILK) is 
an important multi-domain focal adhesion protein involved in transducing signals from the 
ECM to HSC cytoskeleton. It has been shown that ILK plays an important role in HSC 
activation and LF (Y. Zhang et al. 2006; Shafiei and Rockey 2006). ILK mediates its 
functions through Rho and Gα12/13 signaling (Shafiei, Rockey, and Diseases 2014). 
Changes in ECM composition also lead to the release of growth factors, from reservoirs 
into the extracellular space, that promote cell proliferation and fibrogenesis (D. Schuppan et 
al. 2001; Friedman 2010b). 
 
1.6.2 Perpetuating Pathways 
The second stage of the HSC activation process is the perpetuation phase. Once these cells 
are activated by initiating stimuli, they respond to different cytokines and growth factors 
released from neighboring cells (by paracrine action) and also perpetuate their own 
activation by secreting cytokines, other mediators in an autocrine manner and by 
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upregulating their respective receptors (Moreira 2007). 
The perpetuation phase is characterized by loss of the retinoid stores, enhanced 
proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis and leukocyte 
chemoattraction (proinflammatory signaling), which collectively contribute to scar 
formation (Li and Friedman 1999; Friedman 2008). 
 
1.6.2.1 Retinoid loss 
Activated HSC are marked by loss of the Vitamin-A and lipid droplets in their cytoplasm. 
It has been shown that in vitro HSC cultures treated with retinoic acid (RA) stop 
proliferating and secrete TGF-β (Davis, Kramer, and Davidson 1990). HSC expresses 
nuclear retinoic acid (RAR) and retinoid X receptors (RXR) by which RA modulates 
proliferation and interstitial collagen expression (Hellemans et al. 2004). However, it is not 
yet clearly known whether the retinoid loss is a required for stellate cell activation. 
 
1.6.2.2 Proliferation 
One important feature of activated HSCs is their proliferative phenotype. The most potent 
mitogen of HSC is platelet-derived growth factor (PDGF). Other HSC mitogens include 
VEGF, thrombin, epidermal growth factor (EGF), TGF-α, keratinocyte growth factor and 
basic fibroblast growth factor (Don C Rockey 2006). Main sources of PDGF-β are 
endothelial cells and activated HSC. Quiescent HSC express the PDGF-α receptor subunit, 
but do not express the β-subunit until activation (Alcolado, Arthur, and Iredale 1997). The 
expression of PDGF-β and its receptor expression is enhanced during HSC activation (M 
Pinzani et al. 1994; Wong et al. 1994). PDGF-β over-expression enhances HSC 
proliferation and liver fibrosis without influencing TGF-β expression, indicating a TGF- β -
independent mechanism (Czochra et al. 2006). Phosphatidyl inositol 3 kinase (PI3K), ERK 
and AKT downstream signaling pathways play an important role in mediating HSC 
proliferation and collagen deposition in response to PDGF-β (Bonner 2004). PDGF-β also 
activates NADPH oxidase (NOX) in HSC to produce ROS which further enhances HSC 
proliferation through the phosphorylation of p38 MAPK (Adachi et al., 1997). Besides, 
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PDGF-β mediates HSC proliferation by stimulating Na+/H+ exchanger (Di Sario et al. 
1999). In cholestatic liver injury, PDGF induces a proliferative response in HSC, which 
precedes HSC phenotypic conversion into myofibroblasts (Kinnman et al. 2001). 
 
1.6.2.3 Chemotaxis 
Injury-associated stimuli induce migration of stellate cell towards damaged areas of the 
liver, where they undergo proliferation, synthesize extracellular matrix, and participate in 
tissue repair. These cells undergo apoptosis once injury resolves, but if injury persists; 
stellate cells drive the development of fibrosis and subsequent cirrhosis (Melton and Yee 
2007). This migration of HSC depends on the extracellular matrix integrity, composition 
and cell-matrix interactions. It has been shown that stimulation of HSC with TGF-β1, 
PDGF-β, and collagen 1 results in an increase in their migratory capacity and it is MMP-2 
and integrin dependent (C. Yang et al. 2003). Endothelin-1 (ET-1) and monocyte 
chemotactic protein (MCP-1) also induce chemotaxis of HSC (Ikeda et al. 1999; Marra et 
al. 1999; Ramón Bataller and Brenner 2001). Focal adhesion disassembly is necessary for 
stellate cell chemotaxis in response to PDGF (Melton et al. 2007). Adenosine and DNA 
from damaged hepatocytes that bind to A2 and TLR9 receptors respectively on HSC, 
inhibit PDGF-induced chemotaxis by blocking Ca+2 influx and up-regulating TGF-β and 
collagen I mRNA expression (Hashmi et al. 2007; Watanabe et al. 2007). Collagen type 4 
has also been shown to inhibit HSC migration (C.Q. Yang et al., 2008).  
 
1.6.2.4 Contractility of stellate cells:  
HSC show contractility similar to myofibroblasts, mediated by α-smooth muscle actin (α–
SMA) and myosin. The main factor involved in HSC contraction is endothelin-1, which 
regulates sinusoidal blood flow via ET-1 receptors expressed on HSC in the liver (Housset, 
Rockey, and Bissell 1993). Other molecules that induce contractility of HSCs include 
prostanoids, substance P, angiotensin II and arginine vasopressin (Don C Rockey 2006). 
Besides promoting contractility, ET- 1 and Angiotensin II also promote proliferation of 
HSC (Cho et al. 2000; Manuscript and Target 2009; R Bataller et al. 2000). Contractility of 
HSC is inhibited by vasodilator compounds such as nitric oxide (NO), carbon monoxide 
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(CO), PGE2, lipo-PGE1 and adrenomedullin (Don C. Rockey 2003). ET-1 exerts 
contractility through a Ca2+ dependent protein kinase (that is, PKC) and Rho pathway 
whereas NO exerts relaxation via the cyclic adenosine monophosphate (cAMP) pathway 
(Reynaert et al. 2002). In the normal liver, ET-1 is produced primarily by sinusoidal 
endothelial cells but, after injury, ET-1 is largely derived from HSC, which also up-regulate 
their receptors (Housset, Rockey, and Bissell 1993; Don C. Rockey 2003). Increased 
contractility by HSC contributes to increased intrahepatic resistance and portal pressure in 
cirrhotic livers (D C Rockey and Weisiger 1996). 
 
1.6.2.5 Fibrogenesis 
Transforming growth factor-β (TGF-β) is the major fibrogenic cytokine in many fibrotic 
diseases, including LF (A. M. Gressner 1996). Fibrotic diseases are associated with 
increased levels of TGF-β, which inhibit ECM degradation by down regulating the 
expression of MMP and upregulating the expression of tissue inhibitor of matrix 
metalloprotease-1 (TIMP-1) (K. Jeong 2008; Dooley and Dijke 2012). TGF-β is derived 
from paracrine sources such as sinusoidal endothelial cells and Kupffer cells as well as 
synthesized in an autocrine manner by HSC (Inagaki and Okazaki 2007). 
 
TGF-β plays important roles in embryonic development, tissue remodeling, inflammation, 
angiogenesis, atherosclerosis, fibrosis and carcinogenesis (Mauviel 2005; Inagaki and 
Okazaki 2007). TGF-β is a potent growth inhibitor of hepatocytes and apoptosis of 
epithelial cells. Conversely, it stimulates fibroblasts to proliferate, produce ECM and 
induce a fibrotic response in various tissues in vivo (Leask and Abraham, 2004). In the 
liver, TGF-β enhances the transdifferentiation of HSC into myofibroblasts (A. M. Gressner 
1996). The blockade of TGF-β signaling prevents progression of LF in experimental 
animals (Yata et al. 2002), whereas overexpression of TGF-β in transgenic models 
inhibited HSC apoptosis and induced HSCs to synthesize excessive amounts of matrix 
proteins, such as collagen types I, III, IV and fibronectin (Kanzler et al. 1999). Studies with 
a tetracycline-regulated gene expression system, in which plasma levels of TGF-β can be 
chemically regulated, showed that TGF-β inhibits MMP and up-regulates TIMP-1 
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expression and that progression of LF could be stopped by inhibiting TGF-β production 
(Ueberham et al. 2003). 
 
1.6.2.5.1 TGF-β activation 
TGF-β is a member of a large family of pleiotropic cytokines that includes bone 
morphogenetic proteins (BMPs), activins and other related factors. The TGF-β family 
contains three closely related isoforms (i.e. TGF-β1, TGF-β2, TGF-β3). They are secreted 
as latent precursor molecules (LTGF-β), which contain an N-terminal secretory signal 
sequence, a long precursor segment, i.e. the latency-associated peptide (LAP), and a C-
terminal part corresponding to the mature TGF-β.  The LTGF-β forms a complex with 
latent TGF-β-binding proteins (LTBP), activated by proteolytic cleavage by various 
proteases such as plasmin and thrombin. The biologically active form is a dimer of 25KDa 
in which the two subunits are linked by a disulfide-bridge (A. M. Gressner and 
Weiskirchen 2006; Y. Shi and Massague 2003) (Figure 3). 
 
1.6.2.5.2 TGF- β receptors  
TGF-β isoforms exert their biological effects through a distinct network of TGF-β type I 
(TβRI), type II (TβRII), and type III (TβRIII) cell-surface receptors. TβRI and TβRII are 
serine/threonine kinases that contain a cysteine-rich extracellular domain, a short 
hydrophobic transmembrane region, and a cytoplasmic region harboring the kinase motif. 
Ligand binding induces the assembly of type I and type II receptors into complexes, within 
which, TβRII phosphorylates and activates TβRI. This phosphorylation event is associated 
with activation of TβRI kinase and subsequent downstream signaling (A. M. Gressner and 
Weiskirchen 2006; Y. Shi and Massague 2003). 
 
1.6.2.5.3 TGF-β signaling by Smad proteins 
Signal transduction from activated TβRI to the nucleus is mediated predominantly via 
phosphorylation of cytoplasmic protein mediators Smads. The receptor-associated Smads 
(R-Smads; Smad1, 2, 3, 5 and 8) are recruited to activate TβRI by auxiliary proteins such as 
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Smad Anchor for Receptor Activation (SARA). Upon phosphorylation by activated TβRI 
on two serine residues, activated R-Smads form heteromeric complexes with a co-Smad, 
Smad4, and translocate into the nucleus where they induce the transcription of genes 
directly or indirectly involved in fibrogenesis namely, several fibrillar ECM proteins 
(collagen, fibronectin), matrix-degrading enzymes (MMPs) and some protease inhibitors 
(plasminogen activator inhibitor type 1, TIMP-1). They also induce genes regulating 
epithelial– mesenchymal cell transition, proliferation (cyclin-dependent kinase inhibitor 
p21) and apoptosis (caspases). The inhibitory Smads, Smad6 and Smad7 antagonize 
signaling by competing with R-Smads for binding to activated TβRI and thus inhibit the 
phosphorylation of R-Smads or recruiting E3 ubiquitin ligases to the activated TβRI 
(Verrecchia and Mauviel 2007; Verrecchia et al. 2010).  
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Figure 2: The TGF-β signaling Pathway: TGF-β is generally secreted as a large 
latent precursor molecule that is complexed with latency-associated peptide (LAP) and 
bound to latent-TGF-β-binding protein (LTBP). Latent TGF-β is activated when it 
dissociates from LAP and LTBP. The active TGF-β binds its receptor, initiates Smad-
dependent and independent signaling. The Smad-dependent signaling pathway 
regulates fibrogenic target genes such as α-smooth muscle actin (SMA), collagen, 
connective tissue growth factor (CTGF), tissue inhibitor of metalloprotease (TIMP-1). 
TGF-β can also induce a number of Smad-independent pathways mediated by Ras, 
JNK, TGF-β-activated kinase (TAK), and phosphatidylinositol-3-kinase (PI3K) that 
promote EMT, apoptosis and fibrotic responses. 
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1.6.2.5.4 Differential Roles of Smads in liver fibrosis 
Even though the structure of Smad proteins is similar, they show functional diversity (F. 
Xu et al. 2016). Smad2 and Smad3 are strongly activated in liver fibrosis, but smad3 is 
essential for the pathogenic process. TGF-β mediates activation of Smad2 primarily in in 
quiescent and intermediate cells, whereas Smad3 activation occurs primarily in 
transdifferentiated cells. (C. Liu et al. 2003). In activated HSC, TGF-β also regulates 
cytoskeletal organization via phosphorylation of Smad3 (Uemura et al. 2005), suggesting 
that the two Smads have distinct roles in the process of HSC activation. Consistently with 
this, Smad3−/− mice are much less susceptible to liver fibrosis than wild type mice 
indicating Smad3 is a main “fibrogenic mediator” in HSC (Latella et al. 2009; Cong et al. 
2012b). Smad3 is also involved in the EMT process and generation of myofibroblasts 
(Masszi and Kapus 2011). Transient overexpression of Smad7 inhibits HSC 
transdifferentiation and experimental fibrosis. However, blockade of TGF-β signaling by 
Smad7 does not decrease α-SMA expression in cultured HSC (Dooley et al. 2003). TGF-β 
also induces the expression of connective tissue growth factor (CTGF), which stimulates 
ECM production by fibroblasts, via a functional Smad3 binding site in the CTGF promoter 
(Branton and Kopp 1999; Verrecchia et al. 2010; U. E. Lee, Mstp, and Friedman 2011). 
 
TGF-β also mediates signaling by non-canonical, “non-Smad” signaling pathways via 
activation of mitogen-activated protein kinase (MAPK), Rho-like GTPase, p38 and c-Jun 
N-terminal kinases (JNKs) and phosphatidylinositol-3-kinase/AKT pathways. These 
pathways regulate EMT, apoptosis and other fibrogenic processes (Cong et al. 2012a; Y. E. 
Zhang 2009; Moustakas and Heldin 2005). 
 
IFN-γ is a well-known anti-fibrotic cytokine that inhibits collagen synthesis (Granstein, 
Flotte, and Amento 1990). Smad7 induction by IFN-γ, blocks TGF-β/Smad signaling 
pathway through Jak1 and Stat1, and prevents the interaction of Smad3 with the TGF-β 
receptor (Ulloa, Doody, and Massagué 1999). IFN-γ promotes direct interaction of Y-box-
binding protein (YB-1) with Smad3 and thus inhibits TGF-β–induced COL1A2 
transcription (Higashi et al. 2003). 
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1.6.2.6 Inflammatory signaling 
Diverse types of immune cells are implicated in the pathogenesis of LF as well as its 
resolution (Friedman 2010a).  
(1) Infiltrating neutrophils do not have or have a minimal role in LF (J. M. Saito et al. 
2003). Similarly, mast cells also have no role in the development of LF (Sugihara et al. 
1999). 
(2) HSC, like kupffer cells, express Toll-like receptors (TLR) on their surface. Activation 
by LPS upregulates IL-8 and MCP-1 gene expression and cell surface expression of ICAM-
1 and VCAM-1 via a NF-kβ-dependent pathway (Paik et al. 2003). Exposure to bacterial 
products enhances a strong inflammatory response in HSC, characterized by IL-6 and 
MCP-1 secretion, which results in the recruitment of Kupffer cells (Brun et al. 2005). The 
TGF-β pseudo-receptor BMP and the activin membrane-bound inhibitor (Bambi) is a 
transmembrane glycoprotein induced by BMP (Bone morphogenetic protein) signaling and 
functions as a negative regulator of TGF-β signaling. TLR4 signaling in HSCs 
downregulates Bambi on quiescent HSC to enhance TGF-β signaling and LF (Seki et al. 
2007; Guo et al. 2009). 
 
(3) HSC also act as antigen-presenting cells (APC) as they express molecules for antigen 
presentation (MHC-I and MHC-II) and lipid-presenting molecules CD1b and CD1c. They 
internalize macromolecules and express molecules that modulate T-lymphocyte 
proliferation (CD40 and CD80) (Viñas et al, 2003). HSC process and present antigen to 
CD8+ and CD4+ T cells and CD1-restricted natural killer T (NKT) cells (Winau et al, 
2007).  
 
(4) Kupffer cells (KC) are liver resident macrophages derived from circulating monocytes 
(R. Xu, Zhang, & Wang, 2012). KCs are involved in LF by promoting HSC activation by 
secreting TGF-β and TNF-α. In mice, depletion of macrophages or inhibition of their 
recruitment to the liver by ablation of Ccr2 inhibited LF, suggesting that macrophage 
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recruitment to the liver via CCR2 and activation of HSC are crucial for inducing LF 
(Duffield et al. 2005; Imamura et al. 2005; Seki et al. 2009; Miura et al. 2012). KCs elicit 
divergent effects on LF by promoting HSC activation during progression (mediated by 
TGF-β secretion) and by inducing HSC apoptosis via TRAIL during regression of LF 
(Friedman 2005). 
 
 (5) NK cells inhibit LF by killing activated HSC in NKG2D-dependent, tumor necrosis 
factor–related apoptosis-inducing ligand (TRAIL)-dependent mechanisms and by 
producing IFN-γ (Gao, Radaeva, and Park 2009; Radaeva et al. 2006; Notas, Kisseleva, and 
Brenner 2009; Guo and Friedman 2007). HSCs express the CXCR3 chemokine receptor, 
whose ligand CXCL10 acts as pro-fibrotic factor by preventing NK cell activity 
(Hintermann et al. 2010). NKT cells display complex roles in liver injury, inflammation 
and fibrosis (Notas, Kisseleva, and Brenner 2009). Hepatic iNKT cells show inhibitory 
activity during early stage of LF but not at the later stages (Park et al. 2009; Gao, Radaeva, 
and Park 2009). 
 
(6) CD8+ T lymphocytes promote fibrogenic activity of HSCs, whereas CD4+ T cells exert 
antifibrotic activity by stimulating NK cells via IL-2 mediated up-regulation of NKG2D 
(Safadi et al. 2004; Glässner et al. 2013). Regulatory T cells (Tregs) attenuate the anti-
fibrotic activity of NK cells against HSC via both direct cell-contact-dependent inhibition 
and by down-regulating the NK cell activating ligands on HSCs (Langhans et al. 2015). B 
lymphocytes influence the development of LF in an antibody and T-cell-independent 
manner (Novobrantseva et al. 2005). 
 
1.6.2.7 Altered matrix degradation or (MMPs and TIMPs imbalance) 
Matrix metalloproteinases (MMPs) comprise a family of 25 zinc-dependent endopeptidases 
capable of degrading components of the ECM. MMPs also act on non-ECM substrates such 
as cytokines, chemokines and play regulatory functions in inflammation and immunity 
(Giannandrea and Parks 2014). MMPs are generally secreted into the extracellular 
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environment or tethered to the cell membranes (Duarte et al. 2015). MMPs are categorized 
into different groups according to their ECM substrate specificity: collagenases, 
gelatinases, membrane-type, stromelysins and matrilysins and others (Hemmann, 
Roderfeld, and Roeb 2007). MMPs are again subdivided into groups on the basis of 
differences in domain composition (Table2).  
 
 
 
Table 2: MMPs nomenclature, their specific substrates 
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MMPs are synthesized by a wide range of cell types such as hepatocytes, HSC, Kupffer 
cells, neutrophils and recruited hepatic macrophages, and are secreted into the extracellular 
space in an inactive form called zymogen or pro-MMP (Page-mccaw, Ewald, and Werb 
2007). MMP synthesis is induced by numerous mediators, which modulate their gene 
expression. The two key regulators of MMP production are IL-1 and TGF-β (Bruschi and 
Pinto 2013). The proteolytic activation of the pro-enzyme is controlled by other MMPs and 
serine proteinases such as plasmin (Hersznyi et al. 2012).  
 
1.6.2.7.1 Tissue inhibitors of metalloproteinases (TIMPs)  
The enzymatic activities of MMPs are controlled by endogenous tissue specific inhibitors 
called tissue inhibitors of metalloproteinases (TIMPs), which are secreted proteins. Four 
types of TIMPs (TIMP-1, 2, 3 and 4) inhibit MMP activity by binding reversibly to the 
catalytic site of MMPs in a 1:1 stoichiometric ratio (Manicone and McGuire 2008). Even 
though, TIMPs are capable of inhibiting all known MMPs, they differ in their affinity for 
specific MMPs (Arpino, Brock, and Gill 2015). Alterations in the MMP–TIMP balance 
lead to different pathologies such as delayed wound healing, tissue fibrosis, angiogenesis 
and tumor invasion (Duarte et al. 2015). 
 
In the human liver, MMP-1 is the major interstitial collagenase. Until 2001, a homolog of 
MMP-1 had not been identified in rodents, MMP-13 was considered as the major 
interstitial collagenase in rodents, as it is capable of degrading type 1 collagen (Henriet, 
Rousseau, and Eeckhout 1992; Krane et al. 1996). Mmp1a, the true homolog of human 
MMP-1, discovered in 2001, demonstrates collagenase activity (Balbín et al. 2001). Several 
studies have shown that its expression is relatively low in healthy tissues but it is 
upregulated during pathological conditions (Foley and Kuliopulos 2014).  Mmp1a is 
implicated in tumorigenesis and metastasis as shown by Mmp1a knockout mice and cancer 
cell lines (Foley et al. 2012). The activation of pro MMP-1 to active MMP-1 is a two-step 
reaction, which requires initial cleavage by plasmin and second cleavage by stromelysin. 
The profibrogenic cytokine TGF-β inhibits this cleavage process thereby inhibits ECM 
degradation, leading to its accumulation (Nagase et al. 1991). 
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In the early primary culture (days 0–3), HSCs express MMP-3 (stromelysin), MMP-1, 
MMP-13 (rat) and but not TIMP-1 and TIMP-2. The expression of MMPs during the early 
phase is affected by the method of HSC isolation, serum components and the culture 
substratum (Benyon and Arthur 2001). The pattern of expression of MMPs and TIMPs 
changes with the duration of culture: stromelysin and MMP-1/MMP-13 expression are 
downregulated with a marked increase in expression of both TIMP-1 and TIMP-2 (J. 
Iredale et al. 1996).  
MMP-13 is expressed by macrophages and HSC; its expression in macrophages is 
relatively constant regardless of the stage or stimulus for activation in models of liver 
injury (John P. Iredale, Thompson, and Henderson 2013). MT1-MMP is involved in the 
conversion of pro MMP-2 to active MMP-2, and its activity is inhibited by excess TIMP-2 
(Kinoshita et al. 1998). Fibrotic livers and cultured HSC show increased expression of 
MMP-2. Collagen-I enhances MMP-2 activation but not collagen-VI (Takahara et al. 1995; 
Théret et al. 1999). Collagen-I is the ligand for descoidin domain receptor 2 (DDR2) 
expressed on activated HSC, and this interaction upregulates MMP-2 expression. In 
fibrosis, a positive feedback mechanism between MMP-2 and collagen -1 enhances the 
pathogenic process (Olaso et al. 2001). TGF-β1 differentially affect MMP expression by 
downregulating interstitial collagenase expression and upregulating expression of 
gelatinase A, TIMP-1, and collagen-I (J P Iredale 1997). 
 
1.7 Reversal of fibrosis 
It has been shown in human and animal models that LF can be reversible. The mechanisms 
of regression of LF have been extensively studied in animal models and potential targets 
for antifibrotic therapy are being defined (Ramón Bataller and Brenner, 2001). There are 
different pathways, which explain the molecular and cellular mechanisms of LF regression 
such as: 
 
Pathway 1: Cessation of underlying liver injury: In patients, reversal of liver fibrosis is 
  
27 
27 
usually achieved by removing underlying etiology factors such as viral agents (hepatitis C 
and B), alcohol, toxins and medication, or by treating the underlying disease. Treatment of 
the HBV or HCV infected patients with interferon-α or ribavirin and lamuvidines 
significantly reduces LF (Poynard et al. 2002; Alaluf and Shlomai 2016). 
 
 
Pathway 2: Transition of the intrahepatic balance from inflammation to restoration 
Recovering hepatocytes and their neighboring non-parenchymal cells alter the 
microenvironment from a pro-inflammatory milieu to resolution, so that restorative and 
anti-inflammatory mediators become dominant. During resolution, macrophages show a 
restorative phenotypic switch characterized by low expression of Ly6C in mice and high 
expression of Mmp-9, Mmp-12, growth factors (favoring hepatocyte recovery) and 
phagocytosis-related receptors (Ramachandran et al. 2012; Hammerich et al. 2014). NK 
cells induce apoptosis of activated and senescent myofibroblasts via NKG2D and TRAIL 
(Langhans et al. 2015; Notas, Kisseleva, and Brenner 2009). During chronic injury, γδ T 
cells recruited to the liver by CCR6 activation, prevent excessive inflammation and fibrosis 
by inhibiting HSCs (Hammerich et al. 2014). 
 
Pathway 3: Elimination of myofibroblasts or enhancing HSC apoptosis: Since HSC are 
the main source of ECM synthesis and the matrix degrading enzymes and their inhibitors in 
the liver, deactivation of myofibroblasts is key to fibrosis regression, which is achieved by 
senescence, apoptosis, and inactivation (Guo and Friedman 2007). 
 
Senescent, activated HSC show activation of endogenous p53, reduced secretion of ECM 
components, enhanced secretion of degrading enzymes and increased susceptibility to NK 
cell-mediated apoptosis (Krizhanovsky et al. 2008). Activated myofibroblasts are able to 
return to a quiescent phenotype (Kisseleva et al. 2012), but these cells can be re-activated to 
myofibroblasts in response to fibrogenic stimuli and contribute to LF albeit less efficiently 
(Troeger et al. 2012; Mallat and Lotersztajn 2013). 
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Integrins are important for HSC survival. Inhibiting their adhesions with either a specific 
antibody or integrin antagonizing peptide results in HSC apoptosis associated with a 
reduction in the Bcl-2/Bax ratio as well as an increase in caspase 3 activity (X. Zhou et al. 
2004; Iwamoto et al. 1999). TIMP-1 protects HSCs from apoptosis and inhibits MMP 
activity thereby favoring progression of LF (Hitoshi Yoshiji et al. 2002). Studies have 
shown that downregulation of TIMP production and administration of anti-TIMP-1 
antibody increases ECM degradation and apoptosis of HSC (Murphy et al. 2002b; Parsons 
et al. 2004). TNF-α also exerts an anti-proliferative effect on HSC and induces HSC 
apoptosis in the presence of cycloheximide, an inhibitor of protein synthesis (Kisseleva and 
Brenner 2006). Activated HSC are more susceptible to TRAIL, since these cells express 
activation-dependent TRAIL-R2/DR5 receptors (Taimr et al. 2003). INFγ also induces 
HSC apoptosis (Saile et al. 2004). NF-kβ enhances survival of HSC, inhibition of NF-kβ or 
inhibition of the inhibitor of κβ kinase (Iκβ) with sulfasalazine or the fungal toxin gliotoxin 
promotes apoptosis of HSC (Oakley et al. 2005; Wright et al. 2001). 
 
Pathway 4: Enhancing extracellular matrix degradation. Another approach for 
achieving reversibility of fibrosis is promoting the degradation of excess ECM. MMP-9 
enhances apoptosis of HSC and inhibition of this protease resulted in increased HSC 
survival (X. Zhou et al. 2004). Collagen-I also provides a survival signal for activated 
HSCs, whereas enhanced activity of collagenase and degradation of collagen-I promotes 
the recovery from LF (Issa et al. 2003; J P Iredale et al. 1998; Tacke and Trautwein 2015). 
 
1.8 Diagnosis of fibrosis 
 
Accurate assessment of LF progression is essential for treatment of the disease. The 
different diagnostic approaches currently available to assess fibrosis progression are 
discussed below. 
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1.8.1 The Liver biopsy 
The liver biopsy remains the “gold standard” method because it provides useful 
information on the current clinical status of the liver injury, allows to take a decision on 
type of therapy, and it reveals the stage of fibrosis that necessitates surveillance for 
hepatocellular carcinoma (HCC) and/or screening for viruses.  
 
This biopsy is assessed for stage and grade of the liver injury. The staging refers to the 
extent of fibrosis and the presence of cirrhosis, whereas grading defines the extent of 
necroinflammatory activity (Goodman 2007). The main determinants of inflammatory 
activity are lymphocytic piecemeal necrosis, lobular necroinflammation and portal 
inflammation, which are graded from 0 to 4 in most classification systems. The main 
determinants of fibrosis are the length in the expansion of fibrotic areas between portal 
tracts and these changes are staged as 0 to 4 in the classification systems (Calculators 2014; 
Standish et al. 2006). Even though several scoring systems are available, the most 
commonly used are French METAVIR, the Batts-Ludwig, the International Association for 
the Study of the Liver (IASL) and the Ishak Scoring systems (Afdhal and Nunes 2004). 
However, in large clinical trials the METAVIR score is more commonly used. 
 
Liver biopsy is direct, quick and has well-established staging systems (Ferrell 2013; 
Goodman 2007). It has some disadvantages such as sampling error and inter-observer 
variation among pathologists, with an average 20% error rate in assessment of fibrosis 
stage. Moreover, these diagnostic methods require frequent samplings, are expensive and 
are more fatal when compared to other  noninvasive diagnostic methods (Regev et al. 
2002). 
 
1.8.2 Noninvasive methods 
Over the past years, various non-invasive methods have become available to assess the 
severity of liver fibrosis. These are routine clinical parameters, such as physical 
examination findings, laboratory tests, radiographic tests, combinations of laboratory tests 
and specific serum markers. These methods can be divided into direct markers, indirect 
markers and imaging techniques. 
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1.8.2.1 Direct markers 
The protein products of extracellular matrix synthesis or degradation are used as direct 
markers, which reflects the activity of the fibrotic process.  
Markers of matrix deposition include procollagen I C-terminal fragment, procollagen III N-
terminal fragment, tenascin, tissue inhibitor of metalloproteinase TIMP and TGF-β. On the 
other hand, markers of matrix removal include procollagen IV C-peptide, Procollagen IV 
N-peptide (7-S collagen), collagen IV, undulin, metalloproteinase MMP, urinary desmosine 
and hydroxylysylpyridinoline. Other non-specific, direct markers are hyaluronan, laminin, 
YKL-40 (O. A. Gressner, Weiskirchen, and Gressner 2007; Afdhal and Nunes 2004). 
The FIBROSpect II is a commercially available test that combines hyaluronic acid, tissue 
inhibitor of a metalloproteinase-1 (TIMP-1), and alpha-2-macroglobulin in a predictive 
algorithm to determine the presence or absence of significant fibrosis. (Strauss 2010). 
 
1.8.2.2 Indirect markers 
Indirect markers are usually represented by algorithms, based on biochemical tests for 
markers that are commonly altered in CLD (Don C Rockey 2008). These include (1) 
Aspartate Aminotransferase-to-Platelet ratio index (APRI), (2) Forns index (combination of 
three biochemical markers AST, platelet count, and gamma globulin), (3) FT/FS (include 
age, gamma-glutamyltransferase (GGT), cholesterol, and platelet count) and (4) FibroTest 
(include patient age, gender and group of six biochemical markers associated with liver 
fibrosis: alpha-2-macroglobulin, haptoglobulin, GGT, apolipoprotein A1, total bilirubin, 
and ALT) (Denzer and Lüth 2009; Guidelines 2015; Calculators 2014). 
 
These indirect markers are safe, convenient, inexpensive, non-invasive, reflect the status of 
the entire liver and can assess severity of fibrosis. These markers are also being used in 
combination with radiological tests to increase accuracy. However, these indirect tests are 
unable to discriminate between intermediate stages of fibrosis, staging scales vary between 
studies and cost varies with combinations (Winau et al. 2007; Das and Vasudevan 2008). 
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1.8.2.3 Imaging techniques 
Imaging techniques are used to detect advanced CLD by recognizing surrogate markers of 
portal hypertension and structural changes in the liver. These are ultrasound, computed 
tomography, magnetic resonance imaging and transient elastography. They have high 
degree of sensitivity and specificity but are unable to diagnose and differentiate early stages 
of fibrosis.  
 
Transient elastography (Fibroscan) measures the elasticity or stiffness of the liver by using 
ultrasound and low frequency elastic waves and can define the extent of fibrosis without 
the need for liver biopsy. It allows diagnosis of liver cirrhosis and significant fibrosis with 
accuracy (Press 2011; Castera 2011). This cannot be used in presence of ascites, obesity 
and are less accurate in low degree of fibrosis (Denzer and Lüth 2009). 
 
Hepatic venous pressure gradient assessment (HVPG) measures presence and severity of 
portal hypertension. It is invasive and accurate in determining which patients with cirrhosis 
are at risk for decompensation, the stage at which the liver is extensively scarred and unable 
to function properly. People with decompensated cirrhosis develops symptoms like ascites, 
jaundice and complications that can be life threatening. It can be used only in patients with 
relatively advanced disease who are at risk of, or already have, portal hypertension 
(Friedman 2010b). 
 
1.9 Current therapeutic approaches to liver Fibrosis 
The various studies in understanding the cellular and molecular mechanisms involved in 
progression of LF has led to the development of new targets to treat the disease. This 
knowledge is also applicable to fibrosis of other organs such as the lung and kidneys. 
Similarly, advances in understanding the fibrogenic process in other organs are being 
evaluated in liver fibrosis. Some of the anti-fibrotic therapies being tested in experimental 
animals and in clinical trials to evaluate their safety and efficacy are discussed below.  
 
  
32 
32 
Targeting myofibroblasts and the TGF-β pathway: Pirfenidone, (Esbriet and Pirespa) 
inhibits fibroblast proliferation and it is being used as a broad antifibrotic agent for the 
treatment of LF and other fibrotic diseases (King et al. 2014). Anti-TGF-β antibodies are 
being used to treat diseases of the newborn lung (Nakanishi et al. 2007). A Human Anti-
Transforming Growth Factor-Beta (TGF-β) monoclonal antibody (fresolimumab) is also 
being explored by Genzyme (owned by Sanofi-Aventis) as a treatment for patients with 
interstitial pulmonary fibrosis (IPF) and myelofibrosis (Wynn and Ramalingam 2012). A 
humanized monoclonal antibody targeting Lysyl oxidase–like-2, an enzyme that catalyzes 
the cross-linking of collagen, is being explored by Gilead Sciences as a treatment for 
cardiac fibrosis, IPF and liver fibrosis. Bortezomib, a proteasomal inhibitor approved by the 
US Food and Drug Administration, induces apoptosis of hepatic stellate cells (Barry-
Hamilton et al. 2010). 
 
Targeting pro-inflammatory pathways is a valuable approach in situations where sustained 
inflammation is the major driving force in the development of fibrosis. IFN-γ is a well-
known antifibrotic cytokine. Experimental studies and clinical studies suggested that IFN-
γ1b is effective in patients with chronic HBV or HCV infection (H.-L. Weng et al. 2005) 
but a large clinical study showed little efficacy or no effect of IFN-γ in advanced LF 
(Pockros et al. 2007).  
 
Tyrosine kinase inhibitor imatinib mesylate (Gleevec), which inhibits PDGF receptor 
signalling, did not affect survival or lung function in patients with IPF (Daniels et al. 2010), 
while another clinical study with the tyrosine kinase inhibitor, BIBF 1120, a triple 
angiokinase inhibitor (VEGFR, PRGFR, FGFR), showed improvement in lung function in 
patients with IPF (Richeldi et al. 2011).  Ruxolitinib (NCB018424), a selective Janus 
kinase 1 (JAK1) and JAK2 inhibitor, is being used to treat myelofibrosis (Verstovsek et al. 
2010). 
 
Monoclonal antibodies against TNF-α (infliximab and etanarcept), CCL2, IL-1 and various 
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anti-inflammatory mediators, such as IL-10, Arg1, programmed death ligand-2 and Relm-α, 
or corticosteroids, to modulate the immune system, are being tested in clinical trials (Detlef 
Schuppan and Kim 2013; Wynn and Ramalingam 2012). One of the plant alkaloids used 
more commonly as a hepatoprotective agent is Silymarin, a flavonoid antioxidant extracted 
from Silybum marianum. It inhibits collagen deposition in animal models (Boigk et al. 
1997) and some clinical tests reported its positive effect in alcoholic patients with early 
stage cirrhosis (Parés et al. 1998). Anti IL-17A monoclonal antibodies that disrupt IL-17 
signaling have been shown to be beneficial for the treatment of pulmonary fibrosis (Mi et 
al. 2011). Chronic fibrotic diseases are also characterized by the excess production of IL-13 
and increased expression of IL-13–inducible genes (Hershey 2003). Lebrikizumab, a 
humanized monoclonal antibody against IL-13 was shown to be effective in a subset of 
adults with poorly controlled asthma (Scheerens et al. 2014). 
 
2.0. Suppressor of cytokine signaling proteins (SOCS) 
Binding of most cytokines and growth factors to their respective receptors leads to 
activation of several intracellular signaling cascades, which mediate different cellular 
responses, such as proliferation, differentiation, survival and functional activation. Their 
excessive signaling can lead to loss of regulation and can promote a variety of diseases. 
Such unwanted excessive signalling by cytokines is controlled by many cell intrinsic 
mechanisms. One such mechanism involves a group of proteins known as Suppressor Of 
Cytokine Signaling (SOCS), which act in a negative feedback manner (Sullivan et al. 
2007). The expression of SOCS family members induced by cytokines displays a tissue-
specific pattern (Starr, Willson, and Viney 1997; Larsen 2002) and varies with respect to 
the cell line and tissue studied (Walter and Hospital 2001).  
 
2.1 Structure of the SOCS family  
SOCS proteins are relatively small proteins of 20 to 50 kDa (Trengove and Ward 2013). 
There are eight mammalian SOCS proteins: SOCS1 to 7 and Cytokine-inducible SH2-
containing protein (CISH). Within each sub-family, pairs of SOCS proteins have similar 
structure and function: CISH/SOCS2, SOCS1/SOCS3, SOCS4/SOCS5 and SOCS6/SOCS7 
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Figure 3. The structure of SOCS family members. All SOCS family proteins contain 
a central SH2 domain and a conserved C-terminal SOCS box domain. The SH2 domain 
is lengthened by the addition of an extended SH2 sequence (ESS). The SOCS box is 
composed of the BC box and the Cul box sub-domains. The N-terminal domain is 
highly variable among SOCS proteins. SOCS1 and SOCS3 contain a unique kinase 
inhibitory region (KIR) immediately upstream of the central SH2 domain.  SOCS4 and 
SOCS5 harbor an N-terminal conserved region (NTCR).  
 
(Trengove and Ward 2013). Even though SOCS proteins are able to regulate downstream 
signaling of different receptors, studies indicate that CISH and SOCS1-3 mostly regulate 
cytokine receptor signaling (Sullivan et al. 2007) while SOCS4-7 predominantly regulate 
growth factor receptor signaling (Segatto, Anastasi, and Alemà 2011). 
 
SOCS family proteins possess three domains (Figure 4): a central Src-homology 2 (SH2) 
domain, a C- terminal domain known as the SOCS box that is highly conserved among 
SOCS proteins (Impson et al. 1999) and an N-terminal domain that is variable in length and 
sequence among SOCS family members and whose function remains largely unknown. 
SOCS proteins can be subdivided on the basis of a short (50-75 residues in CISH, SOCS1, 
2 and 3) or long N-terminal region (270-385 residues in SOCS4, 5, 6, 7) (Cooney 2002; 
Linossi et al. 2013). SOCS1 and SOCS3 also contain a conserved 12-residue sequence 
called kinase- inhibitory region (KIR) within their N-terminal region, which is responsible 
for inhibition of cytokine receptor-associated Janus kinases (JAKs) (Tamiya et al. 2016; 
Walter and Hospital 2001). SOCS4 and SOCS5 possess a highly conserved region called 
N-terminal conserved region (NTCR) within their N-terminal domain but, the role of this 
sequence is not yet known. The N-terminal domains of SOCS6 and SOCS7 are required for 
their respective nuclear translocation (Cheng, Huang, Ma, Xu, Wang, and Zhang 2016; 
Walter and Hospital 2001) 
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2.2 Functional domains of SOCS proteins 
The two main functional domains of SOCS proteins are the SH2 and the SOCS box 
domains. The central SH2 domain determines the target of each SOCS proteins.  SH2 
domain contains ∼100 amino acids with two α-helixes and seven β-strands arranged in a 
βαβββββαβ order. The SH2 domain can recognize phospo-tyrosine residues via a p-tyrosine 
binding pocket and a specificity determining region, which binds on the C-terminal side of 
the p-tyrosine (Machida and Mayer 2005). 
 
 
One 12-amino-acid stretch N-terminal to the SH2 domain, called the Extended SH2 
Subdomain (ESS), stabilizes the association of SOCS1 with the kinase activation loop of 
JAK2. An additional 12-amino-acid N-terminal segment, termed the Kinase Inhibitory 
Region (KIR), is required to inhibit JAK2 kinase activity (Yasukawa et al. 1999). The 
diversity of SOCS family functions also depends on the specificity of the SH2 domain. 
Even though, SOCS1 and SOCS-3 have a similar domain composition, SOCS1 SH2 binds 
to JAKs, while the SOCS-3 SH2 binds to receptors (Machida and Mayer 2005).  
 
The SOCS box is a 40-amino acid motif with two core interaction sites: the BC-box and the 
Cul-box. Elongin B and Elongin C bind to BC- box (Linossi and Nicholson 2012). The 
SOCS box serves to assemble the ubiquitin ligase complex through interaction with 
Elongins B and C, Cullin-5 or Cullin-2, and Rbx-1 (Kamura et al. 2004; Cheng, Huang, 
Ma, Xu, Wang, and Zhang 2016; Walter and Hospital 2001). This culling Ring Ligase 
called CRLSOCS1 promotes ubiquitination of substrate proteins bound to SOCS via the SH2 
domain or N-terminal sequences, and thereby promotes their degaradation by proteasomes 
(Figure 5). Notable SOCS1 ubiquitination substrates include the JAK kinases, cytokine 
receptor chains, p65 subunit of NF-kB, the MAL signalling adaptor of the LPS signalling 
complex and receptor tyrosine kinases such as MET (Ilangumaran, Ramanathan, and 
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Rottapel 2004; Yirui Gui et al. 2014). 
  
 
2.3 Mechanisms of Action of SOCS proteins 
The members of the Janus Kinase (JAK) family are JAK1, 2, 3 and TYK2. JAKs contain a 
FERM domain that mediates receptor association and regulates catalytic activity (Cheng, 
Huang, Ma, Xu, Wang, Zhang, et al. 2016). Binding of cytokines and growth factors to 
their receptors leads to the activation of receptor-associated Janus kinases (JAKs), which 
undergo transphosphorylation. The activated JAKs phosphorylate tyrosine residues on the 
cytoplasmic side of receptors that serve as docking sites to the SH2 domain of Signal 
Transducer and Activator of Transcription (STAT) proteins (Rawlings, Kristin, and 
Figure 4. Schematic illustration of the SOCS box domain and its function. The SH2 
domain of the SOCS protein recognizes the target protein (substrate) via its phospho-tyrosine 
(pY) residue. The SOCS protein recruits Elongin C/B (BCbox) and Cullin5 (Culin box) to its 
C-terminal SOCS-box domain and the whole complex functions as an E3 ubiquitin ligase 
called CRLSOCS.  This complex binds to RBX2 (RING-finger-domain-only protein-2) leading 
in turn to recruitment of the remaining components of an E3 ubiquitin ligase complex to 
mediate ubiquitination of target proteins and their subsequent proteasomal degradation.  
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Figure 5 JAK-STAT signaling pathway and its negative regulation by SOCS proteins: 
(A). The binding of cytokine to its receptor leads to activation of the receptor. The 
members of JAK family undergo transphosphorylation and phosphorylate the tyrosine 
residues (pY) on the cytoplasmic segment of the receptor that acts as the docking sites for 
STAT proteins. Phosphorylated STAT proteins dimerize and translocate into the nucleus to 
promote transcription of target genes, including members of SOCS family. (B) SOCS 
proteins inhibit signaling by (1) inhibiting JAK activity (2) binding to pY residues via their 
SH2 domain and competitively block the JAK- STAT signalling axis (3) Preventing 
nuclear entry of STAT molecules. (4) By conjugating ubiquitin (Ub) monomers to the 
target receptor and/or JAKs and facilitate their subsequent proteasomal degradation. 
Harrison 2004). 
There are 7 members in the STAT family (Levy and Darnell 2002). STATs are proteins 
containing amino-terminal, coiled-coil, SH2, linker, DNA binding, and transcriptional 
activation domains. The SH2 domain is required for STAT activation to dock the protein to 
tyrosine-phosphorylated receptor subunits to facilitate phosphorylation by JAKs.  STATs 
possess conserved tyrosine residues near their C-terminus, which are phosphorylated by 
JAKs. Once STATs are phosphorylated, they undergo dimerization and translocate into the 
nucleus, where they induce the transcription of their target genes including SOCS proteins 
(Harrison 2012).  
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The SOCS proteins can inhibit cytokine signaling using 3 different mechanisms, which 
vary among the SOCS family members (Nicola and Greenhalgh 2000), (Figure 3). First, by 
binding phosphotyrosines on the receptors SOCS physically block the recruitment of signal 
transducers, such as STATs, to the activated receptor. CISH, SOCS2, and SOCS3 also 
inhibit signaling via their ability to bind to phosphotyrosine residues typically on receptors, 
thereby blocking access of other SH2-containing signaling molecules (Trengove and Ward 
2013; Starr, Willson, and Viney 1997). Second, SOCS proteins can bind directly to JAKs to 
specifically inhibit JAK kinase activity. SOCS1 and SOCS3 are able to directly inhibit JAK 
kinases, binding via their KIR domain to the JAK activation loop to inhibit kinase activity 
(Atsuo Sasaki et al. 1999). Third, SOCS interact with the elongin BC complex and promote 
ubiquitination of the SOCS-interacting signalling proteins including JAKs and receptor 
chains. 
 
2.4. Functions of SOCS1 protein 
2.4.1 SOCS1 
Mouse and human SOCS1 proteins share 95–99% amino-acid identity. The mouse SOCS1 
gene encodes a protein of 212 amino acids (Starr, Willson, and Viney 1997), while human 
SOCS1 is 211 amino acids long. The SOCS1 gene lies within a large CpG island spanning 
2.5 kb (Yoshikawa et al. 2001). SOCS1 was also known as SSI-1 and JAB, when it was 
discovered in 1997 by three groups using different experimental approaches: (i) as an IL-6-
induced macrophage differentiation factor in murine monocytic leukemic M1 cells (Starr, 
Willson, and Viney 1997), (ii) as a protein named STAT-induced STAT-inhibitor (SSI), 
recognized by a monoclonal antibody directed against the STAT3 SH2 domain (Naka, 
Narazaki, and Hirata 1997) and (iii) as a protein that bound to the catalytic domain of JAK2 
in a yeast two-hybrid screen that was named JAK-binding protein (JAB) (Endo and 
Masuhara 1997).  
 
SOCS1 negatively regulates downstream signaling pathways of IFNα, IFN-γ, EPO, PRL, 
GH, LIF, TNF-α, IL-2, IL-3, IL-4, IL-6, IL-7, IL-12, IL-15, EPO, TPO, TSLP, Oncostatin 
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M (OSM) and Leptin as well as the receptors for insulin and IGF-1, and the TLRs (Walter 
& Hospital,2001). As discussed earlier, SOCS1 inhibits signaling by binding to JAK1, 
JAK2 and TYK2 and acts as a pseudosubstrate (Naka, Narazaki, and Hirata 1997; Endo 
and Masuhara 1997). Another mechanism is by proteasomal degradation of many signaling 
molecules including JAK1, JAK2, TEL-JAK2 and other substrates like the guanine 
nucleotide exchange factor VAV, insulin receptor substrate (IRS1 or IRS2) and focal 
adhesion kinase (FAK) (Piessevaux et al. 2008). 
 
2.4.1.2 Role of SOCS1 in immunity  
SOCS1 plays an important role in immunity. SOCS1-deficient mice die within 3 weeks of 
age before weaning due to fatty degeneration of the liver and infiltration of mononuclear 
cells in several organs. These mice exhibit decrease in the size of their thymus and loss of 
B lymphocytes in the bone marrow (Sciences 1998). The livers of SOCS1-deficient mice 
also show enhanced STAT1 activity and IFN-γ-inducible genes like iNOS and IRF-1 
(Alexander et al. 1999). Abnormal T cell development and elevated IFN-γ levels are 
observed in SOCS1 deficient mice, suggesting that activated T cells are the source for IFN-
γ. Hyper-responsiveness to IFN-γ signaling is the main cause of perinatal lethality in these 
mice and indicates that SOCS1 is a potent in vivo regulator of IFN-γ and T cell 
differentiation. These phenotypes were significantly reduced in IFN-γ/SOCS1 double 
knockout mice and in SOCS1 knockout mice treated with anti-IFN-γ antibodies or by 
crossing Socs1-deficient mice with RAG2-deficient animals (RAG2, recombinant 
activating gene, is a key gene in lymphoid cell maturation (Marine et al. 1999; Nicola and 
Greenhalgh 2000; Cooney 2002; Alexander et al. 1999)). T cell conditional SOCS1 null 
mice show increased CD8+ differentiation as well as increased FOXP3+ CD4+ regulatory T 
cells in the thymus (Y. Zhan et al. 2009). 
 
SOCS1 and SOCS3 play important regulatory roles in macrophages and dendritic cells 
(DCs) by modulating TLR signalling (Hanada et al. 2003; Nakagawa et al. 2002; Kinjyo et 
al. 2002). SOCS1 negatively regulates not only the JAK/STAT pathway, but also the TLR-
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NFkB pathway (Ryo et al 2003 Molecular Cell; Yoshimura et al. 2004). SOCS1 KO mice 
also show enhanced insulin signaling (Jamieson et al. 2005). SOCS1 deficiency is 
associated with inflammatory pathologies such as arthritis, where exacerbated extent of 
joint destruction and synovial inflammation are observed due to deregulated pro-
inflammatory cytokine signaling (Egan et al. 2003). Idiopathic pulmonary fibrosis is 
associated with enhanced inflammation and fibrosis, which is decreased by adenoviral 
delivery of SOCS1 (Nakashima et al., 2008). However, SOCS1 does not always confer 
protection against inflammatory or immune diseases. It has been shown that SOCS1 
transgenic mice spontaneously develop colitis, with severe intestinal inflammation due to 
impaired expression of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which is a 
negative regulator of T cell activation (A Sasaki et al. 2006). 
 
2.4.1.2 SOCS1 as a tumor suppressor 
SOCS1 is known as a tumor suppressor protein and is silenced by promoter 
hypermethylation and micro RNAs in various solid and non-solid cancers such as 
hepatocellular carcinoma (HCC), acute myeloid leukemia, glioblastoma multiforme, 
chronic myeloid leukemia (CML), breast cancer, ovarian cancer, cervical carcinogenesis 
and esophageal squamous cell carcinoma (Trengove and Ward 2013).  
Aberrant methylation of CpG islands, which silences transcription of the genes, has been 
shown to be associated with cancer. The incidence of aberrant methylation of SOCS1 was 
found in up to 65% of human primary HCC tumor samples suggesting a tumor suppressor 
role of SOCS1 (Yoshikawa et al. 2001; B. Yang et al. 2003; Nagai et al. 2002). 
Heterozygous deletion of the Socs1 gene in mice has shown enhanced carcinogenesis in a 
chemical (DEN) induced liver cancer model (T. Yoshida 2004) and confirms an antitumor 
role of SOCS1. This was subsequently confirmed in hepatocyte-specific Socs1-deficient 
mice (Yeganeh et al. 2016). Hepatitis C virus (HCV) is one of the causes of liver cancer. 
HCV core protein suppresses the expression of SOCS1 gene in human HCV-positive liver 
tissues. It is also reported that livers of HCV core protein gene transgenic mice and HepG2 
cells expressing this protein down regulate the expression of SOCS1 (Miyoshi et al. 2005). 
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In addition to CpG methylation, micro RNAs have been implicated in downmodulating 
SOCS1 expression in tumors by directly binding to 3’-UTR of SOCS1. In breast cancer, 
miR-155 exerts its oncogenic role by negatively regulating SOCS1 (S. Jiang et al. 2010). 
Similarly, miR-30d is implicated in downregulating SOCS1 expression in prostate cancer 
(Kobayashi et al. 2012). 
 
The molecular mechanisms of tumor suppression by SOCS1 are far from clear. While 
attenuation of JAK-STAT signalling would be the key mechanism in controlling 
hematologic malignancies, other mechanisms may also operate. For instance, SOCS1 
overexpression studies have reported SOCS1-mediated activation of the p53 tumor 
suppressor gene and inhibition of the paradoxical oncogenic functions of the cyclin-
dependent kinase inhibitor 1A (CDKN1A, also known as p21) or by regulating Met 
receptor tyrosine kinase signaling as a tumor suppressor in cancer cells (Mallette et al. 
2009; Warfel and El-deiry 2013; Y Gui et al. 2015; Yeganeh et al. 2016). 
2.4.1.3 SOCS1 and its role in liver fibrosis (LF) 
Cirrhotic nodules have long been considered to be premalignant lesions receding the 
pathogenesis of HCC. It has been suggested that genetic alterations accumulated during 
continuous regeneration of hepatocytes in an inflammatory milieu might lead to the 
development of HCC.  
SOCS1 gene methylation was observed more frequently in HCC derived from cirrhotic 
livers than in those HCC that were not associated with cirrhosis (Okochi et al. 2003; Ogata 
et al. 2006). Yoshida and his group studied SOCS1 gene methylation in patients with 
chronic liver diseases to determine if SOCS1 genetic alteration is involved in LF 
progression as well as in HCC (Yoshida et al., 2004). This study reported a strong 
correlation between SOCS1 gene methylation and severity of LF. They also reported that 
Socs1+/- mice developed more severe LF than control mice following administration of the 
fibrogenic agent dimethylnitrosamine (DMN) suggesting a role for SOCS1 in controlling 
LF. However, it is not known how SOCS1 regulates the development of LF. 
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THESIS PREMISES 
Liver fibrosis results from chronic damage to the liver characterized by the accumulation of 
ECM proteins, which is a typical feature of most types of chronic liver diseases. 
Continuous damage to the liver leads to the development of cirrhosis, which is associated 
with a significant mortality and morbidity. More than 90% of HCC is observed in cirrhotic 
livers (D. Y. Zhang and Friedman 2014). HCC is the 5th most common and 3rd most lethal 
cancer globally. Currently, there are a very few therapeutic options available to treat cancer.  
LF is reversible and is the final common pathological pathway of CLD regardless of its 
etiology. Therefore, understanding the cellular and molecular mechanisms involved in the 
progression of LF and development of rational antifibrotic strategies are considered the 
most promising approach in the fight against HCC. 
 
Chronic damage to the liver results in the release of various cytokines and growth factors 
from liver resident cells as well as from recruited inflammatory cells, which are 
subsequently involved in the fibrogenic process. Cytokine and growth factor signaling is 
negatively regulated by cell intrinsic endogenous molecules such as the suppressor of 
cytokine signaling (SOCS) family proteins. It has been shown that the SOCS1 gene is 
frequently suppressed in human HCC samples due to CpG methylation of its promoter 
region, suggesting an antitumor role of SOCS1 (Yoshikawa et al. 2001; B. Yang et al. 
2003; Nagai et al. 2002). Yoshida et al observed methylation of SOCS1 gene in patients 
with CLD and found a strong correlation between SOCS1 gene methylation and the 
severity of LF (Takafumi Yoshida et al. 2004). Moreover, they also reported that SOCS1 
haploinsufficient mice developed more severe LF than control mice following 
administration of the fibrogenic agent dimethylnitrosamine (DMN), suggesting a role of 
SOCS1 in the regulation of LF. Increased LF in these haploinsufficient mice was attributed 
to elevated STAT1 phosphorylation and interferon response factor 1 (IRF1) expression 
resulting from the increased IFN-γ signaling in the absence of SOCS1 (T. Yoshida 2004). 
 
SOCS1 is an important regulator of IFN-γ signaling. Several experimental and clinical 
studies have shown that IFN-γ acts as an antifibrotic cytokine, (Czaja, Weiner, and Zern 
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1989; H. L. Weng, Cai, and Liu 2001; Z. Shi, Wakil, and Rockey 1997; Hong et al. 2002; 
W. Il Jeong et al. 2006; W.-I. Jeong, Park, and Gao 2008). However, another study reported 
that IFN-γ induces fibrosis (Knight et al. 2007). Thus, to clearly understand the role of 
SOCS1 and IFN-γ in LF, and whether SOCS1-regulated fibrogenic response is dependent 
on IFN-γ or not, we used Socs1-/-Ifng-/- mice in models of chemical induction of LF.  
 
Activated hepatic stellate cells (HSC) are the prime source for ECM production in the liver 
and play an important role in fibrogenesis (Friedman 2008). Though, activation pathways 
of HSCs have been well characterized, the regulatory mechanisms are not yet known. Thus, 
it is possible that SOCS1 might control LF by regulating HSC activation. In our study, we 
also examined the role of SOCS1 in HSC activation by isolating the primary HSC from  
Socs1-/-Ifng-/-, Ifng-/- and C57BL/6 mice. 
HYPOTHESIS 
SOCS1 is a critical regulator of hepatic fibrogenic response and part of this regulation may 
occur in HSC. 
 
Objective of the study: 
The specific aims of my research project are 
1) To evaluate liver fibrosis in a Socs1-deficient mouse model. 
I. Induction of liver fibrosis with Dimethylnitrosamine (DMN) and Carbon 
tetrachloride (CCL4) 
II. Liver function test   (measure ALT enzymes levels in the serum) 
III. Gross anatomy and histopathological evaluation of the damaged liver    
(collagen deposition and accumulation of ECM) 
IV. Quantitative Measurement of Collagen in the Liver by Hydroxyproline   
Content   
V. Evaluation of inflammatory cytokines, chemokines, and fibrogenic genes 
expression  
VI. Immunohistochemical localization of α-SMA (specific marker of HSC) 
VII. Western blot evaluation of α-SMA (HSC marker), p-SMADs (TGF-β 
signaling), IL-6 and IFN-γ downstream signaling molecules. 
2. To determine the role of SOCS1 in HSC activation in vitro. 
I. Isolation of primary HSC from Socs1-deficient and control mice 
II. Proliferation of HSC cells from Socs1-deficient and control mice by 3H-
(thymidine) incorporation assays. 
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Résumé :  
Le suppresseur de la signalisation des cytokines 1 (SOCS1) est un régulateur indispensable 
de la signalisation de l'IFN-γ et a été aussi impliqué dans la régulation de la fibrose 
hépatique. Cependant, on ne sait pas si les fonctions anti-fibrotiques sont médiées 
directement dans le foie par SOCS1 ou par la modulation de l'IFN-γ, qui est connu pour son 
effet atténuateur de la fibrose hépatique. En outre, il est possible que SOCS1 contrôle la 
fibrose hépatique par la régulation des cellules stellaires hépatiques (CSH), un acteur clé 
dans la réponse fibrogénique. Alors que les voies d'activation des CSH ont été bien 
caractérisées, les mécanismes de régulation ne sont pas encore clairs. Les buts de cette 
étude étaient de dissocier la régulation de la réponse fibrogénique hépatique médiée par 
SOCS1 et celle dépendante de IFN-γ et d'élucider les fonctions régulatrices de SOCS1 dans 
l'activation des CSH. La fibrose hépatique a été induite chez des souris Socs1-/-Ifng-/- par la 
diméthylnitrosamine ou le tétrachlorure de carbone. Les souris Ifng-/- et C57BL6 ont servi 
comme contrôles. Après les traitements fibrogéniques, les souris Socs1-/-Ifng-/- ont montré 
des niveaux sériques élevés d'ALT ainsi que l'augmentation de la fibrose du foie par rapport 
à des souris Ifng-/-. Le dernier groupe a montré des niveaux plus élevés d'ALT et de fibrose 
par rapport aux souris C57BL/6 contrôles. Les foies des souris déficientes en SOCS1 ont 
montré une fibrose septale, qui a été associée à une augmentation de l'accumulation des 
myofibroblastes et à un dépôt abondant du collagène. Les foies déficients en SOCS1 ont 
montré une expression accrue de gènes codant pour l'actine musculaire lisse, le collagène et 
les enzymes impliquées dans le remodelage de la matrice extracellulaire, à savoir les 
métalloprotéinases de la matrice et l'inhibiteur tissulaire des métalloprotéinases. Les CSH 
primaires de souris déficientes en SOCS1 ont montré une prolifération accrue en réponse à 
des facteurs de croissance tels que le HGF, EGF et le PDGF. Aussi, les foies fibrotiques de 
souris déficientes en SOCS1 ont montré une expression élevée du gène Pdgfb. Pris 
ensemble, ces données indiquent que SOCS1 contrôle la fibrose hépatique 
indépendamment de l'IFN γ et qu'une partie de cette régulation peut se produire en régulant 
la prolifération des HSC et en limitant la disponibilité des facteurs de croissance. 
 
Mots clés : SOCS1, Diméthylnitrosamine, Tétrachlorure de carbone, Cellules stellaires 
hépatiques, PDGF. 
Abstract 
Suppressor of cytokine signaling 1 (SOCS1) is an indispensable regulator of IFN signaling 
and has been implicated in the regulation of liver fibrosis. However, it is not known 
whether SOCS1 mediates its anti-fibrotic functions in the liver directly, or via IFN , which 
has been implicated in attenuating hepatic fibrosis. Additionally, it is possible that SOCS1 
controls liver fibrosis by regulating hepatic stellate cells (HSC), a key player in fibrogenic 
response. While the activation pathways of HSCs have been well characterized, the 
regulatory mechanisms are not yet clear. The goals of this study were to dissociate IFN -
dependent and SOCS1-mediated regulation of hepatic fibrogenic response, and to elucidate 
the regulatory functions of SOCS1 in HSC activation.  Liver fibrosis was induced in Socs1-
/-Ifng-/- mice with dimethylnitrosamine or carbon tetrachloride. Ifng-/- and C57BL/6 mice 
served as controls. Following fibrogenic treatments, Socs1-/-Ifng-/- mice showed elevated 
serum ALT levels and increased liver fibrosis compared to Ifng-/- mice. The latter group 
showed higher ALT levels and fibrosis than C57BL/6 controls. The livers of SOCS1-
deficient mice showed bridging fibrosis, which was associated with increased accumulation 
of myofibroblasts and abundant collagen deposition. SOCS1-deficient livers showed 
increased expression of genes coding for smooth muscle actin, collagen, and enzymes 
involved in remodeling the extracellular matrix, namely matrix metalloproteinases and 
tissue inhibitor of metalloproteinases. Primary HSCs from SOCS1-deficient mice showed 
increased proliferation in response to growth factors such as HGF, EGF and PDGF, and the 
fibrotic livers of SOCS1-deficient mice showed increased expression of the Pdgfb gene. 
Taken together, these data indicate that SOCS1 controls liver fibrosis independently of 
IFN and that part of this regulation may occur via regulating HSC proliferation and 
limiting growth factor availability. 
 
Keywords: liver fibrosis; SOCS1; dimethylnitrosamine; carbon tetrachloride; hepatic 
stellate cells; PDGF. 
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Highlights 
 SOCS1 regulates hepatic fibrogenic response independently of IFN γ. 
 SOCS1 modulates the expression of matrix metalloproteinases and their inhibitors in 
the liver. 
 SOCS1 regulates hepatic stellate cell proliferation in response to growth factors. 
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1. Introduction 
Liver fibrosis (LF)1, which results from a deregulated tissue repair process, is a common 
feature of hepatitis virus infections and alcoholic liver disease [1-3]. LF also occurs in 
obesity, an important risk factor for hepatocellular carcinoma (HCC) [4]. These chronic 
inflammatory stimuli induce abnormal deposition of extra-cellular matrix (ECM), 
progressively replacing the liver parenchyma with fibrous scar tissue, leading to the end-
stage disease called cirrhosis [1, 5]. Cirrhotic livers typically harbor regenerative nodules 
wherein hepatocytes undergo compensatory proliferation to restore the declining metabolic 
functions of the liver. The increased rate of hepatocyte proliferation in an inflammatory 
milieu leads to accumulation of genetic aberrations that give rise to hyperplastic and 
dysplastic nodules, and eventually to HCC [6]. Indeed, more than 90% of HCC occurs in 
cirrhotic livers [7]. 
 
Cirrhosis is a major healthcare burden and an important cause of global mortality, while 
HCC ranks as the 5th most common and 3rd most lethal cancer worldwide [8-11].  The 
pathogenesis of HCC spans over decades and the clinical onset is so insidious that very few 
therapeutic options are available to treat HCC [12]. On the other hand, the fibrogenic 
process that precedes cirrhosis is amenable to treatment, although the current therapeutic 
methods have not yet achieved the desired objective [7, 13, 14]. A greater understanding of 
the cellular and molecular underpinnings of liver fibrosis and HCC, and the normal 
regulatory controls of these pathogenic processes will accelerate the efforts to develop 
effective and targeted therapies for LF, cirrhosis and HCC [1, 7, 12, 15-17]. 
 
 
                                                 
1  Abbreviations: ALT, alanine transferase; CCl4, carbon tetrachloride; DMN, 
dimethylnitrosamine; ECM, extra-cellular matrix; GBSS, Gey's Balanced Salt Solution; 
HCC, hepatocellular carcinoma; HSC, hepatic stellate cells; LF, Liver fibrosis; MMP, 
matrix metalloproteinase; NDP, nanazoomer Digital Pathology; RTK, receptor tryrosine 
kinase; SOCS, suppressor of cytokine signaling; SMA, alpha smooth muscle actin; TIMP, 
tissue inhibitors of MMP. 
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Cytokines and growth factors play crucial roles in hepatic fibrogenesis and compensatory 
proliferation of hepatocytes following liver damage [18-20]. An important regulatory 
mechanism of cytokine and growth factor signaling involves feedback inhibition by the 
suppressor of cytokine signaling (SOCS) family proteins [21-24]. The SOCS1 gene is 
frequently repressed by epigenetic CpG methylation in up to 65% of HCC [25, 26], 
suggesting a tumor suppressor role of SOCS1 in the liver. This notion is supported by 
increased susceptibility of Socs1+/- mice to experimental HCC [27] and suppression of the 
SOCS1 gene by hepatitis C virus [28].  
 
SOCS1 is also implicated in controlling LF. Indeed, methylation of the SOCS1 gene 
correlates with fibrosis and cirrhosis in human HCC [27, 29, 30]. Yoshida et al., have 
reported that Socs1+/- mice developed more severe LF than control mice following 
administration of the fibrogenic agent dimethylnitrosamine (DMN) [27]. This study did not 
use Socs1-/- mice as they die within two weeks after birth due to uncontrolled IFN  
signaling in the liver, necrosis of hepatocytes and fatty degeneration of the liver, all of 
which could be prevented by administration of neutralizing anti-IFN  antibody or by 
deleting the Ifng gene [31, 32]. Yoshida et al., correlated the increased liver fibrosis in 
Socs1+/- mice to elevated STAT1 phosphorylation and interferon response factor 1 (IRF1) 
expression [27], presumably resulting from increased IFN  signaling in the absence of 
SOCS1. However, IFN  has also been shown to protect against liver fibrosis and ablation 
of the Ifng gene exacerbates liver fibrosis induced by DMN or carbon tetrachloride (CCl4) 
[33-37]. In agreement, mice lacking STAT1 developed accelerated CCl4-induced liver 
fibrosis, and the protective function of STAT1 was attributed to inhibition of HSC 
proliferation and stimulation NK-cell-mediated killing of HSCs [38]. In contrast to these 
reports, IFN  has been shown to exacerbate liver fibrosis in mice fed with choline-
deficient, ethionine-supplemented diet via enhancing hepatic progenitor cell response [39]. 
 
In the light of the above reports, increased hepatic fibrosis observed in Socs1+/- mice with 
intact Ifng gene is untenable with the protective functions of IFN , which ought to be more 
efficient in these mice. Given that SOCS1 is an indispensable regulator of IFN  signaling 
[31, 32], it is also possible that SOCS1 haplo-insufficiency might have exacerbated the pro-
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fibrogenic role of IFN  [39] in the absence of one Socs1 allele. Alternatively, the 
protective functions of IFN  may be mediated by SOCS1, requiring both alleles for 
efficient control of the fibrogenic response. Lastly, SOCS1 may be induced to exert its anti-
fibrogenic functions independently of IFN , probably by regulating other pro-fibrogenic 
pathways. To test these possibilities, we studied chemical-induced liver fibrosis in the 
absence of both alleles of SOCS1 without the influence IFN  by using Socs1-/-Ifng-/- 
mice in two different liver fibrosis models. As controls, we used Ifng-/- and C57BL/6 mice. 
Our findings show that SOCS1 is a critical regulator of hepatic fibrogenic response and that 
part of this regulation may occur in HSCs. 
 
2. Material and Methods 
2.1. Animals 
Socs1-/-Ifng-/- and Ifng-/- mice in C57BL/6 background have been previously described [40]. 
Only male mice were used to induce HCC due to the protective effects of female sex 
hormones [41]. All experimental protocols on animals were carried out with the approval of 
the Université de Sherbrooke Animal Ethics Committee. 
 
2.2. Induction of liver fibrosis 
Liver fibrosis was induced in 8-10 week-old mice by intra-peritoneal injection of DMN or 
CCl4 following published methods [27, 42] (Fig. 1A). Briefly, DMN (Supelco, Bellefonte, 
PA; Cat #48552) was administered via intra-peritoneal (i.p) route (10 g/g body weight) 
every 2-3 days for three weeks. CCl4 (Sigma-Aldrich, Oakville, ON; 0.5 l/g body weight) 
was diluted in corn oil (1:2) and injected i.p. twice a week for five weeks.  Treated mice 
were sacrificed three or four days after the last treatment.  Serum samples and liver tissues 
were collected. Parts of the livers were fixed in buffered formalin or snap frozen and stored 
at -80oC until use.  
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2.3. Gene expression analysis 
RNA was extracted using RiboZol™ (AMRESCO, Solon, OH) and reverse transcribed 
using QuantiTect Kit (Qiagen).  RNA purity was evaluated by UV absorption and RNA 
quality was tested by denaturing formaldehyde-agarose gel electrophoresis. The first 
complementary strand was made from 1µg total RNA using QuantiTect® reverse 
transcription kit (Qiagen). The primers for gene expression analysis (Supplementary Table 
1) showed 90-100% efficiency and a single melting curve in the MyQi5® cycler (Bio-Rad, 
Mississauga, ON). Expression levels of the housekeeping gene Gapdh was used to 
calculate fold induction of the specific genes modulated by the presence or absence of 
SOCS1. 
 
2.4. Histology and immunohistochemistry 
Liver tissues were fixed in 10% buffered formalin and embedded in paraffin. 5µM thick 
liver sections were deparaffinized, rehydrated, and stained with hematoxylin and eosin 
(H&E), Sirius red or Mason’s trichrome stains following standard histochemical protocols. 
For immunohistochemistry of alpha smooth muscle actin (SMA), rehydrated liver sections 
were immersed in citrate buffer (pH 6.0) and microwaved intermittently for 10 min to 
retrieve antigenic epitopes. Slides were incubated in 3% hydrogen peroxide for 10min to 
eliminate endogenous peroxidase activity. After blocking with 5% BSA in Tris-buffered 
saline (TBS) containing 20% Tween-20 (TBS-T), the slides were incubated with mouse 
anti-SMA Ab (Abcam) at 4˚C overnight before applying horseradish peroxidase (HRP)-
conjugated secondary Ab for 1h and developed with 3, 3’-diaminobenzidine (Sigma-
Aldrich). The sections were counterstained with hematoxylin and mounted with a coverslip. 
Digital images of the stained sections were acquired using a Nanozoomer Slide Scanner 
and analyzed by the Nanozoomer Digital Pathology software (Hamamatsu Photonics, 
Japan). The NIH ImageJ software was used to quantify Sirius red staining and the SMA-
positive areas.  
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2.5. Hydroxyproline assay 
Hydroxyproline content was measured following published methods with slight 
modifications [43, 44]. Approximately 10 mg of liver tissue was homogenized in 1ml of 6N 
HCl using the bead mill MM 400 (Retsch, Hann, Germany), transferred to screw-capped 
glass tubes and topped up with 2ml of 6N HCl.  The tubes were kept on a heat block at 
110oC for 16 hours in a fume hood to hydrolyze proteins into amino acids. The hydrolysate 
was filtered through Whatman #1 filter paper, aliquots were evaporated on the heat block 
and the pellet was dissolved in 50% 2-propanol. Samples and hydroxyproline standards 
were distributed in a 96-well microtiter plate, and oxidized by adding chloramine T reagent 
(Sigma-Aldrich; dissolved in 50% isopropanol and adjusted to pH 6.5 with acetate/citrate 
buffer) and incubating for 25min at room temperature. Following the addition of Ehrlich 
reagent (p-dimethylaminobenzaldehyde dissolved in n-propanol/perchloric acid (2:1)), the 
chromophore was developed by incubating the samples at 50oC for 10min. Absorbance was 
read at 550nm using a spectrophotometer and the results were expressed as micrograms of 
hydroxyproline per gram of liver tissue. 
 
2.6. Serum ALT level and ELISA 
Serum alanine transferase (ALT) levels were measured using a kinetic assay (Pointe 
Scientific Inc, Brussels, Belgium). Serum IL-6 and TNF-α levels were measured by 
sandwich ELISA, using capture and detection Ab from BD Pharmingen Biosciences (San 
Diego, CA). 
 
2.7. Western blot 
Liver tissues were homogenized in a pH8.0 buffer containing 150mM NaCl, 50mM Tris-
HCl, 1mM EDTA and protease and phosphatase inhibitor coctails (Roche, Indianapolis, 
IN) for 2min using the bead mill MM 400 (Retsch, Hann, Germany). Equal volume of the 
same buffer containing the detergents 0.2% SDS, 1% Triton X- 100 and 1% sodium 
deoxycholate was added and the lysates were kept on a shaker at 4oC for 30min. Following 
centrifugation at 15000g for 20min, the supernatant was collected and protein concentration 
determined using the RC-DC Protein Assay Kit (Bio-Rad, Mississauga, ON). Aliquots of 
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30-50µg proteins were analyzed by western blot using Ab listed in Supplementary Table 2.  
Secondary antibodies and enhanced chemiluminescence reagents were from GE Healthcare 
Life Sciences (Pittsburg, PA). Western blot images were captured by the VersaDOC 5000 
imaging system (Bio-Rad). 
 
2.8. Hepatic stellate cell isolation and proliferation assay 
HSCs were isolated following published methods [38, 45].  Briefly, 12-16 week-old mice 
were anesthetized with an i.p. injection of a mixture of Ketaset® (100mg/kg, Wyeth) and 
Xylazine (10mg/kg, Rompun®, Bayer). The liver was first perfused with calcium-free 
Gey's Balanced Salt Solution (GBSS) containing 0.5mM EGTA at the rate of 7ml/min 
through the inferior vena cava. The liver was then digested by perfusion with collagenase 
type IV (100U/ml, Worthington, Lakewood, NJ) in GBSS supplemented with CaCl2 
(1.8mM). The liver was resected into a culture dish, the capsule was removed and minced 
to release the cells into medium. The cell suspension was filtered through 70 m nylon 
mesh and centrifuged at 500rpm (60g) for 5min three times to remove hepatocytes. The 
supernatant was centrifuged at 1600rpm (600g) for 10min at 4oC. After one washing step, 
the pellet was resuspended in 4 ml of 20% of Optiprep, 5ml of 11.5% Optiprep was gently 
overlaid and topped with 2ml of GBSS. The density gradient was centrifuged at 3000rpm 
for 17min without brake and stellate cells that collect at the interface of 11.5% optiprep and 
GBSS were centrifuged at 1600rpm for 10min at 4oC. The cells were washed in DMEM 
containing 20% fetal bovine serum (FBS) and cell number and viability were assessed by 
Tryptan blue exclusion. The cells were plated at a density of 1x105 cells/well in uncoated 6-
well tissue culture dishes and examined by phase contrast microscopy for the presence of 
lipid droplets and by fluorescence microscopy for auto-fluorescence from their vitamin A 
content. 
 
To assess cell proliferation, HSCs were resuspended in serum-free DMEM and plated in 
96-well flat bottom microtiter plates in the presence of the indicated growth factors (PDGF, 
EGF, TGF-β, HGF - 10ng/ml) and cytokines (IL-6, TNF-α - 10ng/ml) purchased from 
R&D systems (Minneapolis, MN) or Peprotech (Ricky Hill, NJ). One Ci of methyl-[3H]-
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thymidine (NEN Life Sciences, Boston, MA) was added during the last 18h of the 72h 
culture period and the incorporated radioactivity measured as described elsewhere [40]. 
 
2.9. Statistical Analysis 
Data were analyzed using the GraphPad Prism (San Diego, CA). Statistical significance 
was calculated by ANOVA or Mann-Whitney test, and p values <0.05 were considered 
significant. 
 
3. Results 
3.1. Fibrogenic treatment induces intrahepatic mononuclear cell infiltration in SOCS1-
deficient mice  
To evaluate the effect of SOCS1 deficiency on hepatic fibrogenic response, we first used 
the DMN-induced liver fibrosis model. Unlike Socs1+/- mice, which showed more than 
50% mortality following DMN injection [27], three weeks of DMN treatment did not cause 
mortality in Socs1-/-Ifng-/- mice. These mice did not show any overt illness, and their serum 
ALT levels were not significantly elevated compared to Ifng-/- and C57BL/6 control mice at 
the end of the treatment regimen (Fig. 1B). However, all groups of mice showed increased 
ALT levels after one week of DMN treatment that subsided after three weeks of exposure. 
Examination of the liver sections at the end of the treatment period by H&E staining did 
not reveal noticeable damage to the micro-architecture in the livers of Socs1-/-Ifng-/- mice 
compared to the control mice (Fig. 1C). However, the SOCS1-deficient livers showed 
marked mononuclear cell infiltration around the portal triads and the central vein, which 
was not observed in the livers of control mice following DMN treatment. 
 
We also examined liver fibrosis induced by CCl4, which has certain advantages over the 
DMN-induced fibrosis model [17]. DMN, which induces hemorrhagic centrilobular 
fibrosis, also displays mutagenic properties that could confound the fibrogenic response. 
This issue is not a concern with CCl4, which induces reversible centrilobular fibrosis. 
Besides, CCl4-induced fibrosis is more reproducible in C57BL/6 mice, which are in 
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general less susceptible to liver fibrosis [34]. In contrast to DMN treatment, serum ALT 
levels at the end of the CCl4 treatment regimen was significantly elevated in all three 
genotypes of the mice examined, and there was no significant difference between SOCS1-
deficient and control mice (Fig. 1B). However, similarly to DMN, CCl4 induced marked 
mononuclear cell infiltration in SOCS1-deficient livers compared to controls, albeit to a 
lesser extent than DMN (Fig. 1C). Collectively, these results indicated that SOCS1 
deficiency exacerbated the inflammatory response in the liver cause by fibrogenic stimuli. 
 
3.2. SOCS1 deficiency increases the expression of inflammatory cytokines and 
chemokines in the liver and the circulating levels of IL-6 and TNF-α 
SOCS1 is an important regulator of macrophage activation by TLR ligands and cytokine-
dependent control of T lymphocyte homeostasis [21, 23]. Therefore, we examined whether 
the mononuclear cell infiltration in the livers of DMN- or CCL4- treated mice is associated 
with an increased inflammatory response. As shown in Fig. 2A, the transcript levels of 
inflammatory cytokines IL-6 and TNF-α were significantly elevated in SOCS1-deficient 
livers following DMN or CCl4 treatment. Accordingly, SOCS1 deficient mice showed 
increased levels of IL-6 and TNF-α in the peripheral circulation (Fig. 2B). Even though the 
induction of Il6 and Tnfa genes in the livers of DMN- or CCl4- treated mice was 
comparable, the circulating levels of IL-6 and TNF-α were markedly elevated in CCl4-
treated mice compared to DMN-treated mice. 
 
CCL-2 (macrophage chemotactic protein 1), a chemokine secreted by HSCs and 
hepatocytes in fibrotic livers, is the principal mediator of monocyte influx into the inflamed 
liver [46]. The Ccl2 gene was strongly induced by both DMN and CCl4, and SOCS1-
deficient livers showed significantly high Ccl2 gene expression compared to control mice 
(Fig. 2A). In contrast to serum ALT levels, which were increased to a comparable extent in 
Socs1-/-Ifng-/- and Ifng-/- mice following CCl4 treatment, hepatic Il6, Tnfa and Ccl2 gene 
expression and circulating IL-6 and TNF  levels were significantly higher in Socs1-/-Ifng-/- 
mice than in Ifng-/- mice. These results indicate that the absence of SOCS1 in the liver 
induces a strong inflammatory response that can occur independently of IFN-α. 
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3.3. SOCS1 deficient mice show increased hepatic fibrosis following chemical injury 
Next, we examined liver sections by Sirius red staining to assess the extent and pattern of 
collagen deposition in the fibrotic livers. As shown in Fig. 3A, livers of Socs1-/-Ifng-/- mice 
showed markedly strong fibrosis compared to Ifng-/- and C57BL/6 mice. Ifng-/- mice 
showed discernibly more fibrosis than C57BL/6 controls. While Socs1-/-Ifng-/- mice showed 
extensive portal fibrosis with the formation of septa around many hepatic lobules, 
resembling the F2 stage fibrosis [47, 48], septal involvement was considerably less in Ifng-/- 
mice. Similar results were obtained following fibrosis induction with CCl4, which induced 
more pronounced fibrosis and produced more consistent results than DMN (Fig. 3A, 
bottom row). Moreover, CCl4 induced extensive septa formation in Socs1-/-Ifng-/- mice, 
resembling the F3 stage fibrosis. Quantification of the Sirius red staining area showed 
significantly more fibrosis in Socs1-/-Ifng-/- mice than in Ifng-/- mice (Fig. 3B). Mason’s 
trichrome staining recapitulated the results of Sirius red staining with similarly high level of 
collagen deposition in Socs1-/-Ifng-/- mice compared to control mice (Fig. 3C). 
 
We quantified total collagen deposition in the liver parenchyma by measuring the 
hydroxyproline content of the fibrotic liver tissues (Fig. 4). Consistent with the 
histochemical staining data, the livers of Ifng-/- mice contained significantly more collagen 
than C57BL/6 mice. These results are in agreement with the anti-fibrotic role of IFN  in 
DMN- or CCl4- induced hepatic fibrosis models [33-37]. However, Socs1-/-Ifng-/- mice 
contained significantly more collagen than the livers of Ifng-/- mice (Fig. 3B). Collectively, 
the above results show that SOCS1 exerts a potent anti-fibrotic role in the liver, 
independently of IFN .  
 
3.4. SOCS1 deficient livers show increased accumulation of myofibroblasts and 
fibrogenic gene expression 
During liver fibrosis, HSCs and other liver-resident and recruited mesenchymal cells 
become activated and differentiate into myofibroblasts that produce ECM [49]. To study 
the collagen-producing myofibroblats, we examined the liver sections of DMN- or CCl4- 
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treated mice by immunohistochemistry for smooth muscle actin (SMA), a marker of 
activated HSCs and myofibroblats. Consistent with the histochemical staining of collagen 
fibers, the livers of Socs1-/-Ifng-/- mice showed more abundant SMA positive cells than the 
livers of Ifng-/- and C57BL/6 mice (Fig. 5A, 5B), indicating an important role for SOCS1 in 
controlling the differentiation and activation of collagen-producing myofibroblats. 
 
To further characterize the SOCS1-dependent control the hepatic fibrogenic response, we 
studied the expression of Acta2, Col1a1, Col3a1 genes coding for SMA and the fibrillar 
collagens I and III, respectively [50]. As shown in Fig. 6A, the expression of Acta2, Col1a1 
and Col3a1 was significantly elevated in the livers of Socs1-/-Ifng-/- mice, showing 2-3-fold 
higher induction than control mice. Induction of these genes was 3-6 fold more pronounced 
in CCl4-induced fibrosis than in DMN-induced fibrosis, in agreement with more severe 
fibrosis in the former model (Fig. 2). The key pro-fibrogenic cytokine gene Tgfb was also 
more strongly induced in the livers of Socs1-/-Ifng-/- mice than in Ifng-/- mice in both DMN 
and CCl4 models. Strikingly, the induction of Acta2, Col1a1, Col3a1 and Tgfb genes was 
only marginally increased in Ifng-/- mice compared to wildtype mice. 
 
3.5. Expression of genes coding for matrix remodeling are differentially regulated by 
SOCS1  
In parallel to assessing the collagen genes, we quantified the expression of genes coding for 
enzymes involved in remodeling the extracellular matrix (ECM), namely, matrix 
metalloproteinases (Mmp1, Mmp2, Mmp3, Mmp9) and tissue inhibitors of MMPs (Timp1 
and Timp2). While TIMP-1 and TIMP-2 play a pro-fibrogenic role, the MMPs may exert 
pro- or anti-fibrotic roles at different stages of fibrosis [51, 52]. The expression of Timp1 
and Timp2 genes was significantly higher in the livers of Socs1-/-Ifng-/- mice than in Ifng-/- 
mice in both DMN and CCl4 models (Fig. 6B). Ifng
-/- mice showed only marginal or 
negligible increase in expression of these genes compared to C57BL/6 controls. The 
expression of MMP genes showed profound variability. Mmp1 was expressed at a 
significantly lower level in Socs1-/-Ifng-/- mice than in Ifng-/- mice in both DMN and CCl4 
models. Mmp2 was marginally increased in SOCS1-deficient livers, and this increase was 
significant only in the DMN-induced fibrosis model. Strikingly, the expression of Mmp3 
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and Mmp9 in SOCS1-deficient livers was differentially modulated in the two models (Fig. 
6B), with a significant decrease in the DMN-induced model, but an increase in the CCl4 
model. Similar to the collagen genes, IFN  deficiency alone caused only moderate, non-
significant changes in the expression of the ECM remodeling genes. These results indicated 
that SOCS1 exerts a more critical control over the induction of fibrogenic genes than 
IFN . 
 
3.6. Fibrotic livers of SOCS1 deficient mice show increased phosphorylation of STAT3 
and Smad3  
Increased DMN-induced hepatic fibrosis observed in Socs1 heterozygous mice has been 
correlated to elevated STAT1 phosphorylation, increased IRF-1 expression and decreased 
STAT3 activation [27]. Previously, IFN  was shown to be the key cytokine in inducing 
STAT1 activation in the ConA-induced model of hepatitis [36]. Therefore, we examined 
phosphorylation of STAT1 and STAT3 in Socs1-/-Ifng-/-, Ifng-/- and control mice following 
the DMN and CCl4 regimens. The DMN-treated Socs1-/-Ifng-/- mice did not show elevated 
STAT1 activation in the liver, but showed increased STAT3 phosphorylation compared to 
both Ifng-/- and C57BL/6 controls mice (Fig. 7A).  Ifng-/- mice showed the same level of 
STAT3 phosphorylation in the liver as C57BL/6 control mice, but showed appreciable 
reduction in STAT1 phosphorylation, in agreement with the absence of IFN .  
Phosphorylation of AKT, which occurs downstream of cytokines and growth factors in 
hepatocytes, was not significantly different among the three groups of DMN-treated mice. 
In agreement with increase fibrosis and SMA staining, the livers of SOCS1 deficient mice 
showed increased levels of SMA and showed elevated Smad3 phosphorylation, which is 
the key signaling protein downstream of the fibrogenic cytokine TGF-β.  These results 
indicated that unlike in other models, fibrosis induction in SOCS1-deificient is associated 
with elevated STAT3 activation. 
 
3.7. SOCS1 controls hepatic stellate cell proliferation 
Elevated levels of Tgfb transcripts (Fig. 6A), increased Smad3 phosphorylation (Fig. 7A), 
and increased proportion of SMA-staining cells (Fig. 5) in SOCS1-deficient livers in the 
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two fibrosis models suggested that quantitative increase in HSC numbers and their 
increased responsiveness to fibrogenic cytokines may underlie the severe hepatic fibrosis 
observed in these mice. Pathogenesis of liver fibrosis is associated with HSC proliferation, 
which can occur in response to several growth factors such as PDGF, FGF, EGF, and TGF-
β that signal via receptor tryrosine kinases (RTK) [53, 54]. Cytokines such as IL-6 and IL-4 
may also induce HSC proliferation directly or indirectly. In recent years, several reports 
have shown that several SOCS proteins including SOCS1 regulate not only JAK-STAT 
signaling, but also control signaling via RTKs [24]. We have shown that SOCS1 regulates 
HGF signaling via its receptor c-MET [40, 55]. Therefore, we evaluated proliferation of 
primary HSCs isolated from SOCS1-deficient and control mice in response to growth 
factor and cytokine stimulation. HSCs from both Socs1-/-Ifng-/- and Ifng-/- mice showed 
significantly higher proliferation to PDGF than control cells. SOCS1 deficient HSCs also 
showed increased proliferation to EGF, TGF-β and HGF as well as IL-6.  
 
Next, we examined the induction of PDGF gene expression in the livers following 
the DMN or CCl4 treatment. As shown in Fig. 8B, the livers of Socs1-/-Ifng-/- mice showed 
significantly higher expression of the Pdgfb gene than Ifng-/- and C57Bl/6 mice. Together, 
these results suggest that SOCS1 may regulate hepatic fibrogenic response, at least partly, 
by controlling the proliferation of HSCs and indirectly by limiting the availability of 
growth factors. 
 
Discussion 
Pathogenesis of liver fibrosis involves chronic injury to hepatocytes, release of 
inflammatory mediators and activation of HSCs, Kupffer cells and lymphocytes. Many 
cytokines and growth factors induced during this inflammatory response impact the 
pathogenesis of liver fibrosis in a very complex, inter-connected manner. Specific gene 
knockout mice have shed light on the complex signaling pathways and control mechanisms 
in liver fibrosis. SOCS1 and SOCS3, which are important feedback negative regulators of 
many cytokines and growth factors, are implicated in hepatic fibrogenic response. 
However, the molecular mechanisms by which SOCS proteins control liver fibrosis remain 
unclear. Using two chemically-induced liver fibrosis models, here we show that (i) SOCS1 
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limits liver fibrosis, (ii) SOCS1 deficiency differentially affects the expression of ECM 
remodeling enzymes and (iii) the anti-fibrotic functions of SOCS1 occurs, at least partly, in 
HSCs.  
 
Our results clearly show that SOCS1 deficiency exacerbates the hepatic fibrogenic 
response in an IFN -independent manner. Yoshida et al., correlated the increased 
susceptibility of Socs1+/- to DMN-induced liver fibrosis to STAT1 activation and IRF1 
expression, and reduced STAT3 activation [27]. This idea was supported by an earlier 
study that showed a pathogenic role for STAT1 and a protective role for STAT3 in the 
ConA–induced hepatitis model [36]. This study showed that IFN-γ, produced by CD4+ T 
cells and NKT cells, activated STAT1, induced IRF1 and Bax, and promoted apoptosis of 
hepatocytes, while STAT3 activation downstream of IL-6 induced Bcl-xL and reduced 
hepatocyte injury caused by IFN  [36]. Contrary to these reports, increased liver injury in 
Socs1-/-Ifng-/- mice occurred in the absence of elevated STAT1 activation but in the 
presence of increased Il6 gene expression, elevated serum IL-6 levels and increased STAT3 
phosphorylation in the liver following DMN or CCl4 treatment.  
 
The elevated STAT1 activation reported in the livers of Socs1+/- mice following 
DMN treatment most likely results from deregulated IFN  signaling due to the limited 
availability of SOCS1. Even though DMN or CCl4-induced liver damage does not usually 
result in extensive T cell and NKT cell activation and IFN  production as in the case of 
ConA-induced hepatitis [56], the lack of SOCS1 may exacerbate the basal IFN  signaling 
that may be induced in these mice with intact Ifng alleles. Indeed several studies have 
shown a pro-fibrotic effect of IFN  and STAT1 in DMN or CCl4 –induced fibrosis [33-
38]. Our finding that Socs1-/-Ifng-/- mice develop severe liver fibrosis despite the absence of 
IFN  and an appreciable increase in STAT1 activation highlight the critical requirement of 
SOCS1 to control pro-fibrogenic pathways that can occur independently of IFN  or 
STAT1 activation. Besides, our findings indicate that SOCS3, which is also implicated in 
attenuating liver fibrosis [30], does not compensate for the loss of SOCS1, and that these 
two SOCS proteins may target distinct fibrogenic mechanisms. 
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The roles of STAT1 and STAT3, their main activators IFN-γ and IL-6, and their 
major regulators SOCS1 and SOCS3, respectively, have been extensively studied in the 
context of hepatitis, fibrosis and HCC [reviewed in [56]]. In this work, Gao and colleagues 
highlighted the dichotomous roles of STAT3 activation and IL-6 in liver injury, hepatic 
inflammation and fibrosis, and modulation of their functions in model-, cell-, and context- 
dependent manner. While STAT3 in hepatocytes confers protection against liver injury and 
fibrosis, it may play a pro-fibrogenic role in HSCs by promoting their survival and 
production of TIMP-1, and in Kupffer cells by increasing TGF-β production [57-59]. 
Similarly, while IL-6 protects hepatocytes from injury that may account for its anti-fibrotic 
role reported in some studies, several lines of evidence support a pro-fibrotic role of IL-6 
by promoting HSC survival and proliferation [56]. Given that the livers of Socs1-/-Ifng-/- 
mice show increased expression of Il6, Tgfb and Timp1 genes following DMN or CCl4 
treatment, it is likely that the extensive fibrosis seen in these livers may result from 
increased IL-6-induced STAT3 activity. In agreement with this possibility, increased 
fibrosis in DMN-treated, hepatocyte-specific SOCS3-null mice has been attributed to 
increased STAT3 activation [30]. 
 
The increased expression of Timp1 and Timp2 in the livers of Socs1-/-Ifng-/- mice 
may also contribute to the exacerbated fibrogenic response in these mice. Both Timp-1 and 
Timp-2 promote fibrosis by inhibiting degradation and clearance of the fibrotic matrix 
[reviewed in [60]]. Besides, they may directly contribute to fibrosis by promoting survival 
of HSCs. As in the case of IL-6 and Stat3, Timp-1 seems to exert a dichotomous role in 
liver fibrosis. While an early study using transgenic model showed a pro-fibrogenic role for 
Timp-1, a recent study using Timp1-null mice showed an anti-fibrotic function [61, 62]. 
The latter study proposed that Timp-1 might promote liver fibrosis via stimulating HSC 
survival, while its anti-fibrotic function may occur via attenuating hepatocyte injury. Given 
the increased SMA positive staining (Fig. 5) and the quantity of SMA (Fig. 7) in the livers 
of DMN- or CCl4- treated SOCS1-null livers, it is likely that Timp-1 might have 
contributed to the survival of HSCs and their activation to myofibroblats in these mice, in 
addition to blocking ECM degradation. 
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A collective analysis of the roles of MMPs in liver, lung and kidney fibrosis models 
have clearly shown that MMPs exert both inhibitory and stimulatory activities in tissue 
fibrosis [52].  The physiological roles of MMPs include not only ECM remodeling, but also 
diverse other functions such as generation of bioactive ligands that act in autocrine and 
paracrine manner to module cell survival, proliferation, differentiation and migration [63]. 
In the liver, HSCs are the major source of MMPs [64]. Even though MMPs can cleave 
diverse collagens and other ECM substrates in vitro, whether all such activities occur in 
vivo is not yet clear. The in vivo biological activities of MMPs are influenced by their 
differential expression at different stages of fibrosis progression and resolution, and their 
ability to degrade the normal ECM versus the interstitial, fibrillar collagens that accumulate 
during fibrosis [50, 52, 64, 65]. While MMP-1 and MMP-2 are implicated in anti-fibrotic 
roles, MMP-3 is and MMP-9 (which is related to MMP-2) are implicated in promoting 
fibrosis [52]. While MMP-1 promotes degradation of collagen matrix, MMP-2 is 
implicated suppressing collagen-I expression, both contributing to the resolution of fibrosis 
[52, 60]. Consistent with these functions, Mmp1 expression is drastically diminished in the 
fibrotic livers of SOCS1 deficient mice, while Mmp2 was not significantly altered 
compared to control livers (Fig. 6B). Few studies have addressed the role of MMP-3 and 
MMP-9 in liver fibrosis. MMP-9 is an important mediator of leukocyte recruitment in acute 
liver injury [60]. A recent study showed that induction of miR155, which represses SOCS1, 
increased the expression of MMP-9 in HCC cells lines and increased their invasive 
potential [66]. Intriguingly, MMP-9 is differentially regulated in DMN- and CCl4-induced 
fibrosis in the livers of SOCS1-null mice (Fig. 6B). The significance of this differential 
expression in the two models, both of which initiate the fibrogenic response by inducing 
centrilobular necrosis, remains to be studied. Similarly, understanding the potential 
contribution of SOCS1-dependent modulation of cytokine and growth factor signaling to 
the induction of MMPs in liver fibrosis requires further investigation. 
 
SOCS1 may exert direct control over the survival, proliferation and activation of 
hepatic stellate cells induced by growth factors that signal via RTKs [53, 54]. Even though 
SOCS molecules were originally discovered as feedback regulators of JAK-STAT 
signaling, accumulating evidence has shown their importance in regulating RTKs [24]. In 
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keeping with that, we have shown that SOCS1 attenuates HGF signaling in hepatocytes 
[40, 55]. Increased proliferation of SOCS1 deficient HSCs in response to many growth 
factors that signal via RTKs (PDGF, TGF-β, EGF and HGF), and increased expression of 
Pdgfb gene in the fibrotic livers of SOCS1-deficient mice suggest control of HSC 
proliferation and limiting the availability of growth factors are important mechanisms by 
which SOCS1 exerts its anti-fibrotic function. 
 
Recent studies have shown that Sorafenib, which inhibits the RAF kinase 
downstream of many RTKs as well as their own enzymatic activity, displays a marked anti-
fibrotic effect in vivo and this effect has been correlated to decreased HSC proliferation and 
collagen production [67, 68]. Repression of the SOCS1 gene by promoter methylation 
frequently occurs in human liver fibrosis, and the frequency of methylation correlates 
positively with the severity of disease [27]. Even though various approaches such as DNA 
demethylases, gene therapy, peptide mimics, protein transfer, microRNA are being tested in 
various experimental disease settings, their optimization and use in human trials are still far 
from realization. Given that Sorafenib is an FDA approved drug, and that SOCS deficiency 
promotes HSC proliferation and fibrogenic gene expression in the mouse models, we 
propose that liver fibrosis patients with SOCS1 promoter methylation may benefit from 
Sorafenib therapy. 
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Figure legends 
Figure 1. SOCS1 deficiency does not worsen liver damage caused by chemical injury, but 
promotes mononuclear cell infiltration. (A) Induction of liver fibrosis using 
dimethylnitrosamine (DMN) or carbon tetrachloride (CCl4). (B) Serum ALT levels in 
SOCS1-deficient and control mice following DMN or CCl4 treatment. Data shown are 
mean  standard error of mean (s.e.m). Mann-Whitney test: * p < 0.05. ** p < 0.01.  (C) 
Representative hematoxylin and eosin-stained sections of the livers collected at the end of 
the DMN or CCl4 treatment regimens. Magnified images depict mononuclear cell 
infiltration in SOCS1-deficient livers. Bars are 100 M. 
 
Figure 2. SOCS1 deficiency increases the expression of inflammatory cytokine and 
chemokine genes in the liver and the circulating levels of IL-6 and TNF-α (A) Real-time 
PCR quantification of Il6, Tnfa and Ccl2 transcripts in the livers of SOCS1-deficient and 
control mice following DMN or CCL4 treatment. Fold induction was calculated by 
comparing the level of expression in treated mice versus untreated control mice within the 
same group. Mean  s.e.m values from 6-8 mice per group are shown. (B) Levels of IL-6 
and TNF-α in the peripheral blood of DMN- or CCL4- treated mice at the time of sacrifice. 
Numbers of mice in each group are indicated within parentheses. Data shown are mean  
s.e.m. Mann-Whitney test: * p < 0.05, ** p < 0.01, *** p < 0.005. 
 
Figure 3. SOCS1 deficient mice show increased hepatic fibrosis following chemical 
injury. (A) Representative images of Sirius red-stained sections of the livers from SOCS1-
deficient and control mice at the end of the DMN or CCl4 treatment regimen. (B) 
Quantification of the Sirius red-stained areas of collagen deposition.  Nanozoomer Digital 
Pathology software was used to select 20 random fields from 4 mice in each group, and the 
Sirius red staining area was quantified using the NIH Image J software. Data shown are 
mean  s.e.m. Statistical significant between the groups are shown over the bar graphs. 
Statistical significance between treated and control groups are shown in the right panel. 
Mann-Whitney test: * p < 0.05, ** p < 0.01, *** p < 0.005. (C) Representative images of 
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the liver sections from the above groups of mice following Masson’s trichrome staining of 
collagen fibers. 
 
Figure 4. Increased collagen deposition in SOCS1-deficient mice following the induction 
of fibrogenesis. Liver tissues from control and SOCS1-deficient collected at the end of the 
DMN or CCl4 treatment regimens were hydrolysed in acid and the hydroxyproline content 
was assessed by spectrophotometry. Data shown are mean  s.e.m values from 5-6 mice per 
group. Mann-Whitney test: * p < 0.05, ** p < 0.01, *** p < 0.005. 
 
Figure 5. SOCS1-deficient livers show increased accumulation of myofibroblasts and 
fibrogenic gene expression. (A) Immunohistochemical staining of a-smooth muscle actin 
(SMA)-positive myofibroblasts in liver sections from SOCS1-deficient and control mice 
following DMN or CCl4 treatment. Representative images from four mice per group are 
shown. (B) Quantification of the SMA-staining.  For each group, 20 digital images from 4 
mice were analyzed as detailed in Fig. 3B. Data shown are mean  s.e.m. Statistical 
significant between the groups are shown over the bar graphs. Statistical significance 
between treated and control groups are shown in the right panel. Mann-Whitney test: * p < 
0.05, ** p < 0.01, *** p < 0.005, *** p < 0.0001. 
 
Figure 6. SOCS1 deficiency profoundly modulates the expression of genes involved in 
hepatic fibrogenesis. Induction of genes involved (A) in the fibrogenic response and (B) in 
the modulation of the extracellular matrix, in the livers of SOCS1-deficient and control 
mice following DMN or CCL4 treatment. Fold induction was calculated by comparing the 
level of expression in treated mice versus untreated control mice within the same group. 
Mean  s.e.m values from 6-10 mice per group are shown. Mann-Whitney test: * p < 0.05, 
** p < 0.01, *** p < 0.005, n.s. not significant. 
 
Figure 7. Fibrotic livers of SOCS1 deficient mice show increased phosphorylation of 
STAT3 and Smad3. Total lysate of SOCS1-deficient and control livers following the 
induction of hepatic fibrosis were evaluated for the phosphorylation and expression of the 
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indicated proteins. Results from one untreated control (C) and three treated mice (+) for 
each group are shown. 
 
Figure 8. Hepatic stellate cells from SOCS1 deficient mice show increase proliferation 
in response to growth factor stimulation. (A) Primary hepatic stellate cells isolated from 
SOCS1-deficient and control mice were cultured in the presence of the indicated cytokines 
or growth factors and cell proliferation was evaluated by tritium-labeled thymidine 
incorporation assay. Cumulative data (mean + s.e.m.) from two different experiments 
carried out in triplicates are shown. (B) Expression of the Pdgfb gene was evaluated by 
qRT-PCR in the DMN- or CCl4- treated livers of SOCS1-deficient and control mice. 
Cumulative data from 6-8 mice per group are shown. Mann-Whitney test: * p < 0.05, ** p 
< 0.01, n.s. not significant. 
  
74 
74 
C
B
A
DMN (10mg/g BW, i.p.) 
CCl4 (0.5ml/g BW, 1:2 in corn oil, i.p.) Serum, Liver
Serum, Liver
1 3 5 8 10 12 15 17 19 22
Week 3Week 2Week 1
1Day
Day
4 118 1815 22 25 29 32 36
Week 3 Week 4 Week 5Week 2Week 1
Kandhi et al., Fig.1
0
50
100
150
200
A
L
T
 (
IU
/L
)
Untreated 1 week 2 weeks 3 weeks
DMN
*
*
*
Untreated CCl4 
(3 weeks)
0
50
100
150
200
A
L
T
 (
IU
/L
)
**
*
*
U
n
tr
e
a
te
d
D
M
N
C
C
l4
Wildtype Socs1-/-Ifng-/-Ifng-/-
Wildtype
Ifng-/-
Socs1-/-Ifng-/-
100mM
  
75 
75 
Kandhi et al., Fig.2
B
A
Wildtype
Ifng-/-
Socs1-/-Ifng-/-
T
N
F
a
  (
p
g
/m
l)
T
N
F
a
  (
p
g
/m
l)
IL
-6
  (
p
g
/m
l)
IL
-6
  (
p
g
/m
l)
***
*
*
*
*
**
Vehicle
(n/gr) (4) (7-8)
Vehicle
(n/gr) (4) (7-8)
0
1000
2000
3000
4000
0
200
400
600
800
0
100
200
300
400
0
500
1000
1500
0
0
2
4
6
0
1
2
3
4
5
Il6 Tnfa Ccl2
0
5
10
15
0
2
4
6
8
0
2
4
6
0
5
10
15
**
*
*ns
**
*
*
**
*
*
**
*
*
*
*
*
*
DMN
CCl4
DMN CCl4
**
**
**
*
F
o
ld
 i
n
d
u
c
ti
o
n
  
76 
76 
B
C
A
Kandhi et al., Fig.3
%
 S
ir
iu
s
 r
e
d
s
ta
in
in
g
 a
re
a
0
20
40
60
****
**
*
****
***
**
DMN CCl4Control
S
ir
iu
s
 R
e
d
M
a
s
s
o
n
’s
 t
ri
c
h
ro
m
e
C
o
n
tr
o
l
D
M
N
 
C
C
l4
Wildtype Socs1-/-Ifng-/-Ifng-/-
500mM
Ifng-/- Socs1-/-Ifng-/-
250mM
Wildtype
C
o
n
tr
o
l
D
M
N
 
C
C
l4
Wildtype
Ifng-/-
Socs1-/-Ifng-/-
***
*******
** **
***
Control vs 
DMN CCl4
  
77 
77 
 
Kandhi et al., Fig. 4
Wildtype
Ifng-/-
Socs1-/-Ifng-/-
***
*
**
H
y
d
ro
x
y
p
ro
lin
e
(m
g
/g
 l
iv
e
r 
ti
s
s
u
e
)
DMN CCl4
0
10
20
30
40 **
**
*
Control 
  
78 
78 
Wildtype Ifng-/- Socs1-/-Ifng-/-
c
o
n
tr
o
l 
D
M
N
 
C
C
l 4
Wildtype
Ifng-/-
Socs1-/-Ifng-/-
0
10
20
30
**
**
****
********
**
*
* *
*
*
**
%
 S
M
A
 s
ta
in
in
g
 a
re
a
Untreated 
Control vs 
DMN
DMN
CCl4
CCl4
Kandhi et al., Fig. 5
B
A
100mM
  
79 
79 
Kandhi et al., Fig.6 B
A
F
o
ld
 i
n
d
u
c
ti
o
n
F
o
ld
 i
n
d
u
c
ti
o
n
F
o
ld
 i
n
d
u
c
ti
o
n
ns
0
1
2
3
4
*
*
Wildtype
DMN
Ifng-/-
Socs1-/-Ifng-/-
1
0
2
3
4
5
**
**
*
ns
**
ns
ns
0
2
4
6
8
10
Mmp1
Mmp9
Acta2
Col3a1
Timp1
Timp2
**
**
ns
ns
2
0
4
6
8
1
0
2
3
1
0
2
3
*
*
*
*
0
1
2
3
4
0
1
2
3
4 *
**
0
1
2
3
4
0
1
2
3
4
0
5
10
15 **
*
ns
ns
ns
ns
ns
ns
CCl4
DMN CCl4
0
5
10
15
**
**
ns
Tgfb
2
0
4
6
8
**
*
ns
20
0
40
60
80 **
*
ns
1
0
2
3
4
5 **
*
ns
20
0
40
60
80
*
*
ns
Mmp3
10
2
0
4
6
8
**
*
ns
0
5
10
15 *
*
ns
Col1a1
5
0
10
15
20
25 **
*
***
Mmp2
1
0
2
3
ns
ns
ns
  
80 
80 
  
81 
81 
 
Kandhi et al., Fig.8
None IL-6PDGF HGFEGF TNFaTGFa
0
200
400
600
800
[3
H
]-
 t
h
y
m
id
in
e
 in
c
o
rp
o
ra
tio
n
  (
c
 p
 m
)
0
1
2
3
4
5
Pdgfb
0
2
4
6*
ns
**
*
*
F
o
ld
 i
n
d
u
c
ti
o
n
Wildtype
Ifng-/-
Socs1-/-Ifng-/-
DMN CCl4
****
****
****
**
**
**
B
A
  
82 
82 
Tables 
Supplementary Table 1: List of qRT-PCR primers used in this study. 
Gene 
name 
Gene ID Sense primer Anti-sense primer Amplicon 
 Size 
Acta2 NM_007392.3 AGTAATGGTTGGAATGG GTGTCGGATGCTCTTCAGG 166 
Col1a1 NM_007742.4 CTCCCAGAACATCACCTATC
AC 
ACTGTCTTGCCCCAAGTTCCG 171 
Col3a1 NM_009930.2  AAGTCAAGGAGAAAGTGGT
CG 
CAGTCTCCCCATTCTTTCCAG 158 
Il6 NM_031168.2  AGTCCGGAGAGGAGACTTC
A 
TTGCCATTGCACAACTCTTT  112 
Ccl2 NM_011333.3 CAGGTCCCTGTCATGCTTCT GTGGGGCGTTAACTGCAT  73 
Mmp1a NM_032006.3  TGTTGCTTCTCTGGGCTG                     TCATCTCCTTGCCATTCACG  132 
Mmp2 NM_008610.2 CAAGTTCCCCGGCGATGTC TTCTGGTCAAGGTCACCTGTC 152 
Mmp3 NM_010809 GATGAACGATGGACAGAGG
ATG 
AAACGGGACAAGTCTGTGG 130 
Mmp9 NM_013599.3 GATCCCCAGAGCGTCATTC CCACCTTGTTCACCTCATTTTG 129 
Pdgfb NM_011057.3 CCTGCAAGTGTGAGACAGTA
G 
CTTTCGGTGCTTGCCTTTG 127 
Tgfb1 NM_011577.1 ATACGCCTGAGTGGCTGTCT CTGATCCCGTTGATTTCCA 129 
Timp1 NM_011593.2 TTGCATCTCTGGCATCTGG TGGTCTCGTTGATTTCTGGG 136 
Timp2 NM_011594.3 CAGGAAAGGCAGAAGGAGA
TG 
GATCATGGGACAGCGAGTG 130 
Timp4 NM_080639.3 TTAAAGGGTTCGAGAAGGC
C 
TTCCATCACTGAGAATCTGGC 132 
Tnfa 
Gapdh 
NM_013693.3 
NM_001289726.1  
CGTCGTAGCAAACCACCAA
G 
ATGACATCAAGAAGGTGGT
GAA  
GAGATAGCAAATCGGCTGAC
G 
GTCTTACTCCTTGGAGGCCAT
GT 
190 
246 
 
Gene names 
Acta2, Actin, alpha 2 
Col1a1, Collagen, type 1, alpha 1 
Col3a1, Collagen, type 3, alpha 1 
Il6, Interleukin-6 
Ccl2, Chemokine (C-C motif) Ligand 2 
Mmp1a, Matrix metalloproteinase 1a 
Mmp2, Matrix metalloproteinase 2 
Mmp3, Matrix metalloproteinase 3 
Mmp9, Matrix metalloproteinase 9 
Pdgfb, Platelet-derived growth factor, beta polypeptide 
Tgfb1, Transforming growth factor, beta 1 
Timp1, Tissue inhibitor of matrix metalloproteinase 1 
Timp2, Tissue inhibitor of matrix metalloproteinase 2 
Tnfa, Tumor necrosis factor alpha 
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Gapdh, Glycerolaldehyde-3-phosphate dehydrogenase 
Supplementary Table 2: List of antibodies used in this study. 
Molecule Company   Cat. #        
ERK1   Santa Cruz Biotechnology    sc-93 
ERK2   Santa Cruz Biotechnology     sc-153 
p-ERK  Cell Signaling Technology #4695 
α-SMA  Abcam   #7817 
Smad-3 Cell Signaling Technology #9513  
p-Smad-3 Cell Signaling Technology #9520 
Stat1   Santa Cruz Biotechnology sc-592 
p-Stat1 (Y701)Cell Signaling Technology #9171 
Stat3   Santa Cruz Biotechnology sc-483 
p-Stat3 (Y705) Cell Signaling Technology #9131 
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4. DISCUSSION 
Cirrhosis is a pathological condition that results from chronic damage or scarring of the 
liver and is the end stage of liver fibrosis. It leads to cancer and is associated with 
significant morbidity and mortality. Cirrhosis is irreversible whereas fibrosis can be 
reversible, and thus is an important focus of HCC research. Fibrosis is the result of chronic 
inflammation characterized by excess deposition of extracellular matrix rich in collagen, 
produced by activated hepatic stellate cells. Chronic damage to the liver results in 
hepatocyte apoptosis and necrosis, recruitment of inflammatory cells, and release of 
cytokines and growth factors by liver resident and infiltrated cells resulting in activation of 
hepatic stellate cells into fibrogenic myofibroblasts. 
 
Cell intrinsic regulatory molecules such as SOCS1 control cytokine and growth factor 
signaling. It has been extensively documented that the SOCS1 gene is frequently repressed 
or silenced by methylation of the CpG islands on its promoter region in HCC and other 
cancers, suggesting an antitumor role of SOCS1. Besides, in patients with CLD, the SOCS1 
gene is silenced during fibrotic stages and there is a strong correlation between SOCS1 
gene methylation and advancement of liver fibrosis (Takafumi Yoshida et al. 2004). 
Yoshida et al, showed for the first time, the antifibrotic role of SOCS1 by using SOCS1 
heterozygous mice. They suggested that increased fibrosis observed in these mice was due 
to increased IFN-γ signaling and activation of the downstream signaling molecules STAT1 
and IRF1 (T. Yoshida 2004). However, numerous experimental and clinical studies have 
reported that IFN-γ exerts antifibrotic functions (H. Weng et al. 2007; W. Il Jeong et al. 
2006; Bansal et al. 2014; Ancini et al. 1996). Hence, we carried out this study in Socs1-
deficient mice also lacking IFN-γ to clearly understand the mechanism by which SOCS1 
regulates liver fibrosis. 
 
Using two chemically induced liver fibrosis models we showed that 1) SOCS1 is a critical 
regulator of hepatic fibrogenic response that does not necessarily require IFN-γ to exhibit 
its antifibrotic functions. 2) A part of this SOCS1 regulation may be mediated by 
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controlling cytokines and growth factor responses of HSC and 3) SOCS1 differentially 
regulates the expression of ECM remodeling enzymes. 
4.1 SOCS1 deficiency does not facilitate hepatocytes damage, but enhances hepatic 
inflammation 
Alanine transaminase (ALT) is an enzyme present in hepatocytes. Upon damage, it is 
released into the blood, which can be used as an indicator to assess the extent of liver 
damage. Following treatment with DMN and CCl4, we observed increased ALT levels in 
the serum of mice with all three genotypes when compared to that of vehicle-treated mice. 
However, we did not notice any statistical difference between Socs1-deficient mice and 
control groups at the end of the treatment indicating that the absence of SOCS1 does not 
worsen DMN- or CCl4-induced hepatocyte damage. 
 
In contrast, Yoshida et al., have shown that mortality rate and serum ALT levels were 
higher in DMN treated Socs1+⁄- mice and suggested that increased liver damage is observed 
in these mice due to elevated expression of STAT1 and pro-apoptotic factor IRF-1. Other 
studies also demonstrated the same by using hepatocyte-specific Socs1 conditional 
knockout mice (Torisu et al. 2008; T. Yoshida 2004). But, this is not the case in our study, 
suggesting that at least part of the liver damage caused by DMN is mediated by increased 
sensitivity of SOCS1 deficient hepatocytes to IFN-γ, which was absent in our model of 
Socs1-/-Ifng-/- mice. 
 
Histological analysis of H&E-stained liver sections showed that the overall morphology of 
the liver was not affected, but infliltration of inflammatory cells was seen in the livers of 
Socs1-/-Ifng-/- mice following treatment with DMN and CCl4 (Fig.1C). In addition to this, 
Socs1-deficient mice also showed increased mRNA and protein levels of inflammatory 
cytokines like IL-6 and TNF-α, suggesting that SOCS1 deficiency enhances hepatic 
inflammation (Fig 2A, 2B). IL-6 and TNF-α are proinflammatory cytokines that come from 
different cellular sources including macrophages, Kupffer cells, T-cells, endothelial cells, 
fibroblasts, and hepatocytes. These cells could all be the cause of increased inflammatory 
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cytokines levels noticed in Socs1-deficient mice livers. However, the type of cells 
infiltrating into the livers of Socs1-/-Ifng-/- mice following liver damage needs to be further 
characterized by using flow cytometry or by immunohistochemical staining (IHC) for 
Ly6G (neutrophils), CD3 (T cells), CD68 (macrophages) and B220 (B cells). 
 
CCL2 (MCP-1) is a chemokine secreted by hepatocytes, HSC and biliary epithelial cells, 
which has been shown to recruit monocytes, macrophages, neutrophils and T-cells to the 
site of injury (Wasmuth, Tacke, and Trautwein 2010). It has been demonstrated that the 
inhibition of MCP-1 results in reduced infiltration of hepatic macrophages and decreased 
intrahepatic levels of pro-inflammatory cytokines (TNF-α, IFN-γ, and IL-6) in the injured 
liver (Baeck et al. 2012). Moreover, mice with a targeted deletion of its receptor CCR2, 
which is expressed on monocytes/macrophages, HSC and Kupffer cells, displayed reduced 
liver fibrosis in CCl4 and bile duct ligation (BDL) models of liver fibrosis (Miura et al. 
2012; Baeck et al. 2012; Seki et al. 2009). Accordingly, the livers of Socs1-deficient mice 
showed increased Ccl2 (Mcp-1) gene expression compared to those of control mice in both 
models (Fig.2A). This may be the reason for enhanced mononuclear cells infiltration and 
increase in IL-6 and TNF-α levels in the livers of Socs1-/-Ifng-/- mice. From these 
observations, we suggest that the absence of SOCS1 induces a strong inflammatory 
response in the liver. 
 
4.2 SOCS1 regulatory function occurs independently of IFN-γ 
Cytokine signaling is stringently regulated by the SOCS family of proteins. Among them, 
SOCS1 is relatively skewed towards controlling STAT1, whereas SOCS3 towards 
regulating STAT3 (Kinjyo et al. 2002; Croker et al. 2002; Yasukawa et al. 2003). Yoshida 
et al., have reported that increased liver fibrosis observed in Socs1+⁄- mice is due to elevated 
STAT1 and pro-apoptotic factor IRF-1 expression as well as reduced STAT3 activation (T. 
Yoshida 2004). The increased STAT1 activation reported in the livers of Socs1+/- mice 
following treatment with DMN most likely results from deregulated IFN-γ signaling due to 
the limited availability of SOCS1. An earlier study using ConA-induced hepatitis model 
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also demonstrated that IFN-γ produced by CD4+ T-cells and NKT cells increased STAT1 
activation, IRF1, and Bax, which induced apoptosis of hepatocytes, whereas STAT3 
downstream of IL-6, protected hepatocytes from injury by inhibiting IFN-γ signaling and 
by induction of anti-apoptotic protein Bcl-xl (Hong et al. 2002).  
 
In contrast to these reports, several studies have demonstrated that IFN-γ and its 
downstream signaling molecule STAT1 are one of the most important negative regulators 
of liver fibrosis. It has been shown in rodents that IFN-γ inhibits liver fibrosis induced by 
carbon tetrachloride (CCl4) or dimethylnitrosamine by inducing apoptosis of HSC (D C 
Rockey, Maher, et al. 1992; Ancini et al. 1996). IFN-γ also stimulates the cytotoxicity of 
NK cells against activated HSC by increasing the number of NK cells and upregulating 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on NK cells (Radaeva et 
al. 2006; W. Il Jeong et al. 2006). Further, clinical studies have shown that IFN-γ treatment 
attenuates liver fibrosis in hepatitis B (HBV) and HCV patients (Muir, Sylvestre, and 
Rockey 2006; H.-L. Weng et al. 2005; H. L. Weng, Cai, and Liu 2001). IFN-γ did not 
suppress HSC activation in Stat1-deficient cells and failed to inhibit liver fibrosis in CCl4-
treated Stat1−/− mice, suggesting that the antifibrogenic effects of IFN-γ are mediated by 
STAT1 (W. Il Jeong et al. 2006). Besides, IFN-γ and STAT1 are reported to inhibit HSC 
activation by inhibiting TGF-β/Smad signaling via increasing expression of Smad7 (Ulloa, 
Doody, and Massagué 1999). Taken together, these studies suggest that IFN-γ exerts its 
antifibrotic functions via STAT1. 
 
In our study, we observed increased liver damage and fibrosis in Socs1-/- Ifng-/- mice 
without a significant change of STAT1 activation or IFN-γ signaling suggesting that 
SOCS1-mediated hepatoprotection or antifibrogenic response does not require IFN-γ or 
STAT1 activation. Besides, SOCS3, which is also implicated in inhibiting liver fibrosis 
(Ogata et al. 2006) did not compensate for the loss of SOCS1 suggesting that mechanisms 
by which SOCS1 and SOCS3 mediate their hepatoprotective activities are likely different. 
In fact, we observed increased Il6 gene expression, elevated serum IL-6 levels and 
increased STAT3 phosphorylation in Socs1-deficinet mice following DMN or CCl4 
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treatment. While STAT3 in hepatocytes confers protection against liver injury and fibrosis, 
it may play a pro-fibrogenic role in HSCs by promoting their survival and production of 
TIMP-1, and in Kupffer cells by increasing TGF-β production (Cao 2003; J P Iredale et al. 
2010; J. X. Jiang et al. 2009). Therefore, our results clearly indicate that SOCS1 deficiency 
exacerbates the hepatic fibrogenic response in an IFN-γ-independent manner and that it 
may involve other mediators such as IL-6 (discussed in detail below). 
 
4.3 SOCS1 deficiency is associated with enhanced fibrosis 
Infiltrated immune cells and ongoing inflammation sustain the development of fibrosis. 
Since fibrosis is characterized by increased deposition of collagen, we have performed 
Sirius red and Masson's trichrome staining for liver tissue sections and quantified deposited 
collagen. We showed increased collagen deposition in the form of portal fibrosis with few 
septa (referred to as F2 stage) in DMN-treated Socs1-deficient livers, while CCl4 treated 
Socs1-deficient livers exhibited more severe fibrosis characterized by portal bridging 
fibrosis (F3 stage) compared with that of the control mice (Fig 3,4). Further, Socs1- 
deficient mouse livers also showed increased expression of collagen genes (Col1a1 and 
Col3a1) (Fig 6A) and hydroxyproline levels (Fig 4) compared to Ifn-γ-/- and control mice. 
Our results are consistent with a previous study showing that SOCS1 insufficiency is 
associated with fibrotic changes in the liver (Takafumi Yoshida et al. 2004). 
 
Socs1-deficient mouse livers also showed increased activation of myofibroblasts, which are 
the main source of collagen (Fig 5A, 5B). It has been demonstrated that fibroblasts from 
idiopathic pulmonary fibrosis (IPF) patients produce an excess of collagen due to the 
diminished expression of SOCS1, which has also been shown by using Socs1-deficient 
mouse fibroblasts. They also suggested that IFN-γ mediated inhibition of IL-4-induced 
collagen synthesis is mediated partly via SOCS1 (Shoda et al. 2007). The same group 
suggested that SOCS1 inhibits pulmonary inflammation and fibrosis using SOCS1 
heterozygous mice (Nakashima et al. 2008). Similar to their reports, in liver fibrosis, 
cytokine-induced modulation of SOCS1 might regulate the activation of hepatic stellate 
cells or myofibroblasts and their collagen synthesis. 
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4.3.1 IL-6 ⁄ STAT3 and fibrosis 
Several cytokines and growth factors are known to activate myofibroblasts, and deregulate 
collagen gene expression in liver fibrosis. In particular, IL-6 and TGF-β are known to act as 
profibrotic cytokines. However, the role of IL-6 and its downstream signalling mediator 
STAT3 in liver fibrosis is controversial. The function of STAT3 in liver inflammation and 
fibrosis is cell type-specific and model-dependent. STAT3 shows protective and 
proliferative functions in hepatocytes and a protective role in liver fibrosis (Taub 2003; H. 
Wang, Lafdil, Kong, et al. 2011; Deng et al. 2013). In contrast to these reports, other 
studies have demonstrated the opposite (pro-fibrotic) role of STAT3 in HSC. It has been 
shown that inhibition of the STAT3 pathway enhances apoptosis of HSC (J. X. Jiang et al. 
2009) and HSC–specific STAT3 null mice mice are less susceptible to fibrosis (Meng et al. 
2012). Accordingly, leptin and IL-6, the major activators of STAT3 in HSC, increase 
collagen mRNA expression during liver fibrosis (Saxena et al.,2002). IL-6 has also been 
shown to increase the expression of a-SMA and collagen in pancreatic stellate cells (Mews 
et al. 2002).  
 
A recent study has found a correlation between IL-6 levels, p-STAT3 and liver fibrosis in 
HBV patients and demonstrated that Sorafenib shows antifibrotic effect through STAT3 
inhibition in HSC (Su et al. 2015). Consistent with these findings, we also observed 
increased expression of IL-6 mRNA levels and protein levels and p-STAT3 in SOCS1 
deficient livers in both DMN and CCl4 models. We speculate that IL-6 secreted from 
inflammatory cells or HSC themselves leads to hyperactivation of STAT3 in the absence of 
SOCS1 and promotes liver fibrosis by activating HSCs via paracrine and autocrine 
mechanisms. In addition, Socs1-deficient HSC showed increased proliferation in response 
to IL-6 (Fig 8A). In agreement with this possibility, increased fibrosis in DMN-treated 
hepatocyte-specific Socs3-null mice has been attributed to increased STAT3 activation 
(Ogata et al. 2006). The absence of SOCS1 in all cells (resident and recruited) of the liver, 
in our model, might lead to deregulated production of IL-6 from diverse cellular sources 
and activation of IL-6 downstream STAT3 signaling pathway. Although STAT3 signaling 
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can have a cell-dependent positive or negative effect on the development of fibrosis, the 
absence of SOCS1 in all cells might have tilted the net balance towards fibrosis. Further 
studies are required to understand the role of SOCS1 and STAT3 in hepatic stellate cells, 
Kupffer cells, sinusoidal cells, and inflammatory cells in the development of liver fibrosis. 
This can be addressed by using cell-specific Socs1-/- or Stat3-/- mice. Since SOCS1 is a 
negative regulator of IL-6 signaling, the absence of SOCS1 may enhance activation of 
stellate cells and collagen expression through STAT3 pathway. This possibility could be 
addressed by using Socs1-deficient HSC or by inhibiting or silencing STAT3 in HSC. 
 
4.3.2 TGF-β ⁄ Smad3 and fibrosis 
Numerous studies have demonstrated the pathogenic role of TGF-β in fibrotic diseases. 
Fibrotic diseases are often associated with increased levels of TGF-β, which inhibits ECM 
degradation by downregulating the expression of MMP and upregulating the expression of 
TIMP-1 (K. Jeong 2008; Dooley and Dijke 2012) TGF-β is known to be involved in 
proliferation and transdifferentiation of HSC into myofibroblasts in various tissues in vivo 
(Leask and Abraham, n.d.; A. M. Gressner 1996). It has been demonstrated in experimental 
animals that progression of LF can be prevented by the blockade of TGF-β signaling (Yata 
et al. 2002) whereas, the overexpression of TGF-β1 in a transgenic model inhibited HSC 
apoptosis and induced synthesis of excessive amounts of matrix proteins (Kanzler et al. 
1999).  
 
TGF-β mainly mediates its signaling through Smad-dependent and independent pathways. 
It has been shown that Smad3-/- mice are less susceptible to LF than wild type mice 
suggesting that Smad3 is a main “fibrogenic mediator” (Latella et al. 2009; Cong et al. 
2012b). Consistent with these reports, in our study, we have demonstrated that Socs1-
deficient mice showed increased expression of TGF-β, and its downstream signaling 
molecules p-Smad-3, collagen genes, TIMP-1 and fibrosis, compared to control mice. 
Based on these findings, we postulate that SOCS1 may play an essential role in regulating 
TGF-β production by diverse cells of the liver and/or its signalling in HSC. Further studies 
using cell-spcific Socs1 KO mice will elucidate how SOCS1 deficiency contributes to the 
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enhancement of the TGF-β pathway in hepatic fibrosis.  
 
A crosstalk between IL-6 and TGF-β has been demonstrated in various models of fibrosis. 
Importantly, Ogata first revealed that TGF-β is a target gene of STAT3 and STAT3 
enhances hepatic fibrosis through upregulation of TGF-β in hepatocytes and in liver 
fibrosis model in mice (Ogata et al. 2006). It has been reported using primary HSC and 
diethylnitrosamine (DEN)-induced rat fibrosis model that STAT3 enhances liver fibrosis 
through up-regulation of TGF-β and fibrotic product expression, this has also been reported 
in chronic hepatitis B (CHB) patients, (M.-Y. Xu et al. 2014).  
 
Il6-/- mice have decreased levels of TGF-β and reduced fibrosis in models of lung fibrosis 
(F. Saito et al. 2008). IL-6 trans signaling drives a STAT3-dependent pathway that leads to 
hyperactive TGF-β signaling (O’Reilly et al. 2014). However, IL-6 can also mediate 
pulmonary fibrosis independently of Smad3-dependent pathways through hyperactivation 
of STAT3 (O’Donoghue et al. 2012). In keloid scar tissue, and in cultured keloid 
fibroblasts the blockade of JAK2 inhibited phosphorylation of STAT3 and reduced 
collagen levels, cell proliferation and migration suggesting that JAK–STATs play a critical 
role in tissue fibrosis (Lim et al. 2006). It has also been reported that in activated pancreatic 
stellate cells, an autocrine loop exists between IL-6 and TGF-β through ERK and Smad2/3-
dependent pathways (Aoki et al. 2006). 
 
In the light of the above reports, we suggest that TGF-β could be a target gene of STAT3 
and that the absence of SOCS1 may enhance JAK-STAT signaling and fibrosis. The 
crosstalk between IL-6/STAT3 and TGF-β/SMAD3 in HSC during liver fibrogenesis 
remains to be determined. 
 
4.4 SOCS1 deficiency enhances the activity of tissue inhibitors of metalloproteinases 
(TIMPs) 
An imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of 
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metalloproteinases (TIMPs) affects the synthesis and degradation of ECM, which plays an 
important role in the pathogenesis of liver fibrosis. TIMP-1, TIMP-2 participates in tissue 
remodeling by inhibiting various types of MMPs. 
 
Similar to IL-6 and STAT3, TIMP-1 seems to exert a dichotomous role in liver fibrosis. 
The major sources for TIMP-1 are activated HSC, macrophages and hepatocytes. Previous 
studies using TIMP-1-deficient mice have shown that TIMP-1 displays a protective role in 
liver fibrosis (H. Wang, Lafdil, Wang, et al. 2011). However, several other studies 
demonstrated in vitro and in vivo that TIMP-1 exerts profibrotic activity by preventing the 
collagen degradation through inhibition of MMPS and also by inhibiting apoptosis of 
activated HSC (Murphy et al. 2002a; Benyon and Arthur 2001). Similar functions are 
further confirmed in Timp-1 transgenic mice (H Yoshiji 2002). TIMP-1 and procollagen 
mRNA expression is increased during progression of liver disease, while interstitial 
collagenase (MMP-1) mRNA expression remained relatively unchanged (J. Iredale et al. 
1996). Silencing TIMP-2 with siRNA in mice followed by CCl4 injury showed reduced 
HSC activation and collagen deposition, suggesting its pro-fibrotic function of TIMP-2 (X. 
Liu et al. 2006). 
 
We have observed increased mRNA expression of Timp1, Timp2, and Col1a1, Col3a1 in 
the livers of Socs1-/-Ifng-/- mice, indicating that these TIMPs might contribute to the 
increased deposition of collagen in Socs1-deficient mice. Similarly, an increase SMA 
positive staining (Fig. 5), the quantity of SMA (Fig. 7) and Acta2 expression in the livers of 
DMN or CCl4 treated Socs1-null mice, in addition to inhibiting MMP activity, suggests that 
increased Timp-1 activity might have contributed to the survival of HSC and their 
activation to myofibroblasts in the absence of SOCS1. Further studies are needed to 
understand how SOCS1 defciency leads to increased TIMP expression. 
 
4.5 SOCS1 differentially regulates MMPs expression in Liver Fibrosis. 
The biological functions of MMPs are complex because the same MMP can have opposing 
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effects based upon the cell type or tissue in which it is being expressed. Some MMPs are 
anti-fibrotic, whereas others show profibrotic functions. The choice of which MMPs to 
target for therapeutic purposes is still uncertain (Giannandrea and Parks 2014; Duarte et al. 
2015). 
 
We have observed reduced expression of Mmp1 in the fibrotic livers of SOCS1 deficient 
mice in both DMN and CCl4-induced liver fibrosis models. The expression of Mmp2 
increased in DMN model whereas it was not significantly altered in the CCl4 model (Fig. 
6B). MMP-1, also known as collagenase, degrades collagens type 1 and 3. Overexpression 
of human MMP1 gene by adenovirus gene delivery inhibits liver fibrosis in a rat model 
while promoting hepatocyte proliferation (Iimuro et al. 2003). Similar findings have been 
reported in myocardial fibrosis upon over expression of MMP1 (Foronjy et al. 2008). An 
antifibrotic role has been reported for MMP-2 (Gelatinase A or Type 4 collagenase) in both 
chemical and cholestasis induced fibrosis models using MMP-2 deficient mice and in vitro 
silencing of MMP-2 in stellate cells (Onozuka et al. 2011; Radbill et al. 2011). 
 
MMP-3 and MMP-9 can activate latent TGF-β suggesting their profibrotic function 
(Giannandrea and Parks 2014). The role of MMP-9 in the liver is not clearly known. Some 
studies suggest a profibrotic function as it can activate TGF-β whereas some other studies 
attribute it an antifibrotic function (Cabrera et al. 2007; C. G. Lee et al. 2001). It has been 
suggested that MMP-3 promotes pulmonary fibrosis by inducing epithelial cells to undergo 
an epithelial-mesenchymal transition (EMT) to generate cells that are myofibroblast-like in 
function (Yamashita et al. 2011). Interestingly, MMP-3 and 9 expression is increased in 
CCl4-induced fibrosis and decreased in DMN- model in the livers of Socs1 deficient mice 
(Fig. 6B). The significance of this differential expression in the two models, both of which 
initiate the fibrogenic response by inducing centrilobular necrosis, remains to be studied. 
Similarly, understanding the potential contribution of SOCS1-dependent modulation of 
cytokine and growth factor signaling to the induction of MMPs in liver fibrosis requires 
further investigation. 
 
  
94 
94 
4.6 SOCS1 regulates HSC activation or proliferation in response to different cytokines 
and growth factors. 
Liver fibrosis is characterized by increased proliferation of hepatic stellate cells. Several 
lines of evidence suggest that PDGF is the most potent mitogen for HSC. Pinzani et al in 
1989 first reported the effect of growth factors on HSC proliferation. They found that 
PDGF, EGF, TGF-α, and βFGF induced a dose-dependent increase in DNA synthesis with 
a peak effect at 24 h. Among them, PDGF showed the maximum, 18-fold increase in DNA 
synthesis, followed by EGF, TGF-α, and βFGF, over control. PDGFβ and PDGFR mRNA 
expression is increased in the rat liver tissue following treatment with CCl4 and in cirrhotic 
human livers (M Pinzani et al. 1996; M Pinzani et al. 1994). In a condition of chronic 
inflammation of the liver, the sustained release of PDGF by inflammatory cells and 
increased expression of PDGF receptors in activated FSC (earlier synonym for HSC) 
greatly contribute to the expansion of FSC population, and to the progression of 
fibrogenesis. TGF-β did not affect DNA synthesis of fat storing cells (FSC) or HSC but 
TGF-β enhanced the stimulatory effects of both EGF and PDGF (M Pinzani et al. 1989). 
 
SOCS1 not only regulates JAK–STAT signaling but also RTKs signalling (Kazi et al. 
2014). Previous study from our laboratory has shown that SOCS1 regulates HGF (c-Met) 
signaling in hepatocytes (Yirui Gui et al. 2011). To date, there is little evidence linking 
SOCS proteins in HSC with liver fibrosis and no previous report showing the role of 
SOCS1 in HSC. We have shown, for the first time, an increased expression of the Pdgfβ 
gene in fibrotic livers of Socs1-deficient mice and increased SOCS1-deficient HSC 
proliferation in response to PDGFβ and/or to other growth factors (TGF-α, EGF and HGF) 
(Fig. 8A). Our findings suggest that the antifibrotic function of SOCS1 is also mediated by 
regulating the availability of growth factors that promote HSC proliferation and/or by 
regulating growth factor signaling in HSC. Further studies are required to elucidate the 
molecular mechanisms by which SOCS1 regulates HSC proliferation. 
 
The antifibrotic effect of IFN-γ is known to be achieved by directly inhibiting proliferation 
and activation of hepatic stellate cells (Ancini et al. 1996). It has been shown that IFN-γ 
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inhibits HSC proliferation via its downstream signaling molecule STAT1. STAT1-deficient 
HSC showed much greater cell proliferation in the presence of PDGFβ and PDGFβ mRNA 
expression than wild-type HSC, suggesting that STAT1 is a negative regulator for the 
proliferative effect of PDGF on HSC (W. Il Jeong et al. 2006). Given that, in this study, we 
showed that IFN-γ deficient HSCs showed enhanced proliferation in the presence of 
PDGFβ compared to wild type cells suggesting that IFN-γ inhibits PDGFβ induced 
proliferation. It is possible that the simultaneous absence of IFN-γ in SOCS1 deficient mice 
used in our study might relieve the inhibitory effects of IFN-γ –induced STAT1 activation. 
However, PDGFβ has also been shown to activate STAT1, STAT3, and ERK pathways 
(Massimo Pinzani 2002; M Pinzani et al. 1989), and STAT3 has been shown to be 
implicated in cell proliferation in different cell types (hirano, ishihara, & hibi, 2000). The 
increased proliferation of Ifn-γ-/-/Socs1-/- HSC and increased STAT3 activation in SOCS1 
deficient livers indicate that PDGF likely mediates HSC proliferation via STAT3 pathway 
rather than diminished STAT1 activation in the absence of IFN-γ. Further studies using 
HSC-specific Socs1-null cells and mice are required to clarify the role of IFN-γ-induced 
STAT1 activation versus PDGF-induced STAT3 activation in HSC proliferation and liver 
ﬁbrosis.  
 
Sorafenib is a RAF (Rapidly Accelerated Fibrosarcoma) kinase inhibitor, downstream of 
many RTKs and is the only Food and Drug Administration-approved drug for the treatment 
of HCC. Recent studies reported the antifibrotic function of sorafenib, which reduces HSC 
proliferation and ECM synthesis by enhancing HSC apoptosis (Hong et al. 2013; Y. Wang 
et al. 2010). A recent study on the underlying molecular mechanisms of Sorafenib and its 
derivatives showed that their anti-fibrogenic effects are mediated via inhibition of STAT3 
activation, down-regulation of TGF-β/Smad2/Smad3 signaling and downstream signalling 
pathways of PDGFR-β (Su et al. 2015). They also reported that correlation exists between 
p-STAT3 overexpression in HSC of chronic hepatitis B patients with advanced liver 
fibrosis score and high plasma IL-6 levels. In human liver fibrosis, SOCS1 gene is 
frequently suppressed by promoter methylation that correlates with disease severity (T. 
Yoshida 2004). Given that Sorafenib shows the antifibrogenic effect by inhibiting STAT3 
activation and TGF-β and PDGF signalling pathways, and that SOCS1 deficiency increases 
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IL-6, pSTAT3, TGF-β, p-Smad-3 and PDGF expression in mouse models of fibrosis and 
enhances HSC proliferation, we propose that Sorafenib can be used as a therapeutic agent 
for the treatment of liver fibrosis in patients with SOCS1 gene methylation. 
 
 
 
 
 
 
5. CONCLUSIONS 
In conclusion, our results suggest that absence of SOCS1 leads to acceleration of hepatic 
inflammation and fibrosis. SOCS1 regulates different cytokines and growth factors and 
thus inhibits fibrosis by attenuating HSC activation and proliferation. We also conclude that 
SOCS1 regulated fibrogenic response occurs in an IFN-γ independent manner. Further in 
vitro and in vivo studies on molecular mechanisms of SOCS1 in liver fibrosis will provide 
new insight in understanding its function and in predicting the disease progression and help 
in the development of targeted therapeutic strategies in preventing the progression of liver 
fibrosis. 
 
Figure 6 Schematic diagram of SOCS1 role in liver fibrosis. Hypothetical model 
illustrating the different cytokines and growth factors pathways in hepatic stellate cell 
(HSC) activation and fibrogenic response such as proliferation, activation, collagen 
deposition and final event fibrogenic response. Induction of SOCS1 in HSC may 
regulate these cytokines and growth factors signaling and thereby inhibit HSC 
activation and fibrogenic response. 
6. ACKNOWLEDGMENTS 
Firstly, I would like to express my sincere gratitude to my supervisor Prof. Subburaj 
Ilangumaran for his continuous support of my Master’s study and related research, for his 
patience, motivation, and immense knowledge. His guidance helped me in all the time of 
research and writing of this thesis. I could not have imagined having a better advisor and 
mentor. 
 
Besides my advisor, I would like to thank my co-advisor Prof. Alfredo Menendez for his 
insightful comments and encouragement to widen my research in various perspectives. 
 
I am grateful to my former colleagues Dr. Mehdi Yeganeh and Yuneivy Cepero Donates 
for their initial encouragement and support at the beginning of the project. I would also like 
to thank my fellow lab mates Dr. Diwakar Bobbala, Alberto V Hernandez, Galaxia M. 
Rodriguez, GM Khan, and Kawila Mafanda for stimulating discussions and for all the fun 
we have had in the past two years.  
 
My sincere thanks also goes to our Director Dr. Sheela Ramanathan for her support, 
encouragement, and critiques, which helped me a lot in completing my project. 
 
I like to mention the kind help from our lab assistant Marian Mayhue for her dedication and 
kind nature in helping us. 
 
I would also like to thank my jury members Dr. Jana Stankova and Dr. Benoit Paquette, for 
agreeing to evaluate my thesis and for the valuable suggestions. 
 
Last but not the least, I would like to thank my husband Diwakar Bobbala, my parents and 
to my brother and sister for supporting me throughout my master’s program. 
7. BIBLIOGRAPHY 
Adachi, Tohru, Hitoshi Togashi, Akihiko Suzuki, Shigenobu Kasai, Junitsu Ito, Kazuhiko 
Sugahara, and Sumio Kawata. n.d. “NAD(P)H Oxidase Plays a Crucial Role in PDGF- 
Induced Proliferation of Hepatic Stellate Cells.” doi:10.1002/hep.20719. 
Afdhal, Nezam H, and David Nunes. 2004. “Evaluation of Liver Fibrosis : A Concise 
Review.” doi:10.1111/j.1572-0241.2004.30110.x. 
Alaluf, Maya Bitton, and Amir Shlomai. 2016. “New Therapies for Chronic Hepatitis B.” 
Liver International : Official Journal of the International Association for the Study of 
the Liver, February. doi:10.1111/liv.13086. 
Alcolado, R, M J Arthur, and J P Iredale. 1997. “Pathogenesis of Liver Fibrosis.” Clinical 
Science (London, England : 1979) 92 (2): 103–12. 
Alexander, Warren S, Robyn Starr, Jennifer E Fenner, Clare L Scott, Emanuela Handman, 
Naomi S Sprigg, Jason E Corbin, et al. 1999. “SOCS1 Is a Critical Inhibitor of 
Interferon ␥ Signaling and Prevents the Potentially Fatal Neonatal Actions of This 
Cytokine” 98: 597–608. 
Alpini, Gianfranco, James M McGill, and Nicholas F Larusso. 2002. “The Pathobiology of 
Biliary Epithelia.” Hepatology (Baltimore, Md.) 35 (5): 1256–68. 
doi:10.1053/jhep.2002.33541. 
Ancini, R Aniero M, A N N E M Arie J Ezequel, A Ntonio B Enedetti, Gianluca Svegliati 
Baroni, Letizia D’Ambrosio, Pierina Curto, Alessandro Casini, Raniero Mancini, 
Anne Marie Jezequel, and Antonio Benedetti. 1996. “Interferon Gamma Decreases 
Hepatic Stellate Cell Activation and Extracellular Matrix Deposition in Rat Liver 
Fibrosis.” Hepatology (Baltimore, Md.) 23 (5): 1189–99. doi:10.1002/hep.510230538. 
Aoki, Hiroyoshi, Hirohide Ohnishi, Kouji Hama, Satoshi Shinozaki, Hiroto Kita, Hironori 
Yamamoto, Hiroyuki Osawa, Kiichi Sato, Kiichi Tamada, and Kentaro Sugano. 2006. 
“Existence of Autocrine Loop between Interleukin-6 and Transforming Growth 
Factor-beta1 in Activated Rat Pancreatic Stellate Cells.” Journal of Cellular 
Biochemistry 99 (1): 221–28. doi:10.1002/jcb.20906. 
Apte, M V, P S Haber, T L Applegate, I D Norton, G W McCaughan, M A Korsten, R C 
Pirola, and J S Wilson. 1998. “Periacinar Stellate Shaped Cells in Rat Pancreas: 
  
100 
100 
Identification, Isolation, and Culture.” Gut 43 (1): 128–33. doi:10.1136/gut.43.1.128. 
Arpino, Valerie, Michael Brock, and Sean E Gill. 2015. “The Role of TIMPs in Regulation 
of Extracellular Matrix Proteolysis.” Matrix Biology. Elsevier B.V., 1–8. 
doi:10.1016/j.matbio.2015.03.005. 
Baeck, C., A. Wehr, K. R. Karlmark, F. Heymann, M. Vucur, N. Gassler, S. Huss, et al. 
2012. “Pharmacological Inhibition of the Chemokine CCL2 (MCP-1) Diminishes 
Liver Macrophage Infiltration and Steatohepatitis in Chronic Hepatic Injury.” Gut 61 
(3): 416–26. doi:10.1136/gutjnl-2011-300304. 
Balbín, M, A Fueyo, V Knäuper, J M López, J Alvarez, L M Sánchez, V Quesada, J 
Bordallo, G Murphy, and C López-Otín. 2001. “Identification and Enzymatic 
Characterization of Two Diverging Murine Counterparts of Human Interstitial 
Collagenase (MMP-1) Expressed at Sites of Embryo Implantation.” The Journal of 
Biological Chemistry 276 (13): 10253–62. doi:10.1074/jbc.M009586200. 
Bansal, Ruchi, Jai Prakash, Marieke De Ruiter, and Klaas Poelstra. 2014. “Interferon 
Gamma Peptidomimetic Targeted to Hepatic Stellate Cells Ameliorates Acute and 
Chronic Liver Fibrosis in Vivo.” Journal of Controlled Release 179. Elsevier B.V.: 
18–24. doi:10.1016/j.jconrel.2014.01.022. 
Barry-Hamilton, Vivian, Rhyannon Spangler, Derek Marshall, Scott McCauley, Hector M 
Rodriguez, Miho Oyasu, Amanda Mikels, et al. 2010. “Allosteric Inhibition of Lysyl 
Oxidase-like-2 Impedes the Development of a Pathologic Microenvironment.” Nature 
Medicine 16 (9): 1009–17. doi:10.1038/nm.2208. 
Bataller, R, P Ginès, J M Nicolás, M N Görbig, E Garcia-Ramallo, X Gasull, J Bosch, V 
Arroyo, and J Rodés. 2000. “Angiotensin II Induces Contraction and Proliferation of 
Human Hepatic Stellate Cells.” Gastroenterology 118 (6): 1149–56. 
http://www.ncbi.nlm.nih.gov/pubmed/10833490. 
Bataller, Ramón, and David A Brenner. n.d. “Hepatic Stellate Cells as a Target for the 
Treatment of Liver Fibrosis.” 
Bataller, Ramón, and David A. Brenner. 2001. “Hepatic Stellate Cells as a Target for the 
Treatment of Liver Fibrosis.” Seminars in Liver Disease 21 (03): 437–52. 
doi:10.1055/s-2001-17558. 
Bellini, Alberto, and Sabrina Mattoli. 2007. “The Role of the Fibrocyte, a Bone Marrow-
  
101 
101 
Derived Mesenchymal Progenitor, in Reactive and Reparative Fibroses.” Laboratory 
Investigation; a Journal of Technical Methods and Pathology 87 (9): 858–70. 
doi:10.1038/labinvest.3700654. 
Benyon, R C, and M J Arthur. 2001. “Extracellular Matrix Degradation and the Role of 
Hepatic Stellate Cells.” Semin Liver Dis 21 (3): 373–84. doi:10.1055/s-2001-17552. 
Blaner, William S., Sheila M. O’Byrne, Nuttaporn Wongsiriroj, Johannes Kluwe, Diana M. 
D’Ambrosio, Hongfeng Jiang, Robert F. Schwabe, Elizabeth M C Hillman, Roseann 
Piantedosi, and Jenny Libien. 2009. “Hepatic Stellate Cell Lipid Droplets: A 
Specialized Lipid Droplet for Retinoid Storage.” Biochimica et Biophysica Acta - 
Molecular and Cell Biology of Lipids 1791 (6). Elsevier B.V.: 467–73. 
doi:10.1016/j.bbalip.2008.11.001. 
Blomhoff R, Berg T. 1990. “Isolation and Cultivation of Rat Liver Stellate Cells.” Methods 
Enzymol. 190: 58–71. 
Boigk, G, L Stroedter, H Herbst, J Waldschmidt, E O Riecken, and D Schuppan. 1997. 
“Silymarin Retards Collagen Accumulation in Early and Advanced Biliary Fibrosis 
Secondary to Complete Bile Duct Obliteration in Rats.” Hepatology (Baltimore, Md.) 
26 (3): 643–49. doi:10.1002/hep.510260316. 
Bonis, P a, S L Friedman, and M M Kaplan. 2001. “Is Liver Fibrosis Reversible?” The New 
England Journal of Medicine 344 (6): 452–54. doi:10.1136/gut.46.4.443. 
Bonner, James C. 2004. “Regulation of PDGF and Its Receptors in Fibrotic Diseases.” 
Cytokine & Growth Factor Reviews 15 (4): 255–73. 
doi:10.1016/j.cytogfr.2004.03.006. 
Bouwens, L, P De Bleser, K Vanderkerken, B Geerts, and E Wisse. 1992. “Liver Cell 
Heterogeneity: Functions of Non-Parenchymal Cells.” Enzyme 46 (1-3): 155–68. 
http://www.ncbi.nlm.nih.gov/pubmed/1289080. 
Branton, Mary H, and Jeffrey B Kopp. 1999. “TGF- and Fibrosis.” 
Brenner, David A, Tim Waterboer, Sung Kyu Choi, Jeffrey N Lindquist, Branko 
Stefanovic, Elmar Burchardt, Mitsui Yamauchi, Andrea Gillan, and Richard A Rippe. 
2000. “New Aspects of Hepatic Fibrosis” 32 (8): 32–38. 
Brun, Paola, Ignazio Castagliuolo, Massimo Pinzani, Giorgio Palù, and Diego Martines. 
2005. “Exposure to Bacterial Cell Wall Products Triggers an Inflammatory Phenotype 
  
102 
102 
in Hepatic Stellate Cells.” American Journal of Physiology. Gastrointestinal and Liver 
Physiology 289 (3): G571–78. doi:10.1152/ajpgi.00537.2004. 
Bruschi, Fabrizio, and Barbara Pinto. 2013. “The Significance of Matrix 
Metalloproteinases in Parasitic Infections Involving the Central Nervous System.” 
Pathogens 2: 105–29. doi:10.3390/pathogens2010105. 
Cabrera, Sandra, Miguel Gaxiola, José Luis Arreola, Remedios Ramírez, Paul Jara, Jeanine 
D’Armiento, Thomas Richards, Moisés Selman, and Annie Pardo. 2007. 
“Overexpression of MMP9 in Macrophages Attenuates Pulmonary Fibrosis Induced 
by Bleomycin.” The International Journal of Biochemistry & Cell Biology 39 (12): 
2324–38. doi:10.1016/j.biocel.2007.06.022. 
Calculators, Bibliography. 2014. “Evaluation and Staging of Liver Fibrosis Liver Biopsy 
and Histologic Assessment of the Liver Direct Markers of Fibrosis,” no. 1. 
doi:10.1186/1758-2652-11-S1-P135. 
Canadian Liver Foundation. 2013. “Liver Disease in Canada: A Crisis in the Making.” 
Canadian Liver Foundation, no. March. 
Canbay, Ali, Ariel E Feldstein, Hajime Higuchi, Nate Werneburg, Annette Grambihler, 
Steve F Bronk, and Gregory J Gores. 2003. “Kupffer Cell Engulfment of Apoptotic 
Bodies Stimulates Death Ligand and Cytokine Expression.” Hepatology (Baltimore, 
Md.) 38 (5): 1188–98. doi:10.1053/jhep.2003.50472. 
Canbay, Ali, Scott Friedman, and Gregory J. Gores. 2004. “Apoptosis: The Nexus of Liver 
Injury and Fibrosis.” Hepatology 39 (2): 273–78. doi:10.1002/hep.20051. 
Cao, Q. 2003. “Leptin Stimulates Tissue Inhibitor of Metalloproteinase-1 in Human 
Hepatic Stellate Cells: RESPECTIVE ROLES OF THE JAK/STAT AND JAK-
MEDIATED H2O2-DEPENDENT MAPK PATHWAYS.” Journal of Biological 
Chemistry 279 (6): 4292–4304. doi:10.1074/jbc.M308351200. 
Cassiman, David, Amanda Barlow, Sara Vander Borght, Louis Libbrecht, and Vassilis 
Pachnis. 2006. “Hepatic Stellate Cells Do Not Derive from the Neural Crest.” Journal 
of Hepatology 44 (6): 1098–1104. doi:10.1016/j.jhep.2005.09.023. 
Castera, Laurent. 2011. “Invasive and Non-Invasive Methods for the Assessment of 
Fibrosis and Disease Progression in Chronic Liver Disease.” Best Practice & 
Research. Clinical Gastroenterology 25 (2). Elsevier Ltd: 291–303. 
  
103 
103 
doi:10.1016/j.bpg.2011.02.003. 
Cheng, Chang, Cheng Huang, Tao-tao Ma, Tao Xu, Ya-rui Wang, and Lei Zhang. 2016. 
“Expert Opinion on Therapeutic Targets New Surprises of Suppressor of Cytokine 
Signalling in Liver Fibrosis New Surprises of Suppressor of Cytokine Signalling in 
Liver Fibrosis” 8222 (February). doi:10.1517/14728222.2014.885953. 
Cheng, Chang, Cheng Huang, Tao-tao Ma, Tao Xu, Ya-rui Wang, Lei Zhang, Takumi 
Kamura, et al. 2016. “Review Article SOCS Proteins in Development and Disease” 
8222 (February): 155–67. doi:10.4103/1319-3767.96445. 
Cho, J J, B Hocher, H Herbst, J D Jia, M Ruehl, E G Hahn, E O Riecken, and D Schuppan. 
2000. “An Oral Endothelin-A Receptor Antagonist Blocks Collagen Synthesis and 
Deposition in Advanced Rat Liver Fibrosis.” Gastroenterology 118 (6): 1169–78. 
http://www.ncbi.nlm.nih.gov/pubmed/10833492. 
Chu, Andrew S., Rosalyn Diaz, Jia Ji Hui, Kilangsungla Yanger, Yiwei Zong, Gianfranco 
Alpini, Ben Z. Stanger, and Rebecca G. Wells. 2011. “Lineage Tracing Demonstrates 
No Evidence of Cholangiocyte Epithelial-to-Mesenchymal Transition in Murine 
Models of Hepatic Fibrosis.” Hepatology 53 (5): 1685–95. doi:10.1002/hep.24206. 
Cong, Min, Keiko Iwaisako, Chunyan Jiang, and Tatiana Kisseleva. 2012a. “Review 
Article Cell Signals Influencing Hepatic Fibrosis” 2012. doi:10.1155/2012/158547. 
———. 2012b. “Cell Signals Influencing Hepatic Fibrosis.” International Journal of 
Hepatology 2012 (January): 158547. doi:10.1155/2012/158547. 
Cooney, Robert N. 2002. “JAK / STAT PATHWAY” 17 (2): 83–90. 
Croker, Ben A, Hiu Kiu, Sandra E Nicholson, Nicos A Nicola, Christopher J Greenhalgh, 
and Lykke Larsen. 2002. “Seminars in Cell & Developmental Biology SOCS 
Regulation of the JAK / STAT Signalling Pathway” 28: 833–44. 
doi:10.1016/j.semcdb.2008.07.010. 
Czaja, Mark J, R Weiner, and Mark A Zern. 1989. “Y-Interferon Treatment Inhibits 
Collagen Deposition in Murine Schistosomiasis” 10 (5): 795–800. 
Czochra, Piotr, Borut Klopcic, Erik Meyer, Johannes Herkel, Jose Francisco Garcia-Lazaro, 
Florian Thieringer, Peter Schirmacher, et al. 2006. “Liver Fibrosis Induced by Hepatic 
Overexpression of PDGF-B in Transgenic Mice.” Journal of Hepatology 45 (3): 419–
28. doi:10.1016/j.jhep.2006.04.010. 
  
104 
104 
D’Amico, Gennaro, Guadalupe Garcia-Tsao, and Luigi Pagliaro. 2006. “Natural History 
and Prognostic Indicators of Survival in Cirrhosis: A Systematic Review of 118 
Studies.” Journal of Hepatology 44 (1): 217–31. doi:10.1016/j.jhep.2005.10.013. 
Daniels, Craig E, Joseph A Lasky, Andrew H Limper, Kathleen Mieras, Edith Gabor, and 
Darrell R Schroeder. 2010. “Imatinib Treatment for Idiopathic Pulmonary Fibrosis: 
Randomized Placebo-Controlled Trial Results.” American Journal of Respiratory and 
Critical Care Medicine 181 (6): 604–10. doi:10.1164/rccm.200906-0964OC. 
Das, S K, and D M Vasudevan. 2008. “Genesis of Hepatic Fibrosis and Its Biochemical 
Markers.” Scandinavian Journal of Clinical and Laboratory Investigation 68 (4): 260–
69. doi:10.1080/00365510701668516. 
Davis, B H, R T Kramer, and N O Davidson. 1990. “Retinoic Acid Modulates Rat Ito Cell 
Proliferation, Collagen, and Transforming Growth Factor Beta Production.” The 
Journal of Clinical Investigation 86 (6): 2062–70. doi:10.1172/JCI114943. 
DeLeve, Laurie D. 2013. “Liver Sinusoidal Endothelial Cells and Liver Regeneration.” 
Journal of Clinical Investigation 123 (5): 1861–66. doi:10.1172/JCI66025. 
Deng, Yan-Ru, Hong-Di Ma, Koichi Tsuneyama, Wei Yang, Yin-Hu Wang, Fang-Ting Lu, 
Cheng-Hai Liu, et al. 2013. “STAT3-Mediated Attenuation of CCl4-Induced Mouse 
Liver Fibrosis by the Protein Kinase Inhibitor Sorafenib.” Journal of Autoimmunity 46 
(October): 25–34. doi:10.1016/j.jaut.2013.07.008. 
Denzer, Ulrike W, and Stefan Lüth. 2009. “Non-Invasive Diagnosis and Monitoring of 
Liver Fibrosis and Cirrhosis.” Best Practice & Research. Clinical Gastroenterology 
23 (3): 453–60. doi:10.1016/j.bpg.2009.03.002. 
Di Sario, A, E Bendia, G Svegliati Baroni, F Ridolfi, L Bolognini, G Feliciangeli, A M 
Jezequel, F Orlandi, and A Benedetti. 1999. “Intracellular Pathways Mediating 
Na+/H+ Exchange Activation by Platelet-Derived Growth Factor in Rat Hepatic 
Stellate Cells.” Gastroenterology 116 (5): 1155–66. 
http://www.ncbi.nlm.nih.gov/pubmed/10220508. 
Dooley, Steven, and Peter Dijke. 2012. “TGF- β in Progression of Liver Disease,” 245–56. 
doi:10.1007/s00441-011-1246-y. 
Dooley, Steven, Jafar Hamzavi, Katja Breitkopf, Eliza Wiercinska, Harun M Said, Johann 
Lorenzen, Peter Ten Dijke, and Axel M Gressner. 2003. “Smad7 Prevents Activation 
  
105 
105 
of Hepatic Stellate Cells and Liver Fibrosis in Rats.” Gastroenterology 125 (1): 178–
91. http://www.ncbi.nlm.nih.gov/pubmed/12851882. 
Duarte, Sergio, John Baber, Takehiro Fujii, and Ana J Coito. 2015. “Matrix 
Metalloproteinases in Liver Injury, Repair and Fibrosis.” Matrix Biology : Journal of 
the International Society for Matrix Biology 44-46C: 147–56. 
doi:10.1016/j.matbio.2015.01.004. 
Duffield, Jeremy S., Stuart J. Forbes, Christothea M. Constandinou, Spike Clay, Marina 
Partolina, Srilatha Vuthoori, Shengji Wu, Richard Lang, and John P. Iredale. 2005. 
“Selective Depletion of Macrophages Reveals Distinct, Opposing Roles during Liver 
Injury and Repair.” Journal of Clinical Investigation 115 (1): 56–65. 
doi:10.1172/JCI22675. 
Durbeej, Madeleine. 2010. “Laminins.” Cell and Tissue Research 339 (1): 259–68. 
doi:10.1007/s00441-009-0838-2. 
Egan, Paul J, Kate E Lawlor, Warren S Alexander, and Ian P Wicks. 2003. “Suppressor of 
Cytokine Signaling-1 Regulates Acute Inflammatory Arthritis and T Cell Activation” 
111 (6): 915–24. doi:10.1172/JCI200316156.Introduction. 
Endo, Takaho A, and Masaaki Masuhara. 1997. “A New Protein Containing an SH2 
Domain That Inhibits JAK Kinases” 387 (June): 921–25. 
Farazi, Paraskevi A., and Ronald A. DePinho. 2006. “Hepatocellular Carcinoma 
Pathogenesis: From Genes to Environment.” Nature Reviews. Cancer 6 (9): 674–87. 
doi:10.1038/nrc1934. 
Fausto, Nelson, Jean S Campbell, and Kimberly J Riehle. 2006. “Liver Regeneration.” 
Hepatology (Baltimore, Md.) 43 (2 Suppl 1): S45–53. doi:10.1002/hep.20969. 
Ferrell, Linda. 2013. “Update on Staging of Fibrosis,” 1–22. 
Foley, Caitlin J, Chi Luo, Katie O’Callaghan, Philip W Hinds, Lidija Covic, and Athan 
Kuliopulos. 2012. “Matrix Metalloprotease-1a Promotes Tumorigenesis and 
Metastasis.” The Journal of Biological Chemistry 287 (29): 24330–38. 
doi:10.1074/jbc.M112.356303. 
Foley, Caitlin J., and Athan Kuliopulos. 2014. “Mouse Matrix Metalloprotease-1a 
(Mmp1a) Gives New Insight into MMP Function.” Journal of Cellular Physiology 
229 (12): 1875–80. doi:10.1002/jcp.24650. 
  
106 
106 
Fomby, Paula, and Andrew J Cherlin. 2011. “NIH Public Access” 72 (2): 181–204. 
doi:10.1038/nature13314.A. 
Foronjy, Robert F, Jie Sun, Vincent Lemaitre, and Jeanine M D’Armiento. 2008. 
“Transgenic Expression of Matrix Metalloproteinase-1 Inhibits Myocardial Fibrosis 
and Prevents the Transition to Heart Failure in a Pressure Overload Mouse Model.” 
Hypertension Research : Official Journal of the Japanese Society of Hypertension 31 
(4): 725–35. doi:10.1291/hypres.31.725. 
Frantz, Christian, Kathleen M Stewart, and Valerie M Weaver. 2010. “The Extracellular 
Matrix at a Glance.” Journal of Cell Science 123: 4195–4200. doi:10.1242/jcs.023820. 
Friedman, Scott L. 2005. “Mac the Knife? Macrophages- the Double-Edged Sword of 
Hepatic Fibrosis.” The Journal of Clinical Investigation 115 (1): 29–32. 
doi:10.1172/JCI23928. 
———. 2008. “Mechanisms of Hepatic Fibrogenesis,” 1655–69. 
doi:10.1053/j.gastro.2008.03.003. 
———. 2010a. “NIH Public Access” 134 (6): 1655–69. 
doi:10.1053/j.gastro.2008.03.003.Mechanisms. 
Friedman, Scott L. 2010b. “Evolving Challenges in Hepatic Fibrosis.” Nature Reviews 
Gastroenterology & Hepatology 7 (8). Nature Publishing Group: 425–36. 
doi:10.1038/nrgastro.2010.97. 
Gao, Bin, Svetlana Radaeva, and Ogyi Park. 2009. “Liver Natural Killer and Natural Killer 
T Cells: Immunobiology and Emerging Roles in Liver Diseases.” Journal of 
Leukocyte Biology 86 (3): 513–28. doi:10.1189/JLB.0309135. 
Geerts, A. 2001. “History, Heterogeneity, Developmental Biology, and Functions of 
Quiescent Hepatic Stellate Cells.” Seminars in Liver Disease 21 (3): 311–35. 
doi:10.1055/s-2001-17550. 
Gelse, K. 2003. “Collagens—structure, Function, and Biosynthesis.” Advanced Drug 
Delivery Reviews 55 (12): 1531–46. doi:10.1016/j.addr.2003.08.002. 
Georges, Penelope C, Jia-Ji Hui, Zoltan Gombos, Margaret E McCormick, Andrew Y 
Wang, Masayuki Uemura, Rosemarie Mick, Paul a Janmey, Emma E Furth, and 
Rebecca G Wells. 2007. “Increased Stiffness of the Rat Liver Precedes Matrix 
Deposition: Implications for Fibrosis.” Am. J. Physiol. Gastrointest. Liver Physiol. 
  
107 
107 
293 (6): 1147–54. doi:10.1152/ajpgi.00032.2007. 
Giannandrea, Matthew, and William C Parks. 2014. “Diverse Functions of Matrix 
Metalloproteinases during Fibrosis.” Disease Models & Mechanisms 7 (2): 193–203. 
doi:10.1242/dmm.012062. 
Glässner, Andreas, Marianne Eisenhardt, Pavlos Kokordelis, Benjamin Krämer, Franziska 
Wolter, Hans Dieter Nischalke, Christoph Boesecke, et al. 2013. “Impaired CD4+ T 
Cell Stimulation of NK Cell Anti-Fibrotic Activity May Contribute to Accelerated 
Liver Fibrosis Progression in HIV/HCV Patients.” Journal of Hepatology 59 (3): 427–
33. doi:10.1016/j.jhep.2013.04.029. 
Goodman, Zachary D. 2007. “Grading and Staging Systems for Inflammation and Fibrosis 
in Chronic Liver Diseases.” Journal of Hepatology 47 (4): 598–607. 
doi:10.1016/j.jhep.2007.07.006. 
Gordon, Marion K, and Rita A Hahn. 2010. “Collagens.” Cell and Tissue Research 339 (1): 
247–57. doi:10.1007/s00441-009-0844-4. 
Granstein, R D, T J Flotte, and E P Amento. 1990. “Interferons and Collagen Production.” 
The Journal of Investigative Dermatology 95 (6 Suppl): 75S – 80S. 
http://www.ncbi.nlm.nih.gov/pubmed/2258640. 
Gressner, A M. 1996. “Transdifferentiation of Hepatic Stellate Cells (Ito Cells) to 
Myofibroblasts: A Key Event in Hepatic Fibrogenesis.” Kidney International. 
Supplement 54 (May): S39–45. http://www.ncbi.nlm.nih.gov/pubmed/8731193. 
Gressner, A M, and R Weiskirchen. 2006. “Modern Pathogenetic Concepts of Liver 
Fibrosis Suggest Stellate Cells and TGF- β as Major Players and Therapeutic Targets.” 
Gressner, Olav A, Ralf Weiskirchen, and Axel M Gressner. 2007. “Biomarkers of Liver 
Fibrosis : Clinical Translation of Molecular Pathogenesis or Based on Liver-
Dependent Malfunction Tests” 381: 107–13. doi:10.1016/j.cca.2007.02.038. 
Gui, Y, M Yeganeh, Y-C Donates, W-S Tobelaim, W Chababi, M Mayhue, a Yoshimura, S 
Ramanathan, C Saucier, and S Ilangumaran. 2015. “Regulation of MET Receptor 
Tyrosine Kinase Signaling by Suppressor of Cytokine Signaling 1 in Hepatocellular 
Carcinoma.” Oncogene, no. October 2014. Nature Publishing Group: 1–11. 
doi:10.1038/onc.2015.20. 
Gui, Yirui, Mehdi Yeganeh, Yuneivy Cepero-Donates, Sheela Ramanathan, Caroline 
  
108 
108 
Saucier, and Subburaj Ilangumaran. 2014. “Regulation of MET Receptor Signaling by 
SOCS1 and Its Implications for Hepatocellular Carcinoma.” Current Pharmaceutical 
Design 20 (17): 2922–33. http://www.ncbi.nlm.nih.gov/pubmed/23944359. 
Gui, Yirui, Mehdi Yeganeh, Sheela Ramanathan, Chantal Leblanc, Véronique Pomerleau, 
Gerardo Ferbeyre, Caroline Saucier, and Subburaj Ilangumaran. 2011. “SOCS1 
Controls Liver Regeneration by Regulating HGF Signaling in Hepatocytes.” Journal 
of Hepatology 55 (6): 1300–1308. doi:10.1016/j.jhep.2011.03.027. 
Guicciardi, M E, and G J Gores. 2005. “Apoptosis: A Mechanism of Acute and Chronic 
Liver Injury.” Gut 54 (7): 1024–33. doi:10.1136/gut.2004.053850. 
Guidelines, EASL-ALEH Clinical Practice. 2015. “EASL-ALEH Clinical Practice 
Guidelines: Non-Invasive Tests for Evaluation of Liver Disease Severity and 
Prognosis.” Journal of Hepatology 63 (1): 237–64. doi:10.1016/j.jhep.2015.04.006. 
Guo, Jinsheng, and Scott L Friedman. 2007. “Hepatic Fibrogenesis.” Seminars in Liver 
Disease 27 (4): 413–26. doi:10.1055/s-2007-991517. 
Guo, Jinsheng, Johnny Loke, Feng Zheng, Feng Hong, Steven Yea, Masayuki Fukata, 
Mirko Tarocchi, et al. 2009. “Functional Linkage of Cirrhosis-Predictive Single 
Nucleotide Polymorphisms of Toll-like Receptor 4 to Hepatic Stellate Cell 
Responses.” Hepatology (Baltimore, Md.) 49 (3): 960–68. doi:10.1002/hep.22697. 
Guyot, Christelle, Chantal Combe, Evelyne Doudnikoff, Paulette Bioulac-sage, Charles 
Balabaud, and Alexis Desmouli. 2006. “Hepatic Fibrosis and Cirrhosis : The ( Myo ) 
Fibroblastic Cell Subpopulations Involved” 38: 135–51. 
doi:10.1016/j.biocel.2005.08.021. 
Hammerich, Linda, J??rg M. Bangen, Olivier Govaere, Henning W. Zimmermann, 
Nikolaus Gassler, Sebastian Huss, Christian Liedtke, et al. 2014. “Chemokine 
Receptor CCR6-Dependent Accumulation of ???? T Cells in Injured Liver Restricts 
Hepatic Inflammation and Fibrosis.” Hepatology 59 (2): 630–42. 
doi:10.1002/hep.26697. 
Hanada, Toshikatsu, Hiroki Yoshida, Seiya Kato, Kentaro Tanaka, Kohsuke Masutani, Jun 
Tsukada, Yoshio Nomura, Hiromitsu Mimata, Masato Kubo, and Akihiko Yoshimura. 
2003. “Suppressor of Cytokine Signaling-1 Is Essential for Suppressing Dendritic Cell 
Activation and Systemic Autoimmunity.” Immunity 19 (3): 437–50. 
  
109 
109 
http://www.ncbi.nlm.nih.gov/pubmed/14499118. 
Harrison, Douglas A. 2012. “The Jak/STAT Pathway.” Cold Spring Harbor Perspectives in 
Biology 4 (3). doi:10.1101/cshperspect.a011205. 
Hashmi, Ardeshir Z, Wyel Hakim, Emma A Kruglov, Azuma Watanabe, William Watkins, 
Jonathan A Dranoff, and Wajahat Z Mehal. 2007. “Adenosine Inhibits Cytosolic 
Calcium Signals and Chemotaxis in Hepatic Stellate Cells.” American Journal of 
Physiology. Gastrointestinal and Liver Physiology 292 (1): G395–401. 
doi:10.1152/ajpgi.00208.2006. 
Hellemans, Karine, Peggy Verbuyst, Erik Quartier, Frans Schuit, Krista Rombouts, Ross A 
S Chandraratna, Detlef Schuppan, and Albert Geerts. 2004. “Differential Modulation 
of Rat Hepatic Stellate Phenotype by Natural and Synthetic Retinoids.” Hepatology 
(Baltimore, Md.) 39 (1): 97–108. doi:10.1002/hep.20015. 
Hellerbrand, Claus. 2013. “Hepatic Stellate Cells—the Pericytes in the Liver.” Springer 
Verlag Berlin Heidelberg, 775–78. doi:10.1007/s00424-012-1209-5. 
Hemmann, Stefanie, Martin Roderfeld, and Elke Roeb. 2007. “Expression of MMPs and 
TIMPs in Liver Fibrosis – a Systematic Review with Special Emphasis on Anti-
Fibrotic Strategies” 46: 955–75. doi:10.1016/j.jhep.2007.02.003. 
Henriet, P, G G Rousseau, and Y Eeckhout. 1992. “Cloning and Sequencing of Mouse 
Collagenase cDNA. Divergence of Mouse and Rat Collagenases from the Other 
Mammalian Collagenases.” FEBS Letters 310 (2): 175–78. 
http://www.ncbi.nlm.nih.gov/pubmed/1383028. 
Hershey, Gurjit K Khurana. 2003. “IL-13 Receptors and Signaling Pathways: An Evolving 
Web.” The Journal of Allergy and Clinical Immunology 111 (4): 677–90; quiz 691. 
http://www.ncbi.nlm.nih.gov/pubmed/12704343. 
Hersz??nyi, L??szl??, Istv??n Hritz, G??bor Lakatos, M??ria Zs??fia Varga, and Zsolt 
Tulassay. 2012. “The Behavior of Matrix Metalloproteinases and Their Inhibitors in 
Colorectal Cancer.” International Journal of Molecular Sciences 13 (10): 13240–63. 
doi:10.3390/ijms131013240. 
Higashi, Kiyoshi, Yutaka Inagaki, Ko Fujimori, Atsuhito Nakao, Hideo Kaneko, and Iwao 
Nakatsuka. 2003. “Interferon-?? Interferes with Transforming Growth Factor-?? 
Signaling through Direct Interaction of YB-1 with Smad3.” Journal of Biological 
  
110 
110 
Chemistry 278 (44): 43470–79. doi:10.1074/jbc.M302339200. 
Hintermann, Edith, Monika Bayer, Josef M Pfeilschifter, Andrew D Luster, and Urs 
Christen. 2010. “CXCL10 Promotes Liver Fibrosis by Prevention of NK Cell 
Mediated Hepatic Stellate Cell Inactivation.” Journal of Autoimmunity 35 (4): 424–35. 
doi:10.1016/j.jaut.2010.09.003. 
Hirano, T, K Ishihara, and M Hibi. 2000. “Roles of STAT3 in Mediating the Cell Growth, 
Differentiation and Survival Signals Relayed through the IL-6 Family of Cytokine 
Receptors.” Oncogene 19 (21): 2548–56. doi:10.1038/sj.onc.1203551. 
Hong, Feng, Hsini Chou, Maria Isabel Fiel, and Scott L Friedman. 2013. “Antifibrotic 
Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory 
Targets, Dosing, and Window of Efficacy in Vivo.” Digestive Diseases and Sciences 
58 (1): 257–64. doi:10.1007/s10620-012-2325-y. 
Hong, Feng, Barbara Jaruga, Won Ho Kim, Svetlana Radaeva, Osama N. El-Assal, 
Zhigang Tian, Van Anh Nguyen, and Bin Gao. 2002. “Opposing Roles of STAT1 and 
STAT3 in T Cell-Mediated Hepatitis: Regulation by SOCS.” Journal of Clinical 
Investigation 110 (10): 1503–13. doi:10.1172/JCI200215841. 
Housset, C, D C Rockey, and D M Bissell. 1993. “Endothelin Receptors in Rat Liver: 
Lipocytes as a Contractile Target for Endothelin 1.” Proceedings of the National 
Academy of Sciences of the United States of America 90 (20): 9266–70. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=47548&tool=pmcentrez&r
endertype=abstract. 
Iimuro, Yuji, Toshihiro Nishio, Taisuke Morimoto, Takashi Nitta, Branko Stefanovic, Sung 
Kyu Choi, David A Brenner, and Yoshio Yamaoka. 2003. “Delivery of Matrix 
Metalloproteinase-1 Attenuates Established Liver Fibrosis in the Rat.” 
Gastroenterology 124 (2): 445–58. doi:10.1053/gast.2003.50063. 
Ikeda, K, T Wakahara, Y Q Wang, H Kadoya, N Kawada, and K Kaneda. 1999. “In Vitro 
Migratory Potential of Rat Quiescent Hepatic Stellate Cells and Its Augmentation by 
Cell Activation.” Hepatology (Baltimore, Md.) 29 (6): 1760–67. 
doi:10.1002/hep.510290640. 
Ilangumaran, Subburaj, Sheela Ramanathan, and Robert Rottapel. 2004. “Regulation of the 
Immune System by SOCS Family Adaptor Proteins.” Seminars in Immunology 16 (6): 
  
111 
111 
351–65. doi:10.1016/j.smim.2004.08.015. 
Imamura, Michio, Tadashi Ogawa, Yasuyuki Sasaguri, Kazuaki Chayama, and Hikaru 
Ueno. 2005. “Suppression of Macrophage Infiltration Inhibits Activation of Hepatic 
Stellate Cells and Liver Fibrogenesis in Rats.” Gastroenterology 128 (1): 138–46. 
doi:10.1053/j.gastro.2004.10.005. 
Impson, R Ichard J S, R Obert L M Oritz, D A L E C Ary, R Achael R Ichardson, and G 
Eorge H Ausmann. 1999. “The Conserved SOCS Box Motif in Suppressors of 
Cytokine Signaling Binds to Elongins B and C and May Couple Bound Proteins to 
Proteasomal Degradation” 96 (March): 2071–76. 
Inagaki, Y, and I Okazaki. 2007. “Emerging Insights into Transforming Growth Factor 
Beta Smad Signal in Hepatic Fibrogenesis.” Gut 56 (2): 284–92. 
doi:10.1136/gut.2005.088690. 
Iredale, J P. 1997. “Tissue Inhibitors Fibrosis of Metalloproteinases in Liver” 29 (I): 43–54. 
Iredale, J P, R C Benyon, J Pickering, M McCullen, M Northrop, S Pawley, C Hovell, and 
M J Arthur. 1998. “Mechanisms of Spontaneous Resolution of Rat Liver Fibrosis. 
Hepatic Stellate Cell Apoptosis and Reduced Hepatic Expression of Metalloproteinase 
Inhibitors.” The Journal of Clinical Investigation 102 (3): 538–49. 
doi:10.1172/JCI1018. 
Iredale, J P, Scott L. Friedman, Ruonan Xu, Zheng Zhang, Fu-sheng Wang, Hiromitsu 
Hayashi, Takao Sakai, et al. 2010. “Evolving Challenges in Hepatic Fibrosis.” Nature 
Reviews Gastroenterology & Hepatology 7 (8). Nature Publishing Group: 425–36. 
doi:10.1038/nrgastro.2010.97. 
Iredale, John P., Alexandra Thompson, and Neil C. Henderson. 2013. “Extracellular Matrix 
Degradation in Liver Fibrosis: Biochemistry and Regulation.” Biochimica et 
Biophysica Acta - Molecular Basis of Disease 1832 (7). Elsevier B.V.: 876–83. 
doi:10.1016/j.bbadis.2012.11.002. 
Iredale, JP, RC Benyon, MJ Arthur, WF Ferris, R Alcolado, PJ Winwood, N Clark, and G 
Murphy. 1996. “Tissue Inhibitor of Metalloproteinase-1 Messenger RNA Expression 
Is Enhanced Relative to Interstitial Collagenase Messenger RNA in Experimental 
Liver Injury and Fibrosis.” Hepatology 24 (1): 176–84. 
doi:10.1053/jhep.1996.v24.pm0008707259. 
  
112 
112 
Issa, Razao, Xiaoying Zhou, Nathan Trim, Harry Millward-Sadler, Stephen Krane, 
Christopher Benyon, and John Iredale. 2003. “Mutation in Collagen-1 That Confers 
Resistance to the Action of Collagenase Results in Failure of Recovery from CCl4-
Induced Liver Fibrosis, Persistence of Activated Hepatic Stellate Cells, and 
Diminished Hepatocyte Regeneration.” FASEB Journal : Official Publication of the 
Federation of American Societies for Experimental Biology 17 (1): 47–49. 
doi:10.1096/fj.02-0494fje. 
Iwaisako, Keiko, David A Brenner, and Tatiana Kisseleva. 2012. “What ’ S New in Liver 
Fibrosis ? The Origin of Myofibroblasts in Liver Fibrosis,” 65–68. doi:10.1111/j.1440-
1746.2011.07002.x. 
Iwaisako, Keiko, Kojiro Taura, and Yukinori Koyama. 2014. “Strategies to Detect Hepatic 
Myofibroblasts in Liver Cirrhosis of Different Etiologies,” 209–15. 
doi:10.1007/s40139-014-0057-8. 
Iwamoto, Hiroaki, Hironori Sakai, Seiya Tada, and Makoto Nakamuta. 1999. “Induction of 
Apoptosis in Rat Hepatic Stellate Cells by Disruption of Integrin-Mediated Cell 
Adhesion,” 83–89. 
Jamieson, Emma, Mark M W Chong, Gregory R Steinberg, Valentina Jovanovska, Barbara 
C Fam, Denise V R Bullen, Ye Chen, et al. 2005. “Socs1 Deficiency Enhances 
Hepatic Insulin Signaling *” 280 (36): 31516–21. doi:10.1074/jbc.M502163200. 
Järveläinen, Hannu, Annele Sainio, Markku Koulu, Thomas N Wight, and Risto Penttinen. 
2009. “Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy.” 
Pharmacological Reviews 61 (2): 198–223. doi:10.1124/pr.109.001289. 
Jeong, Won Il, Ogyi Park, Svetlana Radaeva, and Bin Gao. 2006. “STAT1 Inhibits Liver 
Fibrosis in Mice by Inhibiting Stellate Cell Proliferation and Stimulating NK Cell 
Cytotoxicity.” Hepatology 44 (6): 1441–51. doi:10.1002/hep.21419. 
Jeong, Kyu-shik. 2008. “Therapeutic Target for Chronic Liver Fibrosis by Regulation of 
Transforming Growth Factor-Beta,” 56–60. doi:10.1111/j.1755-9294.2008.00013.x. 
Jeong, Won-Il, Ogyi Park, and Bin Gao. 2008. “Abrogation of the Antifibrotic Effects of 
Natural Killer Cells/interferon-Gamma Contributes to Alcohol Acceleration of Liver 
Fibrosis.” Gastroenterology 134 (1): 248–58. doi:10.1053/j.gastro.2007.09.034. 
Jiang, Joy X., Kenichiro Mikami, Senthil Venugopal, Yong Li, and Natalie J. Török. 2009. 
  
113 
113 
“Apoptotic Body Engulfment by Hepatic Stellate Cells Promotes Their Survival by the 
JAK/STAT and Akt/NF-kappaB-Dependent Pathways.” Journal of Hepatology 51 (1). 
Elsevier: 139–48. doi:10.1016/j.jhep.2009.03.024. 
Jiang, Shuai, Hong-wei Zhang, Ming-hua Lu, Xiao-hong He, Yong Li, and Hua Gu. 2010. 
“MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting the 
Suppressor of Cytokine Signaling 1 Gene,” no. 6: 3119–28. doi:10.1158/0008-
5472.CAN-09-4250. 
Kamura, Takumi, Katsumi Maenaka, Shuhei Kotoshiba, Masaki Matsumoto, Daisuke 
Kohda, Ronald C Conaway, Joan Weliky Conaway, and Keiichi I Nakayama. 2004. 
“VHL-Box and SOCS-Box Domains Determine Binding Specificity Modules of 
Ubiquitin Ligases” 2: 3055–65. doi:10.1101/gad.1252404.ferred. 
Kandhi, Rajani, Diwakar Bobbala, Mehdi Yeganeh, Marian Mayhue, Alfredo Menendez, 
and Subburaj Ilangumaran. 2016. “Negative Regulation of the Hepatic Fibrogenic 
Response by Suppressor of Cytokine Signaling 1.” Cytokine 82 (June): 58–69. 
doi:10.1016/j.cyto.2015.12.007. 
Kanzler, S, A W Lohse, A Keil, J Henninger, H P Dienes, P Schirmacher, S Rose-John, K 
H zum Büschenfelde, and M Blessing. 1999. “TGF-beta1 in Liver Fibrosis: An 
Inducible Transgenic Mouse Model to Study Liver Fibrogenesis.” The American 
Journal of Physiology 276 (4 Pt 1): G1059–68. 
http://www.ncbi.nlm.nih.gov/pubmed/10198351. 
Kazi, Julhash U, Nuzhat N Kabir, Amilcar Flores-Morales, and Lars Rönnstrand. 2014. 
“SOCS Proteins in Regulation of Receptor Tyrosine Kinase Signaling.” Cellular and 
Molecular Life Sciences : CMLS 71 (17): 3297–3310. doi:10.1007/s00018-014-1619-
y. 
Kensler, Thomas W, Geng-Sun Qian, Jian-Guo Chen, and John D Groopman. 2003. 
“Translational Strategies for Cancer Prevention in Liver.” Nature Reviews. Cancer 3 
(5): 321–29. doi:10.1038/nrc1076. 
King, Talmadge E, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, 
Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, et al. 2014. “A Phase 3 Trial of 
Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.” The New England 
Journal of Medicine 370 (22): 2083–92. doi:10.1056/NEJMoa1402582. 
  
114 
114 
Kinjyo, Ichiko, Toshikatsu Hanada, Kyoko Inagaki-Ohara, Hiroyuki Mori, Daisuke Aki, 
Masanobu Ohishi, Hiroki Yoshida, Masato Kubo, and Akihiko Yoshimura. 2002. 
“SOCS1/JAB Is a Negative Regulator of LPS-Induced Macrophage Activation.” 
Immunity 17 (5): 583–91. http://www.ncbi.nlm.nih.gov/pubmed/12433365. 
Kinnman, N, O Goria, D Wendum, M C Gendron, C Rey, R Poupon, and C Housset. 2001. 
“Hepatic Stellate Cell Proliferation Is an Early Platelet-Derived Growth Factor-
Mediated Cellular Event in Rat Cholestatic Liver Injury.” Laboratory Investigation; a 
Journal of Technical Methods and Pathology 81 (12): 1709–16. 
doi:10.1038/labinvest.3780384. 
Kinoshita, T, H Sato, A Okada, E Ohuchi, K Imai, Y Okada, and M Seiki. 1998. “TIMP-2 
Promotes Activation of Progelatinase A by Membrane-Type 1 Matrix 
Metalloproteinase Immobilized on Agarose Beads.” The Journal of Biological 
Chemistry 273 (26): 16098–103. http://www.ncbi.nlm.nih.gov/pubmed/9632662. 
Kisseleva, Tatiana, and David A Brenner. 2007. “Role of Hepatic Stellate Cells in 
Fibrogenesis and the Reversal of Fibrosis” 22. doi:10.1111/j.1440-1746.2006.04658.x. 
Kisseleva, Tatiana, and David A. Brenner. 2006. “Hepatic Stellate Cells and the Reversal 
of Fibrosis.” Journal of Gastroenterology and Hepatology (Australia) 21 (SUPPL. 3). 
doi:10.1111/j.1440-1746.2006.04584.x. 
Kisseleva, Tatiana, Min Cong, Yonghan Paik, David Scholten, Chunyan Jiang, Chris 
Benner, Keiko Iwaisako, et al. 2012. “Myofibroblasts Revert to an Inactive Phenotype 
during Regression of Liver Fibrosis.” Proceedings of the National Academy of 
Sciences of the United States of America 109 (24): 9448–53. 
doi:10.1073/pnas.1201840109. 
Kisseleva, Tatiana, Hiroshi Uchinami, Nikki Feirt, Oscar Quintana-Bustamante, Jose 
Carlos Segovia, Robert F Schwabe, and David A Brenner. 2006. “Bone Marrow-
Derived Fibrocytes Participate in Pathogenesis of Liver Fibrosis.” Journal of 
Hepatology 45 (3). Elsevier: 429–38. doi:10.1016/j.jhep.2006.04.014. 
Knight, Belinda, Rebecca Lim, George C Yeoh, and John K Olynyk. 2007. “Interferon-
Gamma Exacerbates Liver Damage, the Hepatic Progenitor Cell Response and 
Fibrosis in a Mouse Model of Chronic Liver Injury.” Journal of Hepatology 47 (6): 
826–33. doi:10.1016/j.jhep.2007.06.022. 
  
115 
115 
Kobayashi, Naohito, Hiroji Uemura, Kiyotaka Nagahama, and Koji Okudela. 2012. 
“Identification of miR-30d as a Novel Prognostic Maker of Prostate Cancer . 
ABSTRACT :” 3 (11): 1455–71. 
Kordes, Claus, Iris Sawitza, and Dieter Häussinger. 2009. “Hepatic and Pancreatic Stellate 
Cells in Focus.” Biological Chemistry 390 (10): 1003–12. doi:10.1515/BC.2009.121. 
Krane, S M, M H Byrne, V Lemaître, P Henriet, J J Jeffrey, J P Witter, X Liu, H Wu, R 
Jaenisch, and Y Eeckhout. 1996. “Different Collagenase Gene Products Have 
Different Roles in Degradation of Type I Collagen.” The Journal of Biological 
Chemistry 271 (45): 28509–15. http://www.ncbi.nlm.nih.gov/pubmed/8910479. 
Kresse, H, and E Schönherr. 2001. “Proteoglycans of the Extracellular Matrix and Growth 
Control.” Journal of Cellular Physiology 189 (3): 266–74. doi:10.1002/jcp.10030. 
Krizhanovsky, Valery, Monica Yon, Ross A Dickins, Stephen Hearn, Janelle Simon, 
Cornelius Miething, Herman Yee, Lars Zender, and Scott W Lowe. 2008. “Senescence 
of Activated Stellate Cells Limits Liver Fibrosis.” Cell 134 (4): 657–67. 
doi:10.1016/j.cell.2008.06.049. 
Langhans, Bettina, Abdel Wahed Alwan, Benjamin Krämer, Andreas Glässner, Philipp 
Lutz, Christian P Strassburg, Jacob Nattermann, and Ulrich Spengler. 2015. 
“Regulatory CD4+ T Cells Modulate the Interaction between NK Cells and Hepatic 
Stellate Cells by Acting on Either Cell Type.” Journal of Hepatology 62 (2): 398–404. 
doi:10.1016/j.jhep.2014.08.038. 
Larsen, Lykke. 2002. “Suppressors of Cytokine Signalling : SOCS Review Article,” 833–
44. 
Latella, Giovanni, Antonella Vetuschi, Roberta Sferra, Valentina Catitti, Angela D’Angelo, 
Giuliana Zanninelli, Kathleen C Flanders, and Eugenio Gaudio. 2009. “Targeted 
Disruption of Smad3 Confers Resistance to the Development of Dimethylnitrosamine-
Induced Hepatic Fibrosis in Mice.” Liver International : Official Journal of the 
International Association for the Study of the Liver 29 (7): 997–1009. 
doi:10.1111/j.1478-3231.2009.02011.x. 
Leask, Andrew, and David J Abraham. n.d. “TGF- ␤ Signaling and the Fibrotic Response.” 
doi:10.1096/fj.03-1273rev. 
Lee, C G, R J Homer, Z Zhu, S Lanone, X Wang, V Koteliansky, J M Shipley, et al. 2001. 
  
116 
116 
“Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating 
Transforming Growth Factor beta(1).” The Journal of Experimental Medicine 194 (6): 
809–21. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2195954&tool=pmcentrez
&rendertype=abstract. 
Lee, Ursula E, B S Mstp, and Scott L Friedman. 2011. “Best Practice & Research Clinical 
Gastroenterology Mechanisms of Hepatic Fi Brogenesis.” Best Practice & Research 
Clinical Gastroenterology 25 (2). Elsevier Ltd: 195–206. 
doi:10.1016/j.bpg.2011.02.005. 
Lemoinne, Sara, Axelle Cadoret, Haquima El Mourabit, Dominique Thabut, and Chantal 
Housset. 2013. “Origins and Functions of Liver Myofibroblasts.” Biochimica et 
Biophysica Acta 1832 (7): 948–54. doi:10.1016/j.bbadis.2013.02.019. 
Levy, David E, and J E Darnell. 2002. “Stats: Transcriptional Control and Biological 
Impact.” Nature Reviews. Molecular Cell Biology 3 (9): 651–62. doi:10.1038/nrm909. 
Li, D, and S L Friedman. 1999. “Liver Fibrogenesis and the Role of Hepatic Stellate Cells: 
New Insights and Prospects for Therapy.” Journal of Gastroenterology and 
Hepatology 14 (February): 618–33. doi:10.1046. 
Lim, C P, T-T Phan, I J Lim, and X Cao. 2006. “Stat3 Contributes to Keloid Pathogenesis 
via Promoting Collagen Production, Cell Proliferation and Migration.” Oncogene 25 
(39): 5416–25. doi:10.1038/sj.onc.1209531. 
Linossi, Edmond M, and Sandra E Nicholson. 2012. “Critical Review The SOCS Box — 
Adapting Proteins for Ubiquitination and Proteasomal Degradation” 64 (April): 316–
23. doi:10.1002/iub.1011. 
Linossi, Edmond M., Jeffrey J. Babon, Douglas J. Hilton, and Sandra E. Nicholson. 2013. 
“Suppression of Cytokine Signaling: The SOCS Perspective.” Cytokine and Growth 
Factor Reviews 24 (3). Elsevier Ltd: 241–48. doi:10.1016/j.cytogfr.2013.03.005. 
Liu, Chenghai, Marianna D A Gaça, E Scott Swenson, Vincent F Vellucci, Michael Reiss, 
and Rebecca G Wells. 2003. “Smads 2 and 3 Are Differentially Activated by 
Transforming Growth Factor-Beta (TGF-Beta ) in Quiescent and Activated Hepatic 
Stellate Cells. Constitutive Nuclear Localization of Smads in Activated Cells Is TGF-
Beta-Independent.” The Journal of Biological Chemistry 278 (13): 11721–28. 
  
117 
117 
doi:10.1074/jbc.M207728200. 
Liu, Xingjun, Han Hu, Yin Jq, Xingjun Liu, and Han Hu. 2006. “Therapeutic Strategies 
against TGF- B Signaling Pathway in Hepatic Fibrosis,” 8–22. doi:10.1111/j.1478-
3231.2005.01192.x. 
Liu, Yan, Christoph Meyer, Chengfu Xu, Honglei Weng, Claus Hellerbrand, Peter ten 
Dijke, and Steven Dooley. 2013. “Animal Models of Chronic Liver Diseases.” 
American Journal of Physiology. Gastrointestinal and Liver Physiology 304 (5): 
G449–68. doi:10.1152/ajpgi.00199.2012. 
Lotersztajn, Sophie, Boris Julien, Fatima Teixeira-Clerc, Pascale Grenard, and Ariane 
Mallat. 2005. “Hepatic Fibrosis: Molecular Mechanisms and Drug Targets.” Annual 
Review of Pharmacology and Toxicology 45 (January). Annual Reviews: 605–28. 
doi:10.1146/annurev.pharmtox.45.120403.095906. 
Machida, Kazuya, and Bruce J Mayer. 2005. “The SH2 Domain : Versatile Signaling 
Module and Pharmaceutical Target” 1747: 1–25. doi:10.1016/j.bbapap.2004.10.005. 
Malinda, K M, and H K Kleinman. 1996. “The Laminins.” The International Journal of 
Biochemistry & Cell Biology 28 (9): 957–59. 
http://www.ncbi.nlm.nih.gov/pubmed/8930117. 
Mallat, Ariane, and Sophie Lotersztajn. 2013. “Reversion of Hepatic Stellate Cell to a 
Quiescent Phenotype: From Myth to Reality?” Journal of Hepatology 59 (2). 
European Association for the Study of the Liver: 383–86. 
doi:10.1016/j.jhep.2013.03.031. 
Mallette, A, Xavier Desche, Sheela Ramanathan, Julien Gagnon, Viviane Calabrese, Adrian 
Moores, Subburaj Ilangumaran, and Gerardo Ferbeyre. 2009. “Article SOCS1 Links 
Cytokine Signaling to p53 and Senescence,” 754–67. 
doi:10.1016/j.molcel.2009.09.044. 
Manicone, Anne M., and John K. McGuire. 2008. “Matrix Metalloproteinases as 
Modulators of Inflammation.” Seminars in Cell and Developmental Biology 19 (1): 
34–41. doi:10.1016/j.semcdb.2007.07.003. 
Manuscript, Author, and Therapeutic Target. 2009. “NIH Public Access” 12 (4): 791–803. 
doi:10.1016/j.cld.2008.07.004.Stellate. 
Mao, Yong, and Jean E Schwarzbauer. 2005. “Fibronectin Fibrillogenesis, a Cell-Mediated 
  
118 
118 
Matrix Assembly Process.” Matrix Biology : Journal of the International Society for 
Matrix Biology 24 (6): 389–99. doi:10.1016/j.matbio.2005.06.008. 
Marine, Jean-christophe, David J Topham, Catriona Mckay, Demin Wang, Evan Parganas, 
Dimitrios Stravopodis, Akihiko Yoshimura, James N Ihle, and Howard Hughes. 1999. 
“SOCS1 Deficiency Causes a Lymphocyte-Dependent Perinatal Lethality” 98 (iv): 
609–16. 
Marra, F, R G Romanelli, C Giannini, P Failli, S Pastacaldi, M C Arrighi, M Pinzani, G 
Laffi, P Montalto, and P Gentilini. 1999. “Monocyte Chemotactic Protein-1 as a 
Chemoattractant for Human Hepatic Stellate Cells.” Hepatology (Baltimore, Md.) 29 
(1): 140–48. doi:10.1002/hep.510290107. 
Masszi, András, and András Kapus. 2011. “Smaddening Complexity : The Role of Smad3 
in Epithelial-Myofibroblast” 8: 41–52. doi:10.1159/000320180. 
Mauviel, Alain. 2005. “Transforming Growth Factor-Beta: A Key Mediator of Fibrosis.” 
Methods in Molecular Medicine 117 (January): 69–80. doi:10.1385/1-59259-940-
0:069. 
Mederacke, Ingmar, Christine C Hsu, Juliane S Troeger, Peter Huebener, Xueru Mu, 
Dianne H Dapito, Jean-philippe Pradere, and Robert F Schwabe. 2013. “Of Its 
Aetiology.” Nature Communications 4. Nature Publishing Group: 1–11. 
doi:10.1038/ncomms3823. 
Melton, Andrew C, Russell K Soon, J Genevieve Park, Luis Martinez, Gregory W Dehart, 
and Hal F Yee. 2007. “Focal Adhesion Disassembly Is an Essential Early Event in 
Hepatic Stellate Cell Chemotaxis.” American Journal of Physiology. Gastrointestinal 
and Liver Physiology 293 (6): G1272–80. doi:10.1152/ajpgi.00134.2007. 
Melton, Andrew C, and Hal F Yee. 2007. “Hepatic Stellate Cell Protrusions Couple 
Platelet-Derived Growth Factor-BB to Chemotaxis.” Hepatology (Baltimore, Md.) 45 
(6): 1446–53. doi:10.1002/hep.21606. 
Meng, Fanli, Kai Wang, Tomonori Aoyama, Sergei I Grivennikov, Yonghan Paik, David 
Scholten, Min Cong, et al. 2012. “Interleukin-17 Signaling in Inflammatory, Kupffer 
Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in Mice.” 
Gastroenterology 143 (3): 765–76.e1–3. doi:10.1053/j.gastro.2012.05.049. 
Mews, P, P Phillips, R Fahmy, M Korsten, R Pirola, J Wilson, and M Apte. 2002. 
  
119 
119 
“Pancreatic Stellate Cells Respond to Inflammatory Cytokines: Potential Role in 
Chronic Pancreatitis.” Gut 50 (4): 535–41. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1773172&tool=pmcentrez
&rendertype=abstract. 
Mi, S., Z. Li, H.-Z. Yang, H. Liu, J.-P. Wang, Y.-G. Ma, X.-X. Wang, H.-Z. Liu, W. Sun, 
and Z.-W. Hu. 2011. “Blocking IL-17A Promotes the Resolution of Pulmonary 
Inflammation and Fibrosis Via TGF- 1-Dependent and -Independent Mechanisms.” 
The Journal of Immunology 187 (6): 3003–14. doi:10.4049/jimmunol.1004081. 
Miura, Kouichi, Ling Yang, Nico van Rooijen, Hirohide Ohnishi, and Ekihiro Seki. 2012. 
“Hepatic Recruitment of Macrophages Promotes Nonalcoholic Steatohepatitis through 
CCR2.” American Journal of Physiology. Gastrointestinal and Liver Physiology 302 
(11): G1310–21. doi:10.1152/ajpgi.00365.2011. 
Miyajima, Atsushi, Minoru Tanaka, and Tohru Itoh. 2014. “Stem/progenitor Cells in Liver 
Development, Homeostasis, Regeneration, and Reprogramming.” Cell Stem Cell 14 
(5). Elsevier Inc.: 561–74. doi:10.1016/j.stem.2014.04.010. 
Miyoshi, Hideyuki, Hajime Fujie, Yoshizumi Shintani, Takeya Tsutsumi, Seiko Shinzawa, 
Masatoshi Makuuchi, Norihiro Kokudo, et al. 2005. “Hepatitis C Virus Core Protein 
Exerts an Inhibitory Effect on Suppressor of Cytokine Signaling ( SOCS ) -1 Gene 
Expression” 43: 757–63. doi:10.1016/j.jhep.2005.03.028. 
Moreira, Roger Klein. 2007. “Hepatic Stellate Cells and Liver Fibrosis.” 
Moustakas, Aristidis, and Carl-Henrik Heldin. 2005. “Non-Smad TGF-Beta Signals.” 
Journal of Cell Science 118 (Pt 16): 3573–84. doi:10.1242/jcs.02554. 
Mouw, Janna K, Guanqing Ou, and Valerie M Weaver. 2014. “Extracellular Matrix 
Assembly :” Nature Publishing Group 15 (12). Nature Publishing Group: 771–85. 
doi:10.1038/nrm3902. 
Muir, A J, P B Sylvestre, and D C Rockey. 2006. “Interferon Gamma-1b for the Treatment 
of Fibrosis in Chronic Hepatitis C Infection.” Journal of Viral Hepatitis 13 (5): 322–
28. doi:10.1111/j.1365-2893.2005.00689.x. 
Murphy, Frank R, Razao Issa, Xiaoying Zhou, Shabna Ratnarajah, Hideaki Nagase, 
Michael J P Arthur, Christopher Benyon, and John P Iredale. 2002a. “Inhibition of 
Apoptosis of Activated Hepatic Stellate Cells by Tissue Inhibitor of 
  
120 
120 
Metalloproteinase-1 Is Mediated via Effects on Matrix” 277 (13): 11069–76. 
doi:10.1074/jbc.M111490200. 
———. 2002b. “Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Tissue 
Inhibitor of Metalloproteinase-1 Is Mediated via Effects on Matrix Metalloproteinase 
Inhibition: Implications for Reversibility of Liver Fibrosis.” The Journal of Biological 
Chemistry 277 (13): 11069–76. doi:10.1074/jbc.M111490200. 
Nagai, Hisaki, Yong Sung, Noboru Konishi, Masaru Baba, and Takeo Kubota. 2002. 
“Combined Hypermethylation and Chromosome Loss Associated with Inactivation of 
SSI-1 / SOCS-1 / JAB Gene in Human Hepatocellular Carcinomas” 186: 59–65. 
Nagase, H, K Suzuki, J J Enghild, and G Salvesen. 1991. “Stepwise Activation 
Mechanisms of the Precursors of Matrix Metalloproteinases 1 (Tissue Collagenase) 
and 3 (Stromelysin).” Biomedica Biochimica Acta 50 (4-6): 749–54. 
http://www.ncbi.nlm.nih.gov/pubmed/1666284. 
Naito, M, G Hasegawa, and K Takahashi. 1997. “Development, Differentiation, and 
Maturation of Kupffer Cells.” Microscopy Research and Technique 39 (4): 350–64. 
doi:10.1002/(SICI)1097-0029(19971115)39:4<350::AID-JEMT5>3.0.CO;2-L. 
Naito, Makoto, Go Hasegawa, Yusuke Ebe, and Takashi Yamamoto. 2004. “Differentiation 
and Function of Kupffer Cells.” Medical Electron Microscopy : Official Journal of the 
Clinical Electron Microscopy Society of Japan 37 (1): 16–28. doi:10.1007/s00795-
003-0228-x. 
Naka, Tetsuji, Masashi Narazaki, and Moritoshi Hirata. 1997. “Structure and Function of a 
New STAT-Induced STAT Inhibitor” 387 (June): 924–30. 
Nakagawa, Reiko, Tetsuji Naka, Hiroko Tsutsui, Minoru Fujimoto, Akihiro Kimura, 
Tatsuo Abe, Ekihiro Seki, et al. 2002. “SOCS-1 Participates in Negative Regulation of 
LPS Responses.” Immunity 17 (5): 677–87. 
http://www.ncbi.nlm.nih.gov/pubmed/12433373. 
Nakanishi, Hidehiko, Takahiro Sugiura, James B Streisand, Scott M Lonning, and Jesse D 
Roberts. 2007. “TGF-Beta-Neutralizing Antibodies Improve Pulmonary 
Alveologenesis and Vasculogenesis in the Injured Newborn Lung.” American Journal 
of Physiology. Lung Cellular and Molecular Physiology 293 (1): L151–61. 
doi:10.1152/ajplung.00389.2006. 
  
121 
121 
Nakashima, Taku, Akihito Yokoyama, Yojiro Onari, Hiroyasu Shoda, and Yoshinori 
Haruta. 2008. “Suppressor of Cytokine Signaling 1 Inhibits Pulmonary Inflammation 
and Fibrosis” 121 (5): 1269–76. doi:10.1016/j.jaci.2008.02.003. 
Nicola, Nicos A, and Christopher J Greenhalgh. 2000. “The Suppressors of Cytokine 
Signaling ( SOCS ) Proteins : Important Feedback Inhibitors of Cytokine Action” 28: 
1105–12. 
Notas, George, Tatiana Kisseleva, and David Brenner. 2009. “NK and NKT Cells in Liver 
Injury and Fibrosis.” Clinical Immunology (Orlando, Fla.) 130 (1): 16–26. 
doi:10.1016/j.clim.2008.08.008. 
Novobrantseva, Tatiana I, Gerard R Majeau, Aldo Amatucci, Sophia Kogan, Ian Brenner, 
Stefano Casola, Mark J Shlomchik, Victor Koteliansky, Paula S Hochman, and 
Alexander Ibraghimov. 2005. “Attenuated Liver Fibrosis in the Absence of B Cells.” 
The Journal of Clinical Investigation 115 (11): 3072–82. doi:10.1172/JCI24798. 
O’Byrne, Sheila M, Nuttaporn Wongsiriroj, Jenny Libien, Silke Vogel, Ira J Goldberg, 
Wolfgang Baehr, Krzysztof Palczewski, and William S Blaner. 2005. “Retinoid 
Absorption and Storage Is Impaired in Mice Lacking Lecithin:retinol Acyltransferase 
(LRAT).” The Journal of Biological Chemistry 280 (42): 35647–57. 
doi:10.1074/jbc.M507924200. 
O’Donoghue, Robert J J, Darryl A Knight, Carl D Richards, Cecilia M Prêle, Hui Ling Lau, 
Andrew G Jarnicki, Jessica Jones, et al. 2012. “Genetic Partitioning of Interleukin-6 
Signalling in Mice Dissociates Stat3 from Smad3-Mediated Lung Fibrosis.” EMBO 
Molecular Medicine 4 (9): 939–51. doi:10.1002/emmm.201100604. 
O’Hara, Steven P, James H Tabibian, Patrick L Splinter, and Nicholas F LaRusso. 2013. 
“The Dynamic Biliary Epithelia: Molecules, Pathways, and Disease.” Journal of 
Hepatology 58 (3): 575–82. doi:10.1016/j.jhep.2012.10.011. 
O’Reilly, S., M. Ciechomska, R. Cant, and J. M. van Laar. 2014. “Interleukin-6 (IL-6) 
Trans Signaling Drives a STAT3-Dependent Pathway That Leads to Hyperactive 
Transforming Growth Factor-  (TGF- ) Signaling Promoting SMAD3 Activation and 
Fibrosis via Gremlin Protein.” Journal of Biological Chemistry 289 (14): 9952–60. 
doi:10.1074/jbc.M113.545822. 
Oakley, Fiona, Muriel Meso, John P. Iredale, Karen Green, Carylyn J. Marek, Xiaoying 
  
122 
122 
Zhou, Michael J. May, Harry Millward-Sadler, Matthew C. Wright, and Derek A. 
Mann. 2005. “Inhibition of Inhibitor of κB Kinases Stimulates Hepatic Stellate Cell 
Apoptosis and Accelerated Recovery from Rat Liver Fibrosis.” Gastroenterology 128 
(1): 108–20. doi:10.1053/j.gastro.2004.10.003. 
Ogata, H, T Chinen, T Yoshida, I Kinjyo, G Takaesu, H Shiraishi, M Iida, T Kobayashi, 
and a Yoshimura. 2006. “Loss of SOCS3 in the Liver Promotes Fibrosis by Enhancing 
STAT3-Mediated TGF-beta1 Production.” Oncogene 25 (17): 2520–30. 
doi:10.1038/sj.onc.1209281. 
Okochi, Osamu, Kenji Hibi, Mitsuru Sakai, Soichiro Inoue, Shin Takeda, and Tetsuya 
Kaneko. 2003. “Methylation-Mediated Silencing of SOCS-1 Gene in Hepatocellular 
Carcinoma Derived from Cirrhosis” 9: 5295–98. 
Olaso, Elvira, Kazuo Ikeda, Francis J Eng, Lieming Xu, Li-hsien Wang, Hsin Chieh Lin, 
and Scott L Friedman. 2001. “DDR2 Receptor Promotes MMP-2 – Mediated 
Proliferation and Invasion by Hepatic Stellate Cells.” Analysis 108 (9): 1369–78. 
doi:10.1172/JCI200112373.Introduction. 
Onozuka, Izumi, Sei Kakinuma, Akihide Kamiya, Masato Miyoshi, Naoya Sakamoto, Kei 
Kiyohashi, Takako Watanabe, et al. 2011. “Cholestatic Liver Fibrosis and Toxin-
Induced Fibrosis Are Exacerbated in Matrix Metalloproteinase-2 Deficient Mice.” 
Biochemical and Biophysical Research Communications 406 (1). Elsevier Inc.: 134–
40. doi:10.1016/j.bbrc.2011.02.012. 
Page-mccaw, Andrea, Andrew J Ewald, and Zena Werb. 2007. “Matrix Metalloproteinases 
and the Regulation of Tissue Remodelling” 8 (March): 221–33. doi:10.1038/nrm2125. 
Paik, Yong-Han, Robert F Schwabe, Ramón Bataller, Maria P Russo, Christian Jobin, and 
David A Brenner. 2003. “Toll-like Receptor 4 Mediates Inflammatory Signaling by 
Bacterial Lipopolysaccharide in Human Hepatic Stellate Cells.” Hepatology 
(Baltimore, Md.) 37 (5): 1043–55. doi:10.1053/jhep.2003.50182. 
Papoulas, Michail, and Stamatios Theocharis. 2009. “Primary Liver Tumors: Origin and 
Target Therapy.” Expert Opinion on Therapeutic Targets 13 (8): 957–65. 
doi:10.1517/14728220903074588. 
Parés, Albert, Ramón Planas, Miguel Torres, Joan Caballería, Josep M. Viver, Doroteo 
Acero, Juliá Panés, Joaquim Rigau, Justiniano Santos, and Joan Rodés. 1998. “Effects 
  
123 
123 
of Silymarin in Alcoholic Patients with Cirrhosis of the Liver: Results of a Controlled, 
Double-Blind, Randomized and Multicenter Trial.” Journal of Hepatology 28 (4): 
615–21. doi:10.1016/S0168-8278(98)80285-7. 
Park, Ogyi, Won-Il Jeong, Lei Wang, Hua Wang, Zhe-Xiong Lian, M Eric Gershwin, and 
Bin Gao. 2009. “Diverse Roles of Invariant Natural Killer T Cells in Liver Injury and 
Fibrosis Induced by Carbon Tetrachloride.” Hepatology (Baltimore, Md.) 49 (5): 
1683–94. doi:10.1002/hep.22813. 
Parola, Maurizio, and Gaia Robino. 2001. “Oxidative Stress-Related Molecules and Liver 
Fibrosis.” Journal of Hepatology 35 (2): 297–306. doi:10.1016/S0168-
8278(01)00142-8. 
Parsons, Christopher J, Blair U Bradford, Clark Q Pan, Ellen Cheung, Michael Schauer, 
Andreas Knorr, Barbara Krebs, et al. 2004. “Antifibrotic Effects of a Tissue Inhibitor 
of Metalloproteinase-1 Antibody on Established Liver Fibrosis in Rats.” Hepatology 
(Baltimore, Md.) 40 (5): 1106–15. doi:10.1002/hep.20425. 
Piessevaux, Julie, Delphine Lavens, Frank Peelman, and Jan Tavernier. 2008. “The Many 
Faces of the SOCS Box” 19: 371–81. doi:10.1016/j.cytogfr.2008.08.006. 
Pinzani, M, L Gesualdo, G M Sabbah, and H E Abboud. 1989. “Effects of Platelet-Derived 
Growth Factor and Other Polypeptide Mitogens on DNA Synthesis and Growth of 
Cultured Rat Liver Fat-Storing Cells.” The Journal of Clinical Investigation 84 (6): 
1786–93. doi:10.1172/JCI114363. 
Pinzani, M, S Milani, C Grappone, F L Weber, P Gentilini, and H E Abboud. 1994. 
“Expression of Platelet-Derived Growth Factor in a Model of Acute Liver Injury.” 
Hepatology (Baltimore, Md.) 19 (3): 701–7. 
http://www.ncbi.nlm.nih.gov/pubmed/8119696. 
Pinzani, M, S Milani, H Herbst, R DeFranco, C Grappone, A Gentilini, A Caligiuri, et al. 
1996. “Expression of Platelet-Derived Growth Factor and Its Receptors in Normal 
Human Liver and during Active Hepatic Fibrogenesis.” The American Journal of 
Pathology 148 (3): 785–800. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1861723&tool=pmcentrez
&rendertype=abstract. 
Pinzani, M, and K Rombouts. 2004. “Liver Fibrosis : From the Bench to Clinical Targets” 
  
124 
124 
36: 231–42. doi:10.1016/j.dld.2004.01.003. 
Pinzani, Massimo. 2002. “PDGF and Signal Transduction in Hepatic Stellate Cells.” 
Frontiers in Bioscience : A Journal and Virtual Library 7 (August): d1720–26. 
http://www.ncbi.nlm.nih.gov/pubmed/12133817. 
Pinzani, Massimo, and Jose Macias-barragan. 2016. “Update on the Pathophysiology of 
Liver Fibrosis Update on the Pathophysiology of Liver Fibrosis” 4124 (January). 
doi:10.1586/egh.10.47. 
Pockros, Paul J, Lennox Jeffers, Nezam Afdhal, Zachary D Goodman, David Nelson, 
Robert G Gish, K Rajender Reddy, et al. 2007. “Final Results of a Double-Blind, 
Placebo-Controlled Trial of the Antifibrotic Efficacy of Interferon-gamma1b in 
Chronic Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.” Hepatology 
(Baltimore, Md.) 45 (3): 569–78. doi:10.1002/hep.21561. 
Poli, Giuseppe. 2000. “Pathogenesis of Liver ® Brosis : Role of Oxidative Stress” 21. 
Poynard, Thierry, John McHutchison, Michael Manns, Christian Trepo, Karen Lindsay, 
Zachary Goodman, Mei-Hsiu Ling, and Janice Albrecht. 2002. “Impact of Pegylated 
Interferon Alfa-2b and Ribavirin on Liver Fibrosis in Patients with Chronic Hepatitis 
C.” Gastroenterology 122 (5): 1303–13. 
http://www.ncbi.nlm.nih.gov/pubmed/11984517. 
Press, Dove. 2011. “Reversal of Hepatic Fibrosis : Pathophysiological Basis of Antifibrotic 
Therapies,” 69–80. 
Racanelli, Vito, and Barbara Rehermann. 2006. “The Liver as an Immunological Organ.” 
Hepatology (Baltimore, Md.) 43 (2 Suppl 1): S54–62. doi:10.1002/hep.21060. 
Radaeva, Svetlana, Rui Sun, Barbara Jaruga, Van T Nguyen, Zhigang Tian, and Bin Gao. 
2006. “Natural Killer Cells Ameliorate Liver Fibrosis by Killing Activated Stellate 
Cells in NKG2D-Dependent and Tumor Necrosis Factor-Related Apoptosis-Inducing 
Ligand-Dependent Manners.” Gastroenterology 130 (2): 435–52. 
doi:10.1053/j.gastro.2005.10.055. 
Radbill, Brian D, Ritu Gupta, Maria Celeste M Ramirez, Analisa DiFeo, John A 
Martignetti, Carlos E Alvarez, Scott L Friedman, et al. 2011. “Loss of Matrix 
Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating 
Collagen I Expression.” Digestive Diseases and Sciences 56 (2): 406–16. 
  
125 
125 
doi:10.1007/s10620-010-1296-0. 
Ramachandran, Prakash, Antonella Pellicoro, Madeleine a Vernon, Luke Boulter, Rebecca 
L Aucott, Aysha Ali, Stephen N Hartland, et al. 2012. “Differential Ly-6C Expression 
Identifies the Recruited Macrophage Phenotype, Which Orchestrates the Regression of 
Murine Liver Fibrosis.” Proceedings of the National Academy of Sciences of the 
United States of America 109 (46): E3186–95. doi:10.1073/pnas.1119964109. 
Rawlings, Jason S, M Kristin, and Douglas A Harrison. 2004. “The JAK / STAT Signaling 
Pathway Th E J AK / S TAT Si G Nalin G P a Thw a Y” 1: 1281–83. 
doi:10.1242/jcs.00963. 
Regev, Arie, Mariana Berho, Lennox J Jeffers, Clara Milikowski, Enrique G Molina, 
Nikolaos T Pyrsopoulos, Zheng-Zhou Feng, K Rajender Reddy, and Eugene R Schiff. 
2002. “Sampling Error and Intraobserver Variation in Liver Biopsy in Patients with 
Chronic HCV Infection.” The American Journal of Gastroenterology 97 (10): 2614–
18. doi:10.1111/j.1572-0241.2002.06038.x. 
Reynaert, H. 2002. “Hepatic Stellate Cells: Role in Microcirculation and Pathophysiology 
of Portal Hypertension.” Gut 50 (4): 571–81. doi:10.1136/gut.50.4.571. 
Reynaert, H, M G Thompson, T Thomas, and A Geerts. 2002. “Hepatic Stellate Cells : Role 
in Microcirculation and Pathophysiology of Portal Hypertension,” no. 3. 
Richeldi, Luca, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, 
Andrew G Nicholson, Kevin K Brown, et al. 2011. “Efficacy of a Tyrosine Kinase 
Inhibitor in Idiopathic Pulmonary Fibrosis.” The New England Journal of Medicine 
365 (12): 1079–87. doi:10.1056/NEJMoa1103690. 
Robertson, Helen, John A Kirby, William W Yip, David E J Jones, and Alastair D Burt. 
2007. “Biliary Epithelial-Mesenchymal Transition in Posttransplantation Recurrence 
of Primary Biliary Cirrhosis.” Hepatology (Baltimore, Md.) 45 (4): 977–81. 
doi:10.1002/hep.21624. 
Rockey, D C, J K Boyles, G Gabbiani, and S L Friedman. 1992. “Rat Hepatic Lipocytes 
Express Smooth Muscle Actin upon Activation in Vivo and in Culture.” Journal of 
Submicroscopic Cytology and Pathology 24 (2): 193–203. 
http://www.ncbi.nlm.nih.gov/pubmed/1600511. 
Rockey, D C, J J Maher, W R Jarnagin, G Gabbiani, and S L Friedman. 1992. “Inhibition 
  
126 
126 
of Rat Hepatic Lipocyte Activation in Culture by Interferon-Gamma.” Hepatology 
(Baltimore, Md.) 16 (15): 776–84. 
Rockey, D C, and R A Weisiger. 1996. “Endothelin Induced Contractility of Stellate Cells 
from Normal and Cirrhotic Rat Liver: Implications for Regulation of Portal Pressure 
and Resistance.” Hepatology (Baltimore, Md.) 24 (1): 233–40. 
doi:10.1002/hep.510240137. 
Rockey, Don C. 2006. “Hepatic Fibrosis , Stellate Cells , and Portal Hypertension” 10: 
459–79. doi:10.1016/j.cld.2006.08.017. 
———. 2008. “Current a Nd Future Anti - Fibrotic Therapies for Chronic Liver Dis Eas 
E.” Clinics in Liver Disease 12 (4). Elsevier Ltd: 939–62. 
doi:10.1016/j.cld.2008.07.011. 
Rockey, Don C. 2003. “Vascular Mediators in the Injured Liver.” Hepatology 37 (1): 4–12. 
doi:10.1053/jhep.2003.50044. 
Rodríguez, Cristina, Antonio Rodríguez-Sinovas, and José Martínez-González. 2008. 
“Lysyl Oxidase as a Potential Therapeutic Target.” Drug News & Perspectives 21 (4): 
218–24. doi:10.1358/dnp.2008.21.4.1213351. 
Rozario, Tania, and Douglas W DeSimone. 2010. “The Extracellular Matrix in 
Development and Morphogenesis: A Dynamic View.” Developmental Biology 341 
(1): 126–40. doi:10.1016/j.ydbio.2009.10.026. 
Ruck, Peter, and Jia-Cheng Xiao. 2002. “Stem-like Cells in Hepatoblastoma.” Medical and 
Pediatric Oncology 39 (5): 504–7. doi:10.1002/mpo.10175. 
Safadi, Rifaat, Masayuki Ohta, Carlos E. Alvarez, M. Isabel Fiel, Meena Bansal, Wajahat 
Z. Mehal, and Scott L. Friedman. 2004. “Immune Stimulation of Hepatic Fibrogenesis 
by CD8 Cells and Attenuation by Transgenic Interleukin-10 from Hepatocytes.” 
Gastroenterology 127 (3): 870–82. doi:10.1053/j.gastro.2004.04.062. 
Saile, Bernhard, Christoph Eisenbach, Jozsef Dudas, Hammoudeh El-Armouche, and 
Giuliano Ramadori. 2004. “Interferon-Gamma Acts Proapoptotic on Hepatic Stellate 
Cells (HSC) and Abrogates the Antiapoptotic Effect of Interferon-Alpha by an 
HSP70-Dependant Pathway.” European Journal of Cell Biology 83 (9): 469–76. 
http://www.ncbi.nlm.nih.gov/pubmed/15540463. 
Saito, Fumitake, Sadatomo Tasaka, Ken-Ichiro Inoue, Keisuke Miyamoto, Yasushi 
  
127 
127 
Nakano, Yuko Ogawa, Wakako Yamada, et al. 2008. “Role of Interleukin-6 in 
Bleomycin-Induced Lung Inflammatory Changes in Mice.” American Journal of 
Respiratory Cell and Molecular Biology 38 (5): 566–71. doi:10.1165/rcmb.2007-
0299OC. 
Saito, Jacqueline M., Michelle K. Bostick, Carson B. Campe, Junquan Xu, and Jacquelyn J. 
Maher. 2003. “Infiltrating Neutrophils in Bile Duct-Ligated Livers Do Not Promote 
Hepatic Fibrosis.” Hepatology Research : The Official Journal of the Japan Society of 
Hepatology 25 (2): 180–91. http://www.ncbi.nlm.nih.gov/pubmed/12644055. 
Sánchez-Valle, V, N C Chávez-Tapia, M Uribe, and N Méndez-Sánchez. 2012. “Role of 
Oxidative Stress and Molecular Changes in Liver Fibrosis: A Review.” Current 
Medicinal Chemistry 19 (28): 4850–60. doi:10.2174/092986712803341520. 
Sasaki, A, G Matsuzaki, T Ikeda, M Hotokezaka, K Chijiiwa, M Kubo, H Yoshida, Y 
Nawa, and A Yoshimura. 2006. “In Mice,” 212–19. doi:10.1136/gut.2004.062653. 
Sasaki, Atsuo, Hideo Yasukawa, Asuka Suzuki, Shintaro Kamizono, Takanori Syoda, 
Ichiko Kinjyo, Mika Sasaki, James A Johnston, and Akihiko Yoshimura. 1999. “Janus 
Tyrosine Kinase by Binding through the N-Terminal Kinase Inhibitory Region as Well 
as SH2 Domain” 3: 339–51. 
Saxena, Neeraj K, Kazuo Ikeda, Don C Rockey, Scott L Friedman, and Frank A Anania. 
2002. “Leptin in Hepatic Fibrosis: Evidence for Increased Collagen Production in 
Stellate Cells and Lean Littermates of Ob/ob Mice.” Hepatology (Baltimore, Md.) 35 
(4): 762–71. doi:10.1053/jhep.2002.32029. 
Scheerens, H, J R Arron, Y Zheng, W S Putnam, R W Erickson, D F Choy, J M Harris, J 
Lee, N N Jarjour, and J G Matthews. 2014. “The Effects of Lebrikizumab in Patients 
with Mild Asthma Following Whole Lung Allergen Challenge.” Clinical and 
Experimental Allergy : Journal of the British Society for Allergy and Clinical 
Immunology 44 (1): 38–46. doi:10.1111/cea.12220. 
Schuppan, D., M. Ruehl, R. Somasundaram, and E. G. Hahn. 2001. “Matrix as a Modulator 
of Hepatic Fibrogenesis.” Seminars in Liver Disease 21 (3): 351–72. doi:10.1055/s-
2001-17556. 
Schuppan, Detlef, and Yong Ook Kim. 2013. “Review Series Evolving Therapies for Liver 
Fi Brosis” 123 (5): 1887–1901. doi:10.1172/JCI66028.The. 
  
128 
128 
Sciences, Medical. 1998. “Liver Degeneration and Lymphoid Deficiencies in Mice Lacking 
Suppressor of Cytokine Signaling-1” 95 (November): 14395–99. 
Segatto, Oreste, Sergio Anastasi, and Stefano Alemà. 2011. “Regulation of Epidermal 
Growth Factor Receptor Signalling by Inducible Feedback Inhibitors.” Journal of Cell 
Science 124 (11): 1785–93. http://jcs.biologists.org/content/124/11/1785.abstract. 
Seki, Ekihiro, Samuele de Minicis, Sayaka Inokuchi, Kojiro Taura, Katsumi Miyai, Nico 
van Rooijen, Robert F Schwabe, and David A Brenner. 2009. “CCR2 Promotes 
Hepatic Fibrosis in Mice.” Hepatology (Baltimore, Md.) 50 (1): 185–97. 
doi:10.1002/hep.22952. 
Seki, Ekihiro, Samuele De Minicis, Christoph H Osterreicher, Johannes Kluwe, Yosuke 
Osawa, David a Brenner, and Robert F Schwabe. 2007. “TLR4 Enhances TGF-Beta 
Signaling and Hepatic Fibrosis.” Nature Medicine 13 (11): 1324–32. 
doi:10.1038/nm1663. 
Senoo, Haruki. 2004. “Structure and Function of Hepatic Stellate Cells.” Medical Electron 
Microscopy 37 (1): 3–15. doi:10.1007/s00795-003-0230-3. 
Senoo, Haruki, Kiwamu Yoshikawa, Mayako Morii, Mitsutaka Miura, Katsuyuki Imai, and 
Yoshihiro Mezaki. 2010. “Hepatic Stellate Cell (Vitamin A-Storing Cell) and Its 
Relative--Past, Present and Future.” Cell Biology International 34 (12): 1247–72. 
doi:10.1042/CBI20100321. 
Shafiei, Mahnoush S, Don C Rockey, and Liver Diseases. 2014. “Healing” 92 (2): 305–16. 
doi:10.1038/labinvest.2011.155.The. 
Shafiei, Mahnoush S., and Don C. Rockey. 2006. “The Role of Integrin-Linked Kinase in 
Liver Wound Healing.” Journal of Biological Chemistry 281 (34): 24863–72. 
doi:10.1074/jbc.M513544200. 
Shi, Yigong, and Joan Massague. 2003. “Mechanisms of TGF- ␤ Signaling from Cell 
Membrane to the Nucleus” 113 (Figure 2): 685–700. 
Shi, Z, a E Wakil, and D C Rockey. 1997. “Strain-Specific Differences in Mouse Hepatic 
Wound Healing Are Mediated by Divergent T Helper Cytokine Responses.” 
Proceedings of the National Academy of Sciences of the United States of America 94 
(20): 10663–68. doi:10.1073/pnas.94.20.10663. 
Shoda, Hiroyasu, Akihito Yokoyama, Ryouhei Nishino, Taku Nakashima, Nobuhisa 
  
129 
129 
Ishikawa, Yoshinori Haruta, Noboru Hattori, Tetsuji Naka, and Nobuoki Kohno. 2007. 
“Overproduction of Collagen and Diminished SOCS1 Expression Are Causally 
Linked in Fibroblasts from Idiopathic Pulmonary Fibrosis” 353: 1004–10. 
doi:10.1016/j.bbrc.2006.12.128. 
Standish, R A, E Cholongitas, A Dhillon, A K Burroughs, and A P Dhillon. 2006. “An 
Appraisal of the Histopathological Assessment of Liver Fibrosis.” Gut 55 (4): 569–78. 
doi:10.1136/gut.2005.084475. 
Starr, Robyn, Tracy A Willson, and Elizabeth M Viney. 1997. “A Family of Cytokine-
Inducible Inhibitors of Signalling” 387 (June): 917–21. 
Strauss, Edna. 2010. “Usefulness of Liver Biopsy in Chronic Hepatitis C” 9: 39–42. 
Su, Tung-hung, Chung-wai Shiau, Ping Jao, Chen-hua Liu, Chun-jen Liu, Wei-tien Tai, and 
Yung-ming Jeng. 2015. “Sorafenib and Its Derivative SC-1 Exhibit Antifibrotic 
Effects through Signal Transducer and Activator of Transcription 3 Inhibition” 112 
(23): 1–6. doi:10.1073/pnas.1507499112. 
Sugihara, A, T Tsujimura, Y Fujita, Y Nakata, and N Terada. 1999. “Evaluation of Role of 
Mast Cells in the Development of Liver Fibrosis Using Mast Cell-Deficient Rats and 
Mice.” Journal of Hepatology 30 (5): 859–67. 
http://www.ncbi.nlm.nih.gov/pubmed/10365813. 
Sullivan, Lynda A O, Clifford Liongue, Rowena S Lewis, Sarah E M Stephenson, and 
Alister C Ward. 2007. “Cytokine Receptor Signaling through the Jak – Stat – Socs 
Pathway in Disease” 44: 2497–2506. doi:10.1016/j.molimm.2006.11.025. 
Tacke, Frank, and Christian Trautwein. 2015. “Mechanisms of Liver Fibrosis Resolution.” 
Journal of Hepatology 63 (4). European Association for the Study of the Liver: 1038–
39. doi:10.1016/j.jhep.2015.03.039. 
Taimr, Pavel, Hajime Higuchi, Eva Kocova, Richard A Rippe, Scott Friedman, and 
Gregory J Gores. 2003. “Activated Stellate Cells Express the TRAIL Receptor-2/death 
Receptor-5 and Undergo TRAIL-Mediated Apoptosis.” Hepatology (Baltimore, Md.) 
37 (1): 87–95. doi:10.1053/jhep.2003.50002. 
Takahara, T, K Furui, J Funaki, Y Nakayama, H Itoh, C Miyabayashi, H Sato, M Seiki, A 
Ooshima, and A Watanabe. 1995. “Increased Expression of Matrix Metalloproteinase-
II in Experimental Liver Fibrosis in Rats.” Hepatology (Baltimore, Md.) 21 (3): 787–
  
130 
130 
95. http://www.ncbi.nlm.nih.gov/pubmed/7875677. 
Tamiya, Taiga, Ikko Kashiwagi, Reiko Takahashi, Hideo Yasukawa, and Akihiko 
Yoshimura. 2016. “ATVB in Focus JAK / STAT Pathways Regulation of T-Cell 
Inflammation by SOCS1 and SOCS3.” doi:10.1161/ATVBAHA.110.207464. 
Taub, Rebecca. 2003. “Hepatoprotection via the IL-6/Stat3 Pathway.” The Journal of 
Clinical Investigation 112 (7): 978–80. doi:10.1172/JCI19974. 
———. 2004. “Liver Regeneration: From Myth to Mechanism.” Nature Reviews. 
Molecular Cell Biology 5 (10): 836–47. doi:10.1038/nrm1489. 
Taura, Kojiro, Kouichi Miura, Keiko Iwaisako, Christoph H. ?? Sterreicher, Yuzo Kodama, 
Melitta Penz-?? Sterreicher, and David A. Brenner. 2010. “Hepatocytes Do Not 
Undergo Epithelial-Mesenchymal Transition in Liver Fibrosis in Mice.” Hepatology 
51 (3): 1027–36. doi:10.1002/hep.23368. 
Theocharis, Achilleas D., Spyros S. Skandalis, Chrysostomi Gialeli, and Nikos K. 
Karamanos. 2015. “Extracellular Matrix Structure.” Advanced Drug Delivery Reviews 
97. Elsevier B.V.: 4–27. doi:10.1016/j.addr.2015.11.001. 
Théret, N, K Lehti, O Musso, and B Clément. 1999. “MMP2 Activation by Collagen I and 
Concanavalin A in Cultured Human Hepatic Stellate Cells.” Hepatology (Baltimore, 
Md.) 30 (2): 462–68. doi:10.1002/hep.510300236. 
Torisu, Takehiro, Mako Nakaya, Satoko Watanabe, Masayuki Hashimoto, Hideyuki 
Yoshida, Takatoshi Chinen, Ryoko Yoshida, et al. 2008. “Suppressor of Cytokine 
Signaling 1 Protects Mice against Concanavalin A-Induced Hepatitis by Inhibiting 
Apoptosis.” Hepatology 47 (5): 1644–54. doi:10.1002/hep.22214. 
Trengove, Monique C, and Alister C Ward. 2013. “Review Article SOCS Proteins in 
Development and Disease.” American Journal of Clinical and Experimental 
Immunology 2 (1): 1–29. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3714205&tool=pmcentrez
&rendertype=abstract. 
Troeger, Juliane S, Ingmar Mederacke, Geum-Youn Gwak, Dianne H Dapito, Xueru Mu, 
Christine C Hsu, Jean-Philippe Pradere, Richard A Friedman, and Robert F Schwabe. 
2012. “Deactivation of Hepatic Stellate Cells during Liver Fibrosis Resolution in 
Mice.” Gastroenterology 143 (4): 1073–83.e22. doi:10.1053/j.gastro.2012.06.036. 
  
131 
131 
Tsochatzis, Emmanuel A., Jaime Bosch, and Andrew K. Burroughs. 2014. “Liver 
Cirrhosis.” The Lancet 383 (9930). Elsevier Ltd: 1749–61. doi:10.1016/S0140-
6736(14)60121-5. 
Ueberham, Elke, Rainer Löw, Uwe Ueberham, Kai Schönig, Hermann Bujard, and Rolf 
Gebhardt. 2003. “Conditional Tetracycline-Regulated Expression of TGF-beta1 in 
Liver of Transgenic Mice Leads to Reversible Intermediary Fibrosis.” Hepatology 
(Baltimore, Md.) 37 (5): 1067–78. doi:10.1053/jhep.2003.50196. 
Uemura, Masayuki, E Scott Swenson, Marianna D A Gaça, Frank J Giordano, Michael 
Reiss, and Rebecca G Wells. 2005. “Smad2 and Smad3 Play Different Roles in Rat 
Hepatic Stellate Cell Function and Alpha-Smooth Muscle Actin Organization.” 
Molecular Biology of the Cell 16 (9): 4214–24. doi:10.1091/mbc.E05-02-0149. 
Ulloa, L, J Doody, and J Massagué. 1999. “Inhibition of Transforming Growth Factor-
beta/SMAD Signalling by the Interferon-gamma/STAT Pathway.” Nature 397 (6721): 
710–13. doi:10.1038/17826. 
Verrecchia, Franck, and Alain Mauviel. 2007. “Transforming Growth Factor-Beta and 
Fibrosis.” World Journal of Gastroenterology 13 (22): 3056–62. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4172611&tool=pmcentrez
&rendertype=abstract. 
Verrecchia, Franck, Alain Mauviel, Franck Verrecchia, Alain Mauviel, World Jour-, Franck 
Verrecchia, and Alain Mauviel. 2010. “Transforming Growth Factor-Beta and Fibrosis 
. To Cite This Version : Transforming Growth Factor- β and  Fibrosis” 13 (22). 
Verstovsek, Srdan, Hagop Kantarjian, Ruben A Mesa, Animesh D Pardanani, Jorge Cortes-
Franco, Deborah A Thomas, Zeev Estrov, et al. 2010. “Safety and Efficacy of 
INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.” The New England 
Journal of Medicine 363 (12): 1117–27. doi:10.1056/NEJMoa1002028. 
Viñas, Odette, Ramón Bataller, Pau Sancho-Bru, Pere Ginès, Cristina Berenguer, Carlos 
Enrich, Josep M Nicolás, et al. 2003. “Human Hepatic Stellate Cells Show Features of 
Antigen-Presenting Cells and Stimulate Lymphocyte Proliferation.” Hepatology 
(Baltimore, Md.) 38 (4): 919–29. doi:10.1053/jhep.2003.50392. 
Wallace, Karen, Alastair D Burt, and Matthew C Wright. 2008. “Liver Fibrosis” 18: 1–18. 
doi:10.1042/BJ20071570. 
  
132 
132 
Walter, The, and Royal Melbourne Hospital. 2001. “S Tem C Ells,” 378–87. 
Wang, Hua, Fouad Lafdil, Xiaoni Kong, and Bin Gao. 2011. “Signal Transducer and 
Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target.” 
International Journal of Biological Sciences 7 (5): 536–50. 
Wang, Hua, Fouad Lafdil, Lei Wang, Shi Yin, Dechun Feng, and Bin Gao. 2011. “Tissue 
Inhibitor of Metalloproteinase 1 (TIMP-1) Deficiency Exacerbates Carbon 
Tetrachloride-Induced Liver Injury and Fibrosis in Mice: Involvement of Hepatocyte 
STAT3 in TIMP-1 Production.” Cell & Bioscience 1 (1). BioMed Central Ltd: 14. 
doi:10.1186/2045-3701-1-14. 
Wang, Yan, Juncha Gao, Di Zhang, Jian Zhang, Junji Ma, and Huiqing Jiang. 2010. “New 
Insights into the Antifibrotic Effects of Sorafenib on Hepatic Stellate Cells and Liver 
Fibrosis.” Journal of Hepatology 53 (1). Elsevier: 132–44. 
doi:10.1016/j.jhep.2010.02.027. 
Warfel, Noel A, and Wafik S El-deiry. 2013. “p21WAF1 and Tumourigenesis : 20 Years 
after” 25 (1): 52–58. doi:10.1097/CCO.0b013e32835b639e. 
Wasmuth, Hermann E., Frank Tacke, and Christian Trautwein. 2010. “Chemokines in Liver 
Inflammation and Fibrosis.” Seminars in Liver Disease 30 (3): 215–25. doi:10.1055/s-
0030-1255351. 
Watanabe, Azuma, Ardeshir Hashmi, Dawidson Assis Gomes, Terrence Town, Abdallah 
Badou, Richard Anthony Flavell, and Wajahat Zafar Mehal. 2007. “Apoptotic 
Hepatocyte DNA Inhibits Hepatic Stellate Cell Chemotaxis via Toll-like Receptor 9.” 
Hepatology (Baltimore, Md.) 46 (5): 1509–18. doi:10.1002/hep.21867. 
Weiskirchen, Ralf, and Frank Tacke. 2014. “Cellular and Molecular Functions of Hepatic 
Stellate Cells in Inflammatory Responses and Liver Immunology.” Hepatobiliary 
Surgery and Nutrition 3 (6): 344–63. doi:10.3978/j.issn.2304-3881.2014.11.03. 
Wells, Rebecca G. 2005. “The Role of Matrix Stiffness in Hepatic Stellate Cell Activation 
and Liver Fibrosis” 39 (2): 158–61. 
Wells, Rebecca G. 2008. “The Role of Matrix Stiffness in Regulating Cell Behavior.” 
Hepatology 47 (4): 1394–1400. doi:10.1002/hep.22193. 
Weng, H L, W M Cai, and R H Liu. 2001. “Animal Experiment and Clinical Study of 
Effect of Gamma-Interferon on Hepatic Fibrosis.” World Journal of 
  
133 
133 
Gastroenterology : WJG 7 (1): 42–48. 
http://www.ncbi.nlm.nih.gov/pubmed/11819731. 
Weng, Honglei, Peter R Mertens, Axel M Gressner, and Steven Dooley. 2007. “IFN-
Gamma Abrogates Profibrogenic TGF-Beta Signaling in Liver by Targeting 
Expression of Inhibitory and Receptor Smads.” Journal of Hepatology 46 (2): 295–
303. doi:10.1016/j.jhep.2006.09.014. 
Weng, Hong-Lei, Bao-En Wang, Ji-Dong Jia, Wan-Fen Wu, Jian-Zhong Xian, Peter R 
Mertens, Wei-Min Cai, and Steven Dooley. 2005. “Effect of Interferon-Gamma on 
Hepatic Fibrosis in Chronic Hepatitis B Virus Infection: A Randomized Controlled 
Study.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice 
Journal of the American Gastroenterological Association 3 (8): 819–28. 
http://www.ncbi.nlm.nih.gov/pubmed/16234012. 
Winau, Florian, Guido Hegasy, Ralf Weiskirchen, Stephan Weber, C??cile Cassan, Peter 
A. Sieling, Robert L. Modlin, Roland S. Liblau, Axel M. Gressner, and Stefan H E 
Kaufmann. 2007. “Ito Cells Are Liver-Resident Antigen-Presenting Cells for 
Activating T Cell Responses.” Immunity 26 (1): 117–29. 
doi:10.1016/j.immuni.2006.11.011. 
Wise, Steven G, and Anthony S Weiss. 2009. “Tropoelastin.” The International Journal of 
Biochemistry & Cell Biology 41 (3): 494–97. doi:10.1016/j.biocel.2008.03.017. 
Wong, L, G Yamasaki, R J Johnson, and S L Friedman. 1994. “Induction of Beta-Platelet-
Derived Growth Factor Receptor in Rat Hepatic Lipocytes during Cellular Activation 
in Vivo and in Culture.” The Journal of Clinical Investigation 94 (4): 1563–69. 
doi:10.1172/JCI117497. 
Wright, Matthew C., Razo Issa, David E. Smart, Nathan Trim, Graeme I. Murray, John N. 
Primrose, Michael J.P. Arthur, John P. Iredale, and Derek A. Mann. 2001. “Gliotoxin 
Stimulates the Apoptosis of Human and Rat Hepatic Stellate Cells and Enhances the 
Resolution of Liver Fibrosis in Rats.” Gastroenterology 121 (3): 685–98. 
doi:10.1053/gast.2001.27188. 
Wynn, Thomas A, and Thirumalai R Ramalingam. 2012. “Review Mechanisms of 
Fibrosis : Therapeutic Translation for Fibrotic Disease.” Nature Medicine 18 (7). 
Nature Publishing Group: 1028–40. doi:10.1038/nm.2807. 
  
134 
134 
Xu, F., C. Liu, D. Zhou, and L. Zhang. 2016. “TGF- /SMAD Pathway and Its Regulation in 
Hepatic Fibrosis.” Journal of Histochemistry & Cytochemistry 64 (3): 157–67. 
doi:10.1369/0022155415627681. 
Xu, Jun, Min Cong, Tae Jun Park, David Scholten, David A Brenner, and Tatiana 
Kisseleva. 2015. “Contribution of Bone Marrow-Derived Fibrocytes to Liver Fibrosis” 
4 (1): 34–47. doi:10.3978/j.issn.2304-3881.2015.01.01. 
Xu, Ming-Yi, Jun-Jie Hu, Jie Shen, Mei-Ling Wang, Qing-Qing Zhang, Ying Qu, and Lun-
Gen Lu. 2014. “Stat3 Signaling Activation Crosslinking of TGF-β1 in Hepatic Stellate 
Cell Exacerbates Liver Injury and Fibrosis.” Biochimica et Biophysica Acta 1842 (11). 
Elsevier B.V.: 1–9. doi:10.1016/j.bbadis.2014.07.025. 
Xu, Ruonan, Zheng Zhang, and Fu-sheng Wang. 2012. “Liver Fibrosis : Mechanisms of 
Immune-Mediated Liver Injury.” Cellular and Molecular Immunology 9 (4). Nature 
Publishing Group: 296–301. doi:10.1038/cmi.2011.53. 
Yamashita, Cory M, Lior Dolgonos, Rachel L Zemans, Scott K Young, Jennifer Robertson, 
Natalie Briones, Tomoko Suzuki, et al. 2011. “Matrix Metalloproteinase 3 Is a 
Mediator of Pulmonary Fibrosis.” The American Journal of Pathology 179 (4): 1733–
45. doi:10.1016/j.ajpath.2011.06.041. 
Yanagishita, M. 1993. “Function of Proteoglycans in the Extracellular Matrix.” Acta 
Pathologica Japonica 43 (6): 283–93. http://www.ncbi.nlm.nih.gov/pubmed/8346704. 
Yang, Bin, Mingzhou Guo, James G Herman, and Douglas P Clark. 2003. “Aberrant 
Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular 
Carcinoma Materials and Methods” 163 (3): 1101–7. 
Yang, Chang-Qing, Li Yang, Wen-Zhuo Yang, Zhong Zhang, Hao Zhang, Yi-Zhong 
Chang, Min Yuan, and Xi-Mei Chen. 2008. “[Mechanism of Hepatic Stellate Cell 
Migration during Liver Fibrosis].” Zhonghua Yi Xue Za Zhi 88 (2): 119–22. 
http://www.ncbi.nlm.nih.gov/pubmed/18353220. 
Yang, Changqing, Michael Zeisberg, Barbara Mosterman, Akulapalli Sudhakar, Udaya 
Yerramalla, Kathryn Holthaus, Lieming Xu, Francis Eng, Nezam Afdhal, and Raghu 
Kalluri. 2003. “Liver Fibrosis: Insights into Migration of Hepatic Stellate Cells in 
Response to Extracellular Matrix and Growth Factors.” Gastroenterology 124 (1): 
147–59. doi:10.1053/gast.2003.50012. 
  
135 
135 
Yasukawa, Hideo, Hiroyuki Misawa, Hiroshi Sakamoto, Masaaki Masuhara, Atsuo Sasaki, 
Toru Wakioka, Satoshi Ohtsuka, et al. 1999. “The JAK-Binding Protein JAB Inhibits 
Janus Tyrosine Kinase Activity through Binding in the Activation Loop” 18 (5): 
1309–20. 
Yasukawa, Hideo, Masanobu Ohishi, Hiroyuki Mori, Masaaki Murakami, Takatoshi 
Chinen, Daisuke Aki, Toshikatsu Hanada, et al. 2003. “IL-6 Induces an Anti-
Inflammatory Response in the Absence of SOCS3 in Macrophages.” Nature 
Immunology 4 (6): 551–56. doi:10.1038/ni938. 
Yata, Yutaka, Philip Gotwals, Victor Koteliansky, and Don C Rockey. 2002. “Dose-
Dependent Inhibition of Hepatic Fibrosis in Mice by a TGF-Beta Soluble Receptor: 
Implications for Antifibrotic Therapy.” Hepatology (Baltimore, Md.) 35 (5): 1022–30. 
doi:10.1053/jhep.2002.32673. 
Yeganeh, M, Y Gui, R Kandhi, D Bobbala, W-S Tobelaim, C Saucier, A Yoshimura, G 
Ferbeyre, S Ramanathan, and S Ilangumaran. 2016. “Suppressor of Cytokine 
Signaling 1-Dependent Regulation of the Expression and Oncogenic Functions of 
p21(CIP1/WAF1) in the Liver.” Oncogene, January. doi:10.1038/onc.2015.485. 
Yin, Chunyue, Kimberley J Evason, Kinji Asahina, and Didier Y R Stainier. 2013. “Review 
Series Hepatic Stellate Cells in Liver Development , Regeneration , and Cancer” 123 
(5). doi:10.1172/JCI66369.1902. 
Yoshida, T. 2004. “SOCS1 Is a Suppressor of Liver Fibrosis and Hepatitis-Induced 
Carcinogenesis.” Journal of Experimental Medicine 199 (12): 1701–7. 
doi:10.1084/jem.20031675. 
Yoshida, Takafumi, Hisanobu Ogata, Masaki Kamio, Akiko Joo, Hiroshi Shiraishi, Yoko 
Tokunaga, Michio Sata, and Hisaki Nagai. 2004. “SOCS1 Is a Suppressor of Liver 
Fibrosis and Hepatitis-Induced Carcinogenesis The Journal of Experimental 
Medicine” 199 (12): 1701–7. doi:10.1084/jem.20031675. 
Yoshiji, H. 2002. “Tissue Inhibitor of Metalloproteinases-1 Attenuates Spontaneous Liver 
Fibrosis Resolution in the Transgenic Mouse.” Hepatology 36 (4): 850–60. 
doi:10.1053/jhep.2002.35625. 
Yoshiji, Hitoshi, Shigeki Kuriyama, Junichi Yoshii, Yasuhide Ikenaka, Ryuichi Noguchi, 
Toshiya Nakatani, Hirohisa Tsujinoue, et al. 2002. “Tissue Inhibitor of 
  
136 
136 
Metalloproteinases-1 Attenuates Spontaneous Liver Fibrosis Resolution in the 
Transgenic Mouse.” Hepatology 36 (4): 850–60. doi:10.1053/jhep.2002.35625. 
Yoshikawa, H, K Matsubara, G S Qian, P Jackson, J D Groopman, J E Manning, C C 
Harris, and J G Herman. 2001. “SOCS-1, a Negative Regulator of the JAK/STAT 
Pathway, Is Silenced by Methylation in Human Hepatocellular Carcinoma and Shows 
Growth-Suppression Activity.” Nature Genetics 28 (1): 29–35. doi:10.1038/88225. 
Yoshimura, Akihiko, Hiroyuki Mori, Masanobu Ohishi, Daisuke Aki, and Toshikatsu 
Hanada. 2004. “Regulation of TLR Signaling and Inflammation by SOCS Family 
Proteins,” 1–6. doi:10.1189/jlb.0403194.1. 
Zeisberg, Michael, Changqing Yang, Margot Martino, Michael B. Duncan, Florian Rieder, 
Harikrishna Tanjore, and Raghu Kalluri. 2007. “Fibroblasts Derive from Hepatocytes 
in Liver Fibrosis via Epithelial to Mesenchymal Transition.” Journal of Biological 
Chemistry 282 (32): 23337–47. doi:10.1074/jbc.M700194200. 
Zhan, Shan-Shan, Joy X Jiang, Jian Wu, Charles Halsted, Scott L Friedman, Mark a Zern, 
and Natalie J Torok. 2006. “Phagocytosis of Apoptotic Bodies by Hepatic Stellate 
Cells Induces NADPH Oxidase and Is Associated with Liver Fibrosis in Vivo.” 
Hepatology (Baltimore, Md.) 43 (3): 435–43. doi:10.1002/hep.21093. 
Zhan, Yifan, Gayle M Davey, Kate L Graham, Hiu Kiu, Nadine L Dudek, Thomas W H 
Kay, and Andrew M Lew. 2009. “SOCS1 Negatively Regulates the Production of 
Foxp3 + CD4 + T Cells in the Thymus,” no. October 2008: 473–80. 
doi:10.1038/icb.2009.23. 
Zhang, David Y, and Scott L Friedman. 2014. “NIH Public Access” 56 (2): 769–75. 
doi:10.1002/hep.25670.Fibrosis-Dependent. 
Zhang, Ying E. 2009. “Non-Smad Pathways in TGF-Beta Signaling.” Cell Research 19 (1): 
128–39. doi:10.1038/cr.2008.328. 
Zhang, Yining, Tadashi Ikegami, Akira Honda, Teruo Miyazaki, Bernard Bouscarel, 
Marcos Rojkind, Ichinosuke Hyodo, and Yasushi Matsuzaki. 2006. “Involvement of 
Integrin-Linked Kinase in Carbon Tetrachloride-Induced Hepatic Fibrosis in Rats.” 
Hepatology (Baltimore, Md.) 44 (3): 612–22. doi:10.1002/hep.21315. 
Zhou, Kun, and Lun Gen Lu. 2009. “Assessment of Fibrosis in Chronic Liver Diseases.” 
doi:10.1111/j.1751-2980.2008.00356.x. 
  
137 
137 
Zhou, Xiaoying, Frank R Murphy, Nitu Gehdu, Junlong Zhang, John P Iredale, and R 
Christopher Benyon. 2004. “Engagement of alphavbeta3 Integrin Regulates 
Proliferation and Apoptosis of Hepatic Stellate Cells.” The Journal of Biological 
Chemistry 279 (23): 23996–6. doi:10.1074/jbc.M311668200. 
 
 
